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The incidence rates of Achilles tendon rupture and Achilles tendinopathy (AT) are 
increasing.  There are clear clinical, histopathological and imaging criteria for the diagnosis 
of AT, however its exact aetiology has not been elucidated.  The number of intrinsic and 
extrinsic risk factors associated with AT emphasise the multifactorial nature of this 
condition.  The risk factors with the strongest supportive evidence and highest degree of 
certainty are previous Achilles tendon injury, neovascularisation of the tendon, treatment 
with fluoroquinolone antibiotics, middle- and long-distance running and genetic variation.  
The certainty for the existence of a genetic predisposition towards AT is increasing as more 
studies are published reporting the association of gene sequence variants with risk of AT.  In 
addition, the increasing number of genes that are reported to be associated with AT 
emphasises the polygenic nature of genetic susceptibility to AT.  It is therefore vital that the 
full spectrum of polymorphisms which influence risk of AT is eventually uncovered.   
AIM OF THE THESIS 
The primary aim of this thesis was to identify additional genetic elements predisposing 
individuals to risk of AT using a candidate gene, case-control genetic association approach, 
and to propose the biological mechanisms underlying this genetic risk.  Candidate genes 
(COMP, THBS2, COL27A1, TNC, COL3A1, COL5A2 and COL5A3) were selected based on their 
chromosomal location and/or the biological function of their encoded proteins within the 
extracellular matrix (ECM) of the tendon.  The objectives of the specific studies which 
addressed this primary aim of the thesis were: 
 To test the association of sequence variants within the COMP and THBS2 candidate 
genes with risk of AT in participants from South Africa and Australia (Chapter 2) 
 To test the association of several sequence variants spanning a 780.9kb region which 
includes the COL27A1 and TNC genes, and a potential haplotype consisting of two or 
















 To investigate the association of polymorphisms within the COL5A2, COL5A3 and 
COL3A1 genes with AT in participants from South Africa and Australia (Chapter 4) 
 To investigate interactions between polymorphisms within the COL5A2, COL5A3 and 
COL3A1 genes and the previously associated BstUI RFLP within the COL5A1 gene in 
modulating risk of AT (Chapter 4) 
The secondary aim of this thesis was to develop and test preliminary polygenic models 
assessing risk of developing AT.  The objectives of the specific studies which addressed this 
secondary aim of the thesis were: 
 To investigate the relative contribution of polymorphisms within genes encoding 
components of the collagen fibril and components of cell-signalling pathways within 
the ECM to overall genetic risk in a polygenic risk model (Chapter 5) 
 To develop and evaluate a preliminary, clinically relevant polygenic risk assessment 
model for AT using (i) polymorphisms that have previously been independently 
associated with AT in two populations, and (ii) polymorphisms with a definitive AT 
risk genotype that were implicated in this thesis in a haplotype or gene-gene 
interaction (Chapter 5) 
METHODS  
One hundred and thirty one (131) physically active South African Caucasian participants 
without any history of tendon or ligament pathology (SA-CON), as well as 94 physically 
active South African Caucasian participants clinically diagnosed with chronic AT (SA-TEN) 
were recruited for the studies presented in chapter’s two to five.  In addition, 209 physically 
active Australian Caucasian participants without any history of tendon or ligament 
pathology (AUS-CON), as well as 85 physically active Australian Caucasian participants 
clinically diagnosed with chronic AT (AUS-TEN) were also recruited for the studies presented 
in this thesis.  To address the primary aim of this thesis, participants were genotyped for 
variants within COMP, THBS2 (Chapter 2), COL27A1, TNC (Chapter 3), COL3A1, COL5A2, and 
COL5A3 (Chapter 4) using standard PCR based methods.  Where appropriate, haplotypes or 
pseudohaplotypes were inferred using genotype data from the respective variants.  















aim of this thesis by identifying polymorphisms which contribute to overall genetic risk of AT 
and to develop a series of AT genetic risk assessment models. 
RESULTS AND DISCUSSION  
Polymorphisms within the COMP (rs284945050, P=0.994; rs730079, P=0.727) and THBS2 
genes (rs9505888, P=0.244; rs6422747, P=0.645; rs9283850, P=0.604) were found not to 
independently associate with AT in the South African and Australian groups (Chapter 2).  In 
addition, polymorphisms within the COL5A3 (rs2303099, P=0.890; rs1559186, P=0.050; 
rs2161468, P=0.473), COL3A1 (rs2056156, P=0.928; rs3106796, P=0.900; rs1800255, 
P=0.726) and COL5A2 (rs13031549, P=0.969; rs4667264, P=0.915) genes were also found 
not to be significantly independently associated with AT in these two groups (Chapter 4).  
Furthermore, four polymorphisms within the COL27A1 gene (rs4143245, P=0.610; 
rs1249744, P=0.106; rs753085, P=0.199; rs946053, P=0.248) and the rs13321 SNP within the 
TNC gene (P=0.291) were also found not to be independently associated with AT (Chapter 
3).  However, allele distributions of two SNPs within the TNC gene (rs2104772, P=0.017; 
rs1330363, P=0.020) were found to differ significantly between the TEN and CON 
participants.  In addition, the GCA haplotype constructed from the COL27A1 rs946053 (T>G), 
TNC rs13321 (G>C) and TNC rs2104772 (T>A) SNPs was significantly associated with AT in 
the South African and Australian participants (TEN: 27% vs CON: 18%, P=0.019).  
Bioinformatic analysis of this region suggests that this haplotype may have functional effects 
on mRNA transcription by influencing the position and accessibility of transcription factor 
binding sites and splici g regulatory elements.  The potential changes in structure and 
properties of the TN-C and α1(XXVII) proteins may modify protein-protein and protein 
environment interactions. 
In addressing the secondary aim of this thesis, stepwise logistic regression with receiver 
operating characteristic (ROC) curve analysis was used to develop two risk models for AT 
which identified the polymorphisms contributing, and their relative contribution, to overall 
genetic risk of AT.  The best fit risk model with the largest area under the curve included the 
variables age (years), sex (male), COL27A1 rs946053 (GT,TT), COL5A1 rs12722 (TC,CC), 
COL5A3 rs1559186 (CG,GG), IL-6 rs1800795 (GC,CC), CASP8 rs1045485 (GC,CC) and CASP8 















86.5% respectively.  These risk models are valuable at a population level, but are not easy to 
interpret in a clinical setting.  Therefore, a series of potentially clinically relevant genetic risk 
assessment models were developed and evaluated using genotype risk scores.  A genetic 
risk assessment model which included risk genotype scores for polymorphisms rs16399 
(COL5A1), rs4919510 (MIR608), rs143383 (GDF5), rs3834129 (CASP8), rs2104772 (TNC) and 
rs946053 (COL27A1) was developed and accurately assessed 90% of CON participants as not 
at-risk of AT but only accurately assessed 37% of TEN participants as at-risk of AT (OR 5.89, 
95% CI:2.39-14.52; P<0.001). 
CONCLUSION 
The novel findings of this thesis provide further evidence that the long arm of chromosome 
9 harbours genetic elements which contribute to risk of AT, and narrows the implicated 
interval to a 759kbp region containing the 3’-end of the COL27A1 gene and the 5’-end of the 
TNC gene.  Polymorphisms investigated within the COMP, THBS2, COL5A3, COL3A1 and 
COL5A2 genes were, however, not associated with AT in these two participant groups.   
In addition, this thesis provides proof of concept that genetic screening tests for AT can be 
of value as a clinical tool.  Future studies are required in order to replicate these findings in 
independent populations and elucidate the biological mechanisms underpinning these 
associations.  Large, prospective cohort studies are required to confirm the involvement of 
genetic and other risk factors in the development of AT and to test the ability of genetic 

















CHAPTER 1: ACHILLES TENDINOPATHY: A REVIEW 
1.1. INTRODUCTION AND SCOPE OF THESIS 
Regular physical activity is important in the maintenance of a healthy lifestyle and the 
reduction of mortality risk.28  However, the risk of musculoskeletal injuries rises with 
increasing physical activity.200  In particular, tendon injuries contribute an estimated 30-50% 
to all sporting injuries.115,131  The Achilles tendon is particularly susceptible to tendinopathy 
which accounts for 55-65% of Achilles tendon disorders.132,233,306  Achilles tendinopathy (AT) 
presents a large burden of morbidity and is the focus of this thesis.  The current chapter 
(Chapter 1) introduces the scope and objectives of this thesis (Section 1.1), presents a brief 
review of tendon anatomy (Section 1.2) and molecular structure (Section 1.3) as well as a 
more detailed review of Achilles tendon pathology (Section 1.4) and the risk factors 
associated with AT (Section 1.5).   
A framework for translating research into injury prevention practice (TRIPP) proposed by 
Finch (2006)82 emphasises the importance of injury surveillance and elucidating the 
aetiology and mechanisms of injury before developing and evaluating preventative 
measures.  The identification of both intrinsic and extrinsic risk factors for AT is an 
important element in understanding the aetiology and mechanism of injury.  A large volume 
of research has been undertak n to establish the prevalence and incidence of AT, as well as 
the risk factors that are associated with the development of AT.  A number of preventative 
measures and treatments have been developed and evaluated based on this research.  
However, research linking genetic variation to risk of AT has yet to be fully translated into 
injury prevention practice and remains at stage 2 of the TRIPP model in which the 
mechanisms for injury that are influenced by genetic variation are still being expounded.   
The primary aim of this thesis was therefore to further identify specific genetic elements 
predisposing individuals to risk of AT and postulate on the biological mechanisms underlying 
this genetic risk.  Candidate genes were selected based on their chromosomal location 
and/or their biological function within the extracellular matrix (ECM) of tendon tissue.  A 















polymorphisms within these genes with risk of AT (Chapters 2, 3 and 4).  The ultimate 
purpose of injury research is the development and implementation of relevant and practical 
injury prevention strategies which reduce risk of injury.  With this in mind, the second 
objective of this thesis was to develop and test preliminary models assessing genetic risk of 
developing AT.  In chapter 5 of this thesis, polymorphisms previously independently 
associated with risk of AT, as well as new polymorphisms identified in this thesis, were 
incorporated into several genetic risk assessment models which were tested in an applied 
case-control analysis.  The final chapter of this thesis, chapter 6, summarises the main 
findings of the thesis and discusses the limitations, implications and context of this research 
as well as suggesting avenues of future research.  
1.2. TENDON ANATOMY  
1.2.1. MACRO-STRUCTURE OF TENDONS 
The general structure and metabolism of tendons is extensively reviewed elsewhere,60,208 
but will be briefly elaborated here.  Tendons are connective tissue structures that link 
muscle to bone, and vary greatly in both shape and size. The myotendinous junction (MTJ) is 
the intersection between the muscle and tendon and is the point from which the tendon 
elongates.  The MTJ is subjected to immense mechanical stress during the transmission of 
contractile force from the muscle to the tendon.  The osteotendinous junction (OTJ), also 
known as the enthesis, is the gradual insertion of the tendon into lamellar bone.  The 
Achilles tendon, in particular, is the merging of the myotendinous areas of the 
gastrocnemius and soleus muscles of the lower leg (Figure 1.1).132  It is the largest and 
strongest tendon in the human body and has a high capacity to withstand tensional 
forces.132  Healthy tendons can, in fact, withstand tensile loads much greater than those 
















Figure 1.1: Gross anatomy of the Achilles tendon 
 [Source: www.photobucket.com] 
 
Tendons are relatively avascular with lower oxygen consumption than other tissues.  
However, they are metabolically active and respond to external stimuli.  Blood supply to the 
tendons extends predominantly from the muscle and divides into three regions - the MTJ, 
tendon length and OTJ, although very few blood vessels cross the OTJ.9,208  The lower 
metabolic rate of tendons allows them to sustain tension for extended periods of time with 
a minimal risk of ischaemia and tissue necrosis.115  However, blood supply to tendons is 
often restricted in areas of friction, torsion or compression, and this is particularly the case 
in the Achilles tendon where the tendon fibres can spiral by up to 90˚.109,208  This twisting 
increases the strength of the tendon under tension and endows greater elastic recoil 
properties but may cause constriction of the associated blood vessels.109,280 
Nerve supply to the tendon is predominantly afferent with mechanoreceptors being found 
near the MTJ.138  These mechanoreceptors are responsible for proprioception and provide 
feedback control of muscle activity to protect the joints.115  An interrupted nerve supply to 















1.2.2. HIERARCHICAL MICRO-STRUCTURE OF TENDONS 
Tendon tissue consists of a cellular component and the surrounding ECM.  The spindle 
shaped fibroblasts, known as tenocytes, are the cellular elements within tendons and are 
responsible for secreting collagen and other molecules, and maintenance of the ECM.115,306  
The ECM consists of tightly packed parallel collagen fibres surrounded by ground substance.    
Ground substance is produced by the tenocytes and is a highly viscous matrix which consists 
of 60-80% water, glycosaminoglycan’s (GAG) and structural proteoglycans.208  The base unit 
of the hierarchical collagen network is a type I procollagen molecule which conglomerates in 
groups of five to form fibrils that are 20-150nm in diameter (Figure 1.2).  Several fibrils 
embedded in parallel in the ECM will form fibres, which in turn group together to form 
fascicles individually encapsulated by the endotenon.  The endotenon is a connective tissue 
sheath that accommodates the nerves and blood vessels.  The fascicles are further 
encapsulated by the epitenon which is surrounded by a fluid layer and the outer 
paratenon.115,208  Crimp is a significant feature of tendon which represents a sinusoidal 
pattern in the ECM.208  It functions as a shock-absorbing buffer so that slight elongation of 
the tendon can occur without the risk of damage. 
Healthy tendon tissue is white in colour with a firm fibroelastic texture.  The parallel 
collagen bundles have a regular, uniform structure and the individual fibres are uniform in 
diameter and orientation.  The tenocytes have uniform, spindle shaped nuclei and are 
























Figure 1.2: The hierarchical structure of tendon. 
















1.3. MOLECULAR STRUCTURE OF TENDONS 
The major molecular components of the tendon ECM include the collagens, elastin and 
other glycoproteins, and proteoglycans (Table 1.1).  As the focus of this thesis is on genes 
that code for selected collagens and glycoproteins, the following review will predominantly 
focus on these molecules. 
Table 1.1: Molecular composition of tendon extracellular matrix 
MOLECULE STRUCTURE 
COLLAGEN 
Type I Fibrillar 
Type II* Fibrillar 
Type III Fibrillar 
Type V Fibrillar 
Type XI Fibrillar 
Type IX* FACIT 
Type XII FACIT 
Type XIV FACIT 
Type IV Forms meshwork 
Type X* Forms meshwork 
Type VI Beaded filaments 
GLYCOPROTEINS 
Elastin Branched network 






Link protein Globular 
Tenascin-C Branched molecule 
Thrombospondins Modular 
PROTEOGLYCANS 
Biglycan Small leucine-rich repeat proteoglycan 
Decorin Small leucine-rich repeat proteoglycan 
Fibromodulin Small leucine-rich repeat proteoglycan 
Lumican Small leucine-rich repeat proteoglycan 
Aggrecan* Hyalectan 
Versican Hyalectan 
* Predominant in fibrocartilaginous regions of tendon  



















Collagen is the most abundant protein, accounting for approximately 30% of all protein in 
the human body.173  In tendons, 60-85% of the dry tissue mass is made up of collagen 
proteins.208  A large number of distinct collagen types have been identified in the ECM and 
the variety in these collagen types allows connective tissue to have a structural diversity and 
adapt to many stimuli.  The focus of this review will be on collagen types that have been 
identified in tendon (Table 1.1).  Collagens are predominantly separated into two groups 
based on their structure and function, (i) fibrillar collagens which form the ECM scaffolding 
network and contain rigid, uninterrupted helices, and (ii) non-fibrillar collagens which 
include, amongst others, the fibril-associated collagens with interrupted triple helices 
(FACIT).216,240   Fibrillar collagens are the most abundant, and are further separated into 
major (types I, II and III) and minor collagens (types V and XI).32,285  More recently type XXVII 
collagen was identified as a unique fibrillar collagen that is primarily expressed in cartilage, 
but also in tendon.35,114,133,216   
The synthesis of collagen is extensively 
reviewed by Banos et al. (2008)24 and 
summarised in Figure 1.3.  Briefly, fibrillar 
collagens are formed within the tenocytes 
where collagen messenger RNA (mRNA) is 
translated and translocated to the rough 
endoplasmic reticulum.  Typically, the 
polypeptide α-chains are composed of 
approximately 1000 amino acids in an 
uninterrupted repeating triplet which 
contains a glycyl residue in every third 
position while the other positions are 
predominantly occupied by proline and 4-
hydroxyproline (Gly-X-Y).142  These α-chains 
also contain uncommon hydroxylysine 
















reticulum, these α-chains undergo post-translational modification which includes 
glycosylation of some hydroxylysine residues, and hydroxylation of proline and lysine 
residues.  Three polypeptide α-chains are then wound together in a triple helix to form 
procollagen units.  The hydroxyproline residues form hydrogen bonds between the α-chains 
and contribute to the stability of the procollagen molecule.208  These procollagen molecules 
are transported to the Golgi apparatus where they are aggregated into organised, lateral 
bundles of procollagen molecules.  The procollagen triple helices are synthesised containing 
propeptides at both the amino (NH2) and carboxyl (COOH) terminals of the triple helical 
domain.  Although the exact process after release from the Golgi apparatus is debated, it is 
accepted that the COOH- and NH2-propeptides are post-translationally cleaved and the 
resulting soluble procollagen bundles are transported into the ECM.24,142,208  This cleavage 
exposes the non-collagenous (NC) telopeptide extensions of the triple helix, which contain 
binding sites for fibrillogenesis and are numbered from the COOH-terminus starting with 
NC1.
142  In the ECM, the procollagen bundles aggregate to from collagen fibrils as described 
in section 1.2.2.115,208  The hydroxylysine residues are important in establishing electrostatic 
cross-links between the procollagen molecules to reinforce the fibrillar structure.208  These 
cross-links are vital in determining the tensile strength of collagen in that they allow for 
increased energy absorption and increase resistance to proteolytic activity.  A reduction in 
the number of cross-links results in a weaker collagen fibre.208   
The major structural domains of collagen proteins are typically highly conserved across 
species.  Mutations within the majority of collagen genes result in serious connective tissue 
disorders including osteogenesis imperfecta (type I),216,222 chondrodysplasias (types II and 
XI)285 and Ehlers-Danlos syndrome (EDS)(types III and V).183,184,193,268  This emphasises the 
importance of the collagen genes and proteins in the determination of a functional 
connective tissue.   
The predominant collagen in tendon is the fibrillar, heterotrimeric type I collagen (two α1(I) 
chains and one α2(I) chain).  Type I collagen is responsible for the hierarchical structure of 
tendons and determines the mechanical and tensile strength of tendon tissue.78,115,234  Type 















cartilage and has been linked to the development of osteoarthritis.144  Its expression in 
tendon is limited to the fibrocartilaginous zones.240   
Type III collagen is also a major fibrillar collagen of tendon and is important in the healing 
process and during fibrillogenesis.24,173  It co-localises with, and in some cases may form 
heterotypic fibrils with type I collagen during tendon development.24  It is thought that type 
III collagen regulates the diameter of type I collagen fibrils during development and healing 
by limiting lateral growth.24   Type III collagen is laid down early during the proliferative 
phase of the healing process and rapidly forms disulphide cross-links which stabilise the 
newly synthesized matrix of the repair site.5,52,261  These cross-links are easily degraded 
which allows for rapid growth and remodelling of tissues, however these fibres are thinner 
and more extensible than type I and its accumulation within tendon tissues during a 
prolonged healing response therefore weakens the mechanical and tensile strength of the 
tissue.52,78  Type III collagen occurs as a homotrimer of three α1(III) chains which are 
encoded by the COL3A1 gene on chromosome 2q31-32.59,268  Mutations within the COL3A1 
gene result in a form of EDS characterised by tissue friability.268  In particular, mutations 
near the COOH-terminal result in dilatation of the rough endoplasmic reticulum and the 
secretion of smaller collagen fibrils, while mutations at the NH2-terminal result in a more 
variable fibril diameter.268   
Type V collagen is a minor fibrillar collagen which is co-expressed with type I collagen.32  The 
predominant isoform of type V collagen is a heterotrimer of two α1(V) and one α2(V) 
chains, however homotrimers of three α3(V) chains also exist.32,59  These chains are 
encoded by the COL5A1 (chr9q34.2-34.3), COL5A2 (chr2q14-32) and COL5A3 (chr19p13.2) 
genes respectively.59,193,285  The triple helical domain of type V collagen is embedded within 
the type I collagen molecule with the NH2-terminal protruding from the fibril (Figure 1.4).  
Through this interaction it plays a vital role in the regulation of type I collagen fibril 
diameter.32,75,193  Recent investigations of the function of type V collagen in tendon 
fibrillogenesis in a murine model suggest a synergistic role with type XI collagen in fibril 
nucleation and the regulation of fibrillogenesis during tendon development and growth of 















Collagen XXVII is a fibrillar collagen expressed primarily in cartilage and sites of transition 
from cartilage to bone, but also in foetal organs and skeletal muscle.35,114,216  The pro-α1 
chain of type XXVII collagen has unusual molecular characteristics and a unique expression 
pattern compared with classical vertebrate fibrillar collagens.35  As described above, typical 
fibrillar collagens share a highly conserved COOH-terminal NC domain and a long 
collagenous domain.  They are traditionally classified into two distinct clades based on 
phylogenetic analyses and these clades differ in the exon arrangement of the relevant 
collagen genes, the sequence of the COOH-propeptide and the size of the NH2-terminal NC 
domain.35,216,265  Collagen XXVII protein is similar to other minor fibrillar collagens in that the 
pro-α1(XXVII) chain consists of a large globular NH2-terminal propeptide and contains 
overlapping laminin-G (lamG) and thrombospondin NH2-terminal like (TSPN) domains, as 
well as a proline/arginine rich (PARP) domain and the characteristic COOH-propeptide.216  
However, the protein differs from previously characterized fibrillar collagens in that the 
variable domain fuses directly with the major triple helical domain and therefore lacks the 
classical telopeptide and minor triple helical domain.35,216  In addition, pro-α1(XXVII) has a 
shorter triple helical domain and two conserved interruptions in the Gly-X-Y repeat in exons 
6 and 42.35,216  The pro-α1(XXVII) chain is highly conserved in man, mouse and Fugu puffer 
fish, particularly the TSPN domain, collagenous domain and the COOH-propeptide, 
suggesting little tolerance for variation in these domains.35  Collagen types III, V and XXVII 
are discussed further and in more detail in chapters three, four and five of this thesis.   
In addition to these fibrillar collagens, other non-fibrillar collagens are also expressed in 
tendon.  These include the FACITs (types IX, XII and XIV), and other types (type IV, VI and 
X).240  The FACITs are important in mediating cell-matrix interactions between the type I 
collagen fibres and cell surfaces.240  In addition, it has recently been confirmed that the NC2 
domain of FACITs, types IX and XIX collagen in particular, are responsible for α-chain 
selection, trimerisation and the stabilisation of attached collagen triple helices.38,39  Further 
description of the non-fibrillar collagens is beyond the scope of this thesis, but is reviewed 

















Figure 1.4: Components of a collagen fibril in tendon 
[Modified from Collins & Raleigh (2009)59] 
 
1.3.2. NON-COLLAGENOUS PROTEINS OF THE EXTRACELLULAR MATRIX 
Although collagen is the major protein in the ECM, other non-collagenous macromolecules 
are important components of the ECM.  These include glycoproteins, particularly elastin, 
proteoglycans and matrix enzymes. 
1.3.2 (I) GLYCOPROTEINS 
Glycoproteins are conjugated proteins with oligosaccharide chains covalently linked to 
polypeptide side chains.  The major glycoprotein in tendon is elastin which makes up 
approximately 2% of the dry weight of tendon.208,240  It is a hydrophobic, highly extensible 
molecule that contributes to the flexibility of the tendon.208  Other glycoproteins include the 
thrombospondins (TSP), tenascin-C (TN-C), fibrillin, laminin and fibronectin.  They fulfil a 
variety of functions in the ECM but are predominantly involved in mediating cell-matrix 
interactions.240  The thrombospondins are a family of calcium binding glycoproteins with 
two subfamilies that have distinct functions.7,36  Group A are the matricellular proteins, TSP-
1 and TSP-2, which modulate cell functions and cell-matrix interactions.36  Group B is made 
up of the structural proteins TSP-3, TSP-4 and the cartilage oligomeric matrix protein 















chapter two of this thesis.  TSP-2 is involved in cell-matrix interactions and has an anti-
angiogenic role during the healing response in connective tissues.7,36,37  COMP is another 
major component of tendon and interacts with type I and type III collagens during matrix 
assembly and healing.108,223,240,243,272  TN-C is also discussed in more detail and investigated 
in chapter three of this thesis.  This mechanosensitive glycoprotein is expressed during 
wound healing and tissue remodelling, particularly in response to high tensile and 
compressive forces.129,136,137  The review of other glycoproteins is beyond the scope of this 
thesis but is reviewed in more detail by Riley et al. (2005).240   
1.3.2 (II) PROTEOGLYCANS 
Proteoglycans are heavily glycosylated proteins which consist of a protein core with GAG 
side chains.  The function and metabolism of proteoglycans in tendon is beyond the scope of 
this thesis and is expertly reviewed elsewhere.217,234,309  Briefly, they interact with the 
fibrillar collagen network and are important in the normal functioning of the tendon ECM.  
They include the large hyalectan type proteins, aggrecan and versican, and the small 
leucine-rich repeat proteoglycans (SLRP) decorin, biglycan, fibromodulin, lumican, 
proteoglycan-4 and keratocan.234,240  Aggrecan resists compressive and shear forces while 
versican is involved in cell migration, adhesion and differentiation.234.  The SLRP’s in 
particular bind to fibrillar collagen and growth-factors and regulate fibrillogenesis.234,240  
Proteoglycans in tendon have a high turnover rate and perturbations in their metabolism 
have been implicated in tendinopathy.86,142,234 
1.3.2 (III) MATRIX ENZYMES AND THEIR INHIBITORS 
Proteolytic activity in the tendon is essential to maintain homeostasis and to remodel tissue 
during healing.125,240  Collagen remodelling in the ECM is mediated by a family of proteases, 
known as the matrix metalloproteinases (MMP), and the tissue inhibitors of 
metalloproteinases (TIMP).  A large number of MMPs are expressed in tendon tissue and are 
tightly regulated in both the physiological and pathological remodelling of tendon.240,306   In 
addition, a disintegrin and metalloproteinase (ADAM) as well as a disintegrin-like and 
metalloproteinase with thrombospondin motifs (ADAMTS) play important roles in cell-
adhesion, and collagen and proteoglycan turnover in tendon.306  Changes in expression of 















the homeostatic balance between MMPs and TIMPs is important in maintaining the tendon 
ECM integrity.240,306  Further review of the role of MMPs and their inhibitors is beyond the 
scope of this thesis but is reviewed by Birkedal-Hansen et al. (1993).33 
1.4. ACHILLES TENDON PATHOLOGY 
1.4.1. PREVALENCE OF ACHILLES TENDON RUPTURE AND TENDINOPATHY 
An increasing emphasis on the benefits of physical activity has led to an increase in the 
active adult population.75  This, together with improvements in health care, has further led 
to an increase in activity in the elderly.74,75  This increase in participation in physical activity 
has resulted in an increased exposure to, and incidence of, sporting injuries.16,140,278  Tendon 
and ligament injuries are a source of considerable morbidity with an estimated 30-50% of all 
sporting injuries being tendon injuries.115,131  The Achilles tendon is particularly susceptible 
to tendinopathy, which is the most common tendon disorder accounting for 55-65% of 
Achilles tendon disorders.132,233,306  In particular, a rospective study of 427 runners 
reported that 7% of runners developed mid-portion Achilles tendinopathy within one 
year.113 
Incidence rates for Achilles tendon ruptures (ATR) and Achilles tendinopathy (AT) within 
different populations vary according to the definitions and clinical diagnostic criteria used, 
and may also reflect international differences in participation rates for particular sports.121  
In a 2009 cross-sectional study of 57 725 Dutch patients registered for primary health care, 
the incidence of adult mid-portion AT in the general population was 2.35 per 1000 
registered patients.68  However, a prospective cohort study of 785 elite Finnish athletes 
showed that middle- and long-distance runners had a higher risk of developing AT before 
the age of 45 years when compared to 416 active controls (OR 31.2, 95% CI:13.5-71.8; 
P<0.001).159 
There is a particularly large difference in the reported incidence values for ATR (6.0 to 37.3 
per 100 000 people).275  A prospective study of ATR in a Scottish population showed an 
increase in incidence from 4.7 per 100 000 people in 1982 to 6.0 per 100 000 people in 















in 1984 to 37.3 per 100 000 in 1996.121  A more recent study in Edmonton, Canada, showed 
an incidence of 8.3 per 100 000 inhabitants over a 5-year period between 1998 and 2002.275  
Notwithstanding the large variations in the reported incidence of ATR, it is clear that the 
incidence of ATR is increasing and that it presents a large burden of morbidity.   
1.4.2. AETIOLOGY 
1.4.2 (I) DEFINITIONS 
There are a number of conditions that affect the Achilles tendon and surrounding tissues 
and as knowledge in this field has grown, there has been a lack of uniformity in the 
terminology used to describe these conditions.178,288  For the purposes of this thesis, and in-
line with current opinion, Achilles tendinopathy is defined as a clinical syndrome 
characterised by swelling in and around the tendon which is tender to palpation and results 
in a pain-induced impairment in physical performance.5,89,128,132,178,234,288,306  This broader 
term assumes no knowledge of the underlying pathology and encompasses, for example, 
paratenonitis, which is characterised by inflammation of the paratenon, and tendinosis 
which is characterised by degeneration of the tendon without histological signs of 
inflammation.233,250,288  The participants included in this thesis were diagnosed with chronic 
overuse AT that, in most cases, was confirmed to be a degenerative tendinosis by 
ultrasound.  These participants will be described in more detail in chapter two. 
1.4.2 (II) HISTOPATHOLOGY AND CLINICAL CHARACTERISTICS 
Although the exact aetiology of tendinopathy is still unclear, there are several 
histopathological changes in the tendon and clinical criteria that are well recognised in the 
diagnosis of AT (Table 1.2).5,17,69,89,128,306  Several types of degeneration have been proposed 
to take place in tendon, adjacent to healthy tissue.128  These include: (i) hypoxic 
degeneration, (ii) mucoid degeneration, (iii) fibrinoid degeneration, (iv) hyaline 
degeneration, (v) fatty degeneration, (vi) calcification and (vii) fibrocartilaginous metaplasia.  
On a macroscopic level, AT is characterised by loose and poorly defined intratendinous 
regions with a focal loss of fibrillar tendon structure.  The tendon loses its glistening white 
appearance and becomes grey and amorphous with diffuse, nodular or fusiform thickening.  















Under light microscopy, there is an increase in ground substance (mucoid degeneration) and 
this increase in proteoglycans and GAGs, with the associated increase in bound water, 
results in the hypoechoic regions seen during ultrasound examination.  There is disruption 
and separation of the collagen fibres which become disordered and lose their hierarchical 
structure.  Collagen fibres become angulated and vary in their diameter and orientation.  
The characteristic crimping of the collagen fibres becomes irregular with increased 
waviness.  Calcification and intratendinous lipid accumulation may accompany the 
degradation of the collagen fibres.128   
There is large variation in the cellular density across the degenerated tendon with areas of 
low cell density and areas with large numbers of metabolically active tenocytes.  Tenocytes 
lose their spindle shape and parallel alignment and have changes characteristic of hypoxia 
with round nuclei, lipid vacuoles, enlarged lysosomes and degranulated endoplasmic 
reticulum.  There is also evidence for increased cellular apoptosis in AT.306     
Although chronic AT was traditionally, and in some clinical practices still is, diagnosed as 
Achilles tendinitis, the role of inflammation in the development of AT has remained elusive.  
Many studies have found no signs of inflammation in degenerate tendons and, particularly, 
in ruptured tendons.5,89,128,146,261,306  However, both ruptures and tendinopathy in human 
tendons are generally only investigated after the degeneration becomes symptomatic.146  In 
addition, animal models of tendinopathy may not fully replicate the early stages of chronic 
overuse injuries.5  The possibility of an acute inflammatory response can therefore not be 
excluded.  There is, in fact, some evidence to suggest this acute inflammatory response in 
rabbit Achilles tendon and equine superficial digital flexor tendon (SDFT).86,189,300  In 
addition, peritendinous injections of prostaglandin E1 and inflammatory cytokines resulted 
in a histopathological profile similar to that of mild tendinopathy.274,276  As originally 
hypothesized by Jarvinen et al. in 1997,128 the current evidence suggests that there is an 
early, acute inflammatory response to overuse which may either be superseded by 
degenerative changes, or proceed in parallel with these degenerative changes in AT.5,233,261  
Both inflammatory and degenerative changes can co-exist in contiguous areas of tendons, 















by supporting the “entangled roles of inflammation and subsequent degeneration within 
tendons”. 
Table 1.2: Histopathological changes of tendon tissue in Achilles tendinopathy  
 HEALTHY TENDON DEGENERATIVE TENDON 
Macroscopic:  
 Glistening white in 
colour 
 Firm, fibroelastic 
texture 
 Grey-brown in colour 
 Fragile and loose texture 
 Fusiform, nodular or diffuse thickening 
 Fibrocartilaginous and bony metaplasia 





 Densely packed, 
organised, parallel 
collagen fibres 
which are uniform 
in diameter & 
orientation 
 Disordered collagen bundles with 
angulated collagen fibres which vary in 
diameter and orientation 
 Large vacuoles 
 Increased ground substance with 
proteoglycans and GAGs (mucoid 
degeneration) 
 Calcification 
 Intratendinous lipid accumulation 
Microscopic: 
Cellular 
 Tenocytes with 
spindle shaped 
nuclei, in parallel 
alignment with 
collagen fibres 
 Tenocytes with round nuclei 
 Loss of parallel alignment 
 Hypoxic changes in tenocytes (lipid 
vacuoles, enlarged lysosomes, 
degranulated endoplasmic reticulum) 





 localised widening of tendon 
 localised hypoechoic areas 
 irregular fibre structure 
 neovascularisation 
















1.4.2 (III) MODELS FOR THE PATHOGENESIS OF ACHILLES TENDINOPATHY 
The exact aetiology of AT has not been elucidated and research in this area is hampered in 
that human tendons are generally only studied after they become symptomatic and not 
during the early stages of the condition.5  Previously, pain in the tendon was diagnosed as 
tendinitis and treated primarily as an inflammatory condition.232  The 1990’s however saw a 
new perspective on tendon disorders as investigators reported evidence which suggested 
tendinopathy was not primarily inflammatory but degenerative in nature.232  Degenerative 
changes in tendons are predominantly considered a result of aging, dysregulated cell-
signalling processes and chronic mechanical stress.128  Several models and hypotheses have 
emerged to explain the development of chronic tendinopathy.       
(a) Mechanical Overuse Theory 
It is generally accepted that mechanical overuse of tendon is the primary inciting event in 
AT.5,89,306  Although tendons can withstand loads much larger than those required in day to 
day functioning, repetitive exposure to high tensile loads can result in excessive strain on 
the tendon tissues.115,132,233,239  Stress is defined as the force or load applied to a tendon, 
and strain is defined as the displacement of tissue resulting from that force.  The 
relationship between these can be plotted as a stress-strain curve (Figure 1.5).132,233,239  
When stress is applied to a tendon, the crimp stretches out resulting in the lag or “toe” 
region of the stress-strain curve.  As the crimp straightens out, collagen fibres experience 
strain in a relatively linear relationship to the load.  Under loads resulting in less than 4% 
strain tendons behave elastically and will return to their original length once the load is 
removed.  Loads resulting in more than 4% strain may exceed the tendons’ physiological 
extensibility and the load is then directly absorbed by the collagen fibres resulting in 
microtears and damage.  In particular, the collagen fibres start to slide past one another 
which disrupts the collagen cross-links.5,89  It should be noted that recently strain loads of up 
to 6% have been suggested to be physiological.233  The chronic accumulation of this damage 
over time has led to the suggestion that tendinopathy may be more degenerative than 
inflammatory in nature.233  Further pathological strain will overwhelm the reparative 
processes, and/or the maximum tensile load of the tendon, and will lead to complete failure 
















Figure 1.5: The relationship between stress and strain in tendons 
 [Reprinted from Riley et al. (2004)239 with permission from Oxford University Press] 
 
This mechanical overload model supports the observation that most ruptures are preceded 
by tendon degeneration78 and the higher incidence of tendinopathy with age and exercise, 
however it does not explain why certain areas of tendons are more susceptible to 
tendinopathy than others, nor spontaneous ruptures in patients with no history of 
exercise.233  The mechanical overuse model assumes that the structural micro-damage of 
the collagen fibrils is the primary cause of tendinopathy and that the cells of the tendon 
respond to this damage in an attempt at repair only after the micro-damage has occurred.  
This simple catastrophic model therefore implies that the cellular component of the ECM 
does not contribute to the mechanoresponse in the tendon during the early stages of 
tendinopathy to prevent micro-damage to the collagen fibril.  The “iceberg” theory, an 
integrated model described in 1.4.2.(iii)(h), is based on this assumption of micro-damage 
during the intitial stages of tendinopathy with a cellular response that occurs as a 
consequence of this micro-damage.  However, it is more likely that the tendon tissue, 
particularly the tenoctyes, responds to mechanical loading earlier than this through the 















physiological mechanical stimuli to biochemical responses and is comprised of three steps: 
(i) mechanocoupling, (ii) cell to cell communication and (iii) an effector response.151  Briefly, 
mechanical loading causes the deformation of cells of the tendon as they experience tensile 
force, and these mechanical signals are transformed into chemical signals both within and 
amongst cells of the tendon.  This chemical signal is transferred to other cells through cell-
signalling pathways and results in the distribution of the effects of the mechanical loading 
stimulus to cells which did not directly receive the stimulus.  Stimulated cells then interact 
with the ECM to effect repair and remodelling in adaptation and/or healing.151 
(b) Vascular insufficiency theory 
The vascular insufficiency theory acknowledges that tendons have a cellular component, are 
metabolically active and therefore require an adequate blood supply.  As the Achilles 
tendon has been shown to have a poor blood supply, it has been suggested that this is a 
major factor which hampers healing and results in a weaker tendon.9,233  In addition, blood 
flow in the tendon is further decreased during exercise and certain areas are therefore 
exposed to hypoxia.  The subsequent hyperemia at cessation of exercise may result in 
reperfusion injury.19,145  It has further been suggested that this reperfusion injury may 
enhance the production of reactive oxygen species and lead to oxidative damage in the 
tendon.145,176  Contrary to this, there is increasing evidence that neovascularisation is a 
contributing factor to AT.  In particular, a prospective trial of asymptomatic runners using 
power Doppler ultrasound found that the presence of intratendinous microvessels, 
indicative of neovascularisation, was a significant predictor of developing mid-portion AT 
within a year (OR 6.9, 95% CI:2.6-18.8; P=0.0001).113  This neovascularisation may however 
occur in response to repeated hypoxic episodes.  The vascular insufficiency theory may 
explain why the mid-portion of the Achilles tendon, which is proposed to be 
hypovascular,233 may be more susceptible to injury.  However, it should be noted that there 
is also evidence which suggests that blood flow is uniform along the length of the Achilles 
tendon.19  In addition, the limited vascular supply results in limited heat dissipation during 
exercise,5,31 and localised hyperthermia may therefore be the factor contributing to the 
development of AT.233  This model is not sufficient to explain all the histological and clinical 
features of tendinopathy, however it does suggest that secondary factors such as hypoxia, 















(c) Failed healing theory 
The failed healing theory is an extension of the mechanical overuse theory and proposes 
that overuse induced micro-damage may not stimulate the normal three-phase healing 
process – inflammation, proliferation, maturation - in tendons.61  Compromised healing then 
results in a pathological tendon with decreased tendon strength which is less able to 
respond to load.61  Fu et al. (2010)91 recently proposed a three-stage process for the 
development of tendinopathy which centres around failed healing.  Briefly, tendinopathy is 
initiated with an insult of various origin which results in damage to the collagen network.  A 
healing response is activated but fails to repair the tissue adequately, possibly due to 
unfavourable environments, genetic predisposition and/or hormonal and pharmaceutical 
factors.  The healing response is not only inadequate, but may also be i correctly diverted 
to an abnormal pathway.  Progressive degeneration of the collagen network will lead to the 
final stage which is the clinical presentation of either rupture or pain.  As in the mechanical 
overuse theory, this catastrophic model of tendinopathy assumes that the metabolically 
active cellular component of tendons only responds after damage has occurred. 
A number of theory’s (described below) take into account the contribution of the cellular 
component, and the secretion or release of chemoactive substances from these cells, in the 
development of tendinopathy. 
(d) Inflammatory theory 
Although the term “tendinitis” has now been widely abandoned, there is emerging evidence 
that chronic tendinopathy is not completely non-inflammatory.5,232,252  It is likely that much 
of the confusion around the role of inflammation in tendinopathy arises as a result of 
differences in the understanding of the term “inflammation”.  As inflammatory markers and 
mediators are not only involved in normal healing responses but also in several cell-
signalling pathways, this thesis refers to the up- and down-regulation of these inflammatory 
mediators in tendinopathy as dysregulated cell-signalling.  Although a traditional cellular 
immune response is not likely to be the primary underlying mechanism of tendinopathy, 
several inflammatory mediators in cell-signalling pathways are clearly dysregulated in 
tendinopathy.232,252  For example, cytokines are produced not only by inflammatory cells but 















shown to result in a histopathological profile that is similar to mild tendinopathy.252,274,276 
Interestingly, these inflammatory markers are increased in response to exercise.89  A recent 
study has shown an association of genetic variation within several components of the 
inflammatory pathway and AT.257  Allele combinations of five polymorphisms within the 
genes encoding interleukin-1β (IL-1β), interleukin-6 (IL-6) and the receptor antagonist of IL-
1β, interleukin-1ra (IL-1ra), were strongly associated with AT and therefore implicated this 
pathway in the pathogenesis of AT.257 
(e) Apoptosis theory 
Cytokine mediated apoptosis of tenocytes is normal in the healing process of tendon 
following overload, however excessive tenocyte apoptosis may disrupt the homeostasis of 
the ECM.205  High doses of cyclical strain have been shown to induce genes in both the 
oxidative stress and cartilage production pathways which ultimately leads to apoptosis, a 
more cartilaginous matrix and the loss of matrix integrity.253,306  In addition, an independent 
study found high levels of apoptosis in both non-insertional AT and rotator cuff 
tendinopathy.219,311  Recently, polymorphisms within the gene coding for caspase-8, which is 
involved in tenocyte apoptosis, were found to be associated with AT.205  
(f) Neuropeptide theory 
This theory proposes that chronic overuse results in excessive neural stimulation with a 
subsequent degranulation of mast cells and release of neurotransmitters such as substance-
P and glutamate.233,239,240  Increased levels of both substance-P and glutamate have been 
found in AT.11,240  Furthermore, recent evidence has shown that loading results in increased 
levels of endogenous substance-P preceding any tissue changes characteristic of tendinosis, 
and this increase in substance-P may be responsible for tenocyte proliferation.21,22  In 
addition, gene expression analysis has shown that loading induced increases in substance-P 
in tendons resulted in increased expression of COL3A1 and MMP3 mRNA as well as 
increased collagen remodelling.84,232  Interestingly, substance-P has also been implicated as 
a pro-inflammatory mediator.232  In summary, there is increasing evidence to support both a 















Although the inflammatory, apoptosis and neuropeptide theories take into account an initial 
mechanical stimulus as well as the effects of this stimulus on the metabolic and cellular 
components, it is not likely that any particular one of these cell-signalling pathways is the 
solo primary cause of tendinopathy.  It is more likely to be a combination of dysregulation in 
a number of pathways involved in cell-signalling and the healing response.  
(g) Pain in tendinopathy 
The traditional model of pain in tendinopathy is that (i) inflammation and (ii) separation of 
the collagen fibres are the causes of pain.89,150  However, inflammation is unlikely to be the 
cause of pain as inflammatory cells and markers are not always found in tendon tissue 
samples from patients experiencing chronic tendon pain.11,149  In addition, there is 
incongruity between collagen integrity and chronic pain.150  For example, there is no pain in 
donor sites during anterior cruciate ligament (ACL) reconstruction despite the excision of 
collagen.150  Khan et al. (2000)150 proposed a biochemical hypothesis for pain in patellar 
tendinopathy that attributed pain to biochemical irritants, such as glutamate and 
chondroitin sulphate, acting on nociceptors.  This is supported by the observation of higher 
glutamate levels in Achilles tendons with painful nodes,11 as well as recent findings that 
glutamate receptors are up-regulated and activated in tendinopathy.251   
(h) Integrative models 
While many models for the pathogenesis of tendinopathy have been proposed, they are not 
necessarily mutually exclusive.  It is highly likely that several mechanisms act synergistically 
in the progression of tendinopathy (Figure 1.6).  Mechanical loading results in several stimuli 
which are detected and mechanotransduced by tenocytes.  The thresholds at which each of 
these stimuli activate either an appropriate or pathological adaptation and healing 
responses is individual and probably influenced by intrinsic risk factors such as biomechanics 
and genetic variation.  An appropriate healing response will lead to repair, healing and 
adaptation.  An inappropriate or failed healing response is characterised by dysregulated 
cell-signalling, failed adaptation, degradation of the matrix and eventually injury.  The 


















Figure 1.6: Response to mechanical loading in tendon 
 
The “iceberg theory” is an integrative model first proposed by Fredberg et al. (2008)89 and 
supported by Abate et al. (2009)5 (Figure 1.7).  This model suggests that AT occurs as a 
continuum from physiological tendon to an overt clinical presentation of AT.5  Again, 
mechanical overuse is the primary inciting factor and leads to disruption of the collagen 
fibres and the simultaneous activation of healing and degenerative pathways.  If the 
conditions for optimal healing – adequate blood supply, adequate recovery time and 
absence of further overloading – are not met, the healing mechanisms are overwhelmed 
and fail.  Micro-damage accumulates in the tendon and the “pathogenetic cascade” of 
inflammation, degradation, neovascularisation and nerve proliferation is initiated.5  The 















proliferation at which glutamate levels are increased and the patient experiences 
symptomatic pain.  This pain is, therefore the “tip of the iceberg”.5,89  A short period of 
rehabilitation may allow the extent of damage to recede below the symptomatic threshold, 
but further loading before adequate healing will lead to relapse of symptoms.5,89  The 
thresholds for damage, repair and pain vary between individuals and are influenced by 
various intrinsic and extrinsic risk factors which results in a very individual susceptibility to 
the progression of AT. 
 
Figure 1.7: The "Iceberg" model of the pathogenesis of tendinopathy 
[Compiled with modifications from Fredberg et al. (2008)89 and Abate et al. (2009)5] 
 
Another integrative model proposed by Cook et al. (2009)62 suggests that tendinopathy is a 
continuum with different tendons, even different areas within one tendon, progressing back 
and forth between stages in response to treatment and interactions with various risk factors 
(Figure 1.8).  Briefly, when healthy tendon is subjected to acute tensile or compressive 
overload it initiates short-term adaptations that result in thickening of the tendon and 
increased stiffness.  Reactive tendinopathy is a non-inflammatory, proliferative stage 















the integrity of the collagen network is maintained and there are no neurovascular changes.  
Tendon properties may revert to normal if load is reduced and with sufficient recovery time.  
Further pathological loading leads to tendon disrepair, an attempt at healing characterised 
by increased matrix breakdown, an increased number of cells, increased protein production 
which results in separation of the collagen fibres and disorganisation of the matrix, as well 
as increased vascularity and neuronal ingrowth.  This stage has limited reversibility with load 
management and other treatment modalities.  At the furthest end of the continuum is 
degenerative tendinopathy in which the tendon has very little capacity to recover.  It is 
characterised by increased apoptosis, areas of acellularity and a vascularised, disordered 
ECM filled with matrix breakdown products.  It is becoming increasingly evident that the 
balance between matrix degradation and synthesis is disrupted in tendinopathy,64 and this 
model best captures the interplay between physiological adaptation of tendon to 
unaccustomed load and the progressive degeneration of tendon tissue as a result of the 
dysregulation of cell-signalling pathways and ECM homeostasis. 
 
Figure 1.8: The tendinopathy continuum as described by Cook et al. (2009)62  
 
1.4.3. GENE EXPRESSION IN TENDINOPATHY 
Ireland et al. (2001)125 reported a number of gene expression changes in chronic human AT.  
The expression of a large number of genes was up-regulated more than two-fold in 















disorders compared to normal cadaver specimens.  These included, amongst others, 
collagen types I and III, tenascin-C, thrombospondin-2 and biglycan, as well as MMP-2, 
MMP-9 and MMP-14.  MMP-3 mRNA was down-regulated in degenerate samples.  As 
proteoglycans are one of MMP-3’s many substrates, decreased MMP-3 activity may account 
for the increase in proteoglycans seen in AT.  In addition, proteoglycan expression decreases 
with age in normal tendon, however in chronic tendinopathy there is increased expression 
of proteoglycans, particularly aggrecan and biglycan.64  Aggrecan has been shown to be 
expressed at a six-fold higher level than versican, an expression ratio opposite to that seen 
in normal tendon.64  These observations support the increasing evidence that suggests the 
balance between ECM synthesis and breakdown is disturbed during remodelling in 
tendinopathy.64,125  Interestingly, there was no increase in expression of several markers for 
inflammatory cells (lymphocytes, monocytes and granulocytes), nor for other markers of 
cytokine mediated inflammation.  However, the degenerate tissue samples examined in this 
study were taken from tendons in a very late stage of chronic tendinopathy.   
Jelinsky et al. (2011)133 recently investigated gene expression in human tendinopathy and 
found 983 mRNA transcripts, across many different biological pathways, to be differentially 
regulated in tendinopathy.  Of particular interest for this thesis was the significant increase 
in expression of the TNC (5.3 fold, P<0.001), COL3A1 (2.0 fold, P<0.05), COL5A1 (2.0 fold, 
P<0.05), COL5A2 (2.1 fold, P<0.005), COL5A3 (2.0 fold, P<0.005) and COL27A1 (2.5 fold, 
P<0.005) genes.  Whilst most MMPs were differentially up-regulated in diseased tendons, 
MMP-3 was again shown to be down-regulated in tendinopathy (0.3 fold, P=0.055).  In 
addition, there was some evidence for the differential regulation of inflammatory cytokines 
and the IL-6 pathway in tendinopathy, although the inflammatory pathway as a whole was 
not implicated.  It should again be noted that the tendon samples investigated in this study 
were from tendons with late stage disease.  Similar results were reported by Pingel et al. 
(2012),221 who observed an increase in the expression of collagen types I and III, as well as 
tenascin-C, in tendinopathic areas compared to a healthy area of the same Achilles tendon.  
There were, again, no observed changes in the expression of inflammatory markers in the 















In summary, gene expression analyses consistently show increased expression of type I, type 
III and type V collagen in tendinopathy, despite a decrease in total collagen content.  In 
addition, the ratio of type III to type I collagen is also increased.306  There is increased 
expression of several proteoglycans and most MMPs, except MMP-3 which is down-
regulated in tendinopathy.  There are no changes in expression of cytokine mediated 
inflammatory markers in late stage tendinopathy. 
1.5. RISK FACTORS FOR ACHILLES TENDON PATHOLOGY 
Although, the exact aetiology of tendon injuries is not well defined it is well accepted that 
tendinopathy is a complex condition influenced by several extrinsic and intrinsic factors.255  
Intrinsic risk factors, which influence risk from within, together with exposure to extrinsic 
risk factors, which influence risk by acting outside the body, determine an individual’s 
susceptibility to developing disease.59  There are varying levels of evidence that these 
factors influence an individual’s risk of developing AT and the evidence supporting the 
inclusion of various traits and factors as recognised risk factors for AT is briefly reviewed 
below.   
For the purposes of this thesis, level of evidence is evaluated using a modified version of the 
guidelines for prognostic studies outlined by Slobogean et al. (2012)267  Level of evidence 
was described as strong, limited or weak.  Strong evidence includes level I studies: well 
conducted prospective cohort studies which control for bias and confounding factors, and 
systematic reviews of level I studies.  Limited evidence includes level II and III studies: 
retrospective studies, cross-sectional studies, prospective cohort studies with issues of bias 
and confounding, case-control studies, meta-analyses and systematic reviews of level II 
studies.  Weak evidence includes level IV and V evidence: case reports, case series and 
published expert opinion.   
Level of certainty is a more subjective evaluation based on the guidelines described by the 
U.S. preventative services task force (2007).248  Level of certainty is described as high, 
moderate or low.  High certainty is assumed when the evidence includes consistent results 
from well-conducted and well-designed studies in appropriate populations.  Where level of 















review.  Moderate certainty is assumed where confidence in the available evidence is 
limited by the number, size or quality of studies, the repeatability of findings, and the use of 
inappropriate populations.  Low certainty is assumed where the evidence is limited by the 
number and size of studies, flawed study design and inconsistent findings.  Where the 
evidence is deemed to be of moderate or low certainty, future studies may alter the 
conclusions of this review.   
The level of evidence and level of certainty for each risk factor is summarised schematically 
at the end of this chapter (Figure 1.10).  The evidence reviewed below may relate to AT, ATR 
or other tendinopathies and tendon injuries, however the level of evidence and certainty is 
evaluated based only on the evidence for being a risk factor for AT. 
1.5.1. EXTRINSIC RISK FACTORS 
1.5.1 (I) CYCLIC LOADING AND SPORT 
Physical training and exercise are important to tendon health as physiological loading 
induces short term adaptations which increase the stiffness, tensile strength and maximum 
static strength of tendons.42,154,208  There is evidence to suggest that increased activity leads 
to increases in type I collagen turnover with net formation, and that prolonged activity will 
therefore result in increases in tendon tissue and strength.154  Conversely, immobilisation 
leads to decreases in collagen synthesis and increased MMP activity which results in 
collagen degeneration and decreases in tensile strength.154,208  These effects result from the 
activation of several signalling pathways by the mechanotransduction of force to a 
biochemical stimulus through integrins, growth factors, inflammatory and vasoactive 
substances, and subsequently changes in gene expression.154,294 
Although tensile load has anabolic effects on tendon tissue, it also has catabolic effects.62  In 
particular, load-induced strain is thought to be the chief mechanical factor in initiating the 
accumulation of tendon damage and, eventually, injury.304  In a 2008 systematic review of 
the available knowledge of tendinopathy, Xu et al. (2008)306 suggested that repetitive 
loading induced expression of genes in both the cartilage gene pathway and the oxidative 
stress pathway.  This leads to apoptosis of tendon cells, a more cartilaginous tendon matrix 















important factors in initiating tendinopathy.62,132,239 A review of the effects of exercise on 
tendon properties suggests that biochemical, biomechanical and structural tendon 
properties respond not only to the absolute load, and its resultant strain, but more so to the 
number of loading cycles.42  In addition, cyclically loaded Achilles tendons were found to 
reach failure significantly faster than would be predicted by time dependant damage 
alone.304 Logically then exposure to elements of training and exercise that influence either 
volume or frequency of loading, such as intensity, running speed, number of repetitions and 
hill running, will influence risk of developing AT.132,159,239,306   
Certain sporting codes have also been shown to result in a high prevalence of Achilles 
tendon injuries.  In a retrospective study of ATR in a Danish population, 46.3% and 23.3% of 
ruptures occurred while playing badminton and soccer (football) respectively, with handball, 
volleyball and athletics contributing to 24.6% of ruptures.121  In a Canadian population, 75% 
of ruptures occurred during sporting activities with soccer (11.8%) and volleyball (9.6%) 
having the highest prevalence.275  A 1987 cross-sectional study of 180 runners with injuries 
reported that 65% of these runners were long-distance runners, and that Achilles 
“tendinitis” was the third most prevalent diagnosis (11%).127  A more recent retrospective 
cohort study of elite male Finnish athletes showed that 42% of middle- and long-distance 
runners developed AT before the age of 45 years compared to 3% in an active control group 
(OR 31.2, 95% CI:13.5-71.8; P<0.001), while sprinters sustained ATR more often than active 
controls (OR 14.9, 95% CI:4.35-50.7; P<0.001).159  Differences in the sporting codes most 
associated with AT and ATR may reflect differences in national sporting cultures and 
preferences but, in general, sports which involve fast changes in direction and bursts of 
power are associated with tendon ruptures while sports such as running, which involve 
repetitive actions, are associated with tendinopathy. 
In summary, there is a large volume of research at the tissue and molecular level describing 
the effects of exercise and physical activity on tendon tissue properties.  It is clear that long-
term cyclic loading affects tendon properties.  However, many of these studies involve in 
vitro studies of tendon specimens from acutely overloaded animal models or human 
cadavers.154  These studies provide valuable information of the basic physiology, or 















exercise.154  To the authors knowledge, there are no prospective cohort studies specifically 
designed to investigate repetitive and/or excessive loading as a risk factor for AT.  However, 
exercise, particularly running, is often used as an inciting factor in prospective studies of 
other potential risk factors for AT.  Therefore, although there is only limited evidence 
directly associating exercise, specifically middle- and long-distance running, as risk factors 
for AT, it is of high certainty. 
1.5.1 (II) TRAINING ERRORS 
Training errors are repeatedly listed as risk factors for AT.132,145,239  In a 1978 observational 
study of 180 runners with injuries by James et al.,127 60% of injuries were associated with 
training errors.  These included excessive mileage, high intensity workouts, rapid changes in 
training routine, hill running and running on hard surfaces.  As the methodology behind this 
study is not outlined, it is hard to draw conclusions from these findings.  There is a scarcity 
of further evidence to support these claims and, therefore, the level of evidence for training 
errors as an independent risk factor for AT is weak and of a low certainty.  It is more likely 
that these factors influence the volume and frequency of loading (reviewed in 1.5.1(i)), or 
are accompanied by biomechanical risk factors (reviewed in 1.5.2(vii)). 
1.5.1 (III) TRAINING SURFACES 
Training surface is also often cited as a risk factor for AT.132,239  In particular, there is concern 
over the effect on injury risk of artificial playing surfaces compared to natural turf i.e. grass.  
A prospective study of two cohorts over two football seasons showed no difference in the 
incidence of muscle/tendon injuries sustained during either training or match play on 
artificial turf versus grass surfaces.92,93  Furthermore, a recent systematic review of injury 
rates in all football codes (rugby union, soccer, American football) provided strong evidence 
that the injury rate on modern artificial turf was comparable to that on natural surfaces.301  
The only possible exception to this was in the incidence of ankle injury which may be higher 
when playing on artificial turf.  It should however be noted that these studies do not 
specifically investigate AT, and there is some evidence to suggest that playing football on 















There is, however, more evidence to support running surface as a risk factor for injury.  Two 
independent cross-over studies on recreational runners have reported differences in 
maximum in-shoe plantar pressure on different running surfaces.  Tessutti et al. (2012)278 
reported 16% less peak pressure in the rear foot and lateral forefoot when running on grass 
versus asphalt, concrete and rubber (P<0.005).  Wang et al. (2012)295 reported an increase in 
maximum plantar pressure when running on concrete compared to natural grass (95% 
CI:8.5-91.7 kPa; P=0.016).  Although there were no differences in maximum plantar force, 
the contact time on grass was significantly longer (95% CI:4.4-32.6 ms; P=0.017).  Similar 
results were found in another study by the same group comparing treadmill running to 
running on concrete and grass.117  Total foot maximum plantar pressure was again found to 
be higher when running on concrete compared to grass (95% CI:22.97-93.08 kPa; P<0.0017), 
with no difference in maximum plantar forces between grass and concrete.  In addition, the 
maximum plantar pressure across the total foot was found to be lower for treadmill running 
compared to running on concrete (95% CI:29.11-116.42 kPa; P<0.0017) and the total foot 
maximum plantar force was found to be decreased during treadmill running compared to 
both grass and concrete (P<0.0017). 
In summary, there is strong evidence of high certainty that different running and playing 
surfaces affect pressure loads across the plantar foot, however there is also strong evidence 
of high certainty that there is no difference in injury rates when playing on artificial turf 
compared to grass.  To the authors’ knowledge, there is no research comparing incidence of 
AT when running on harder surfaces compared to grass or treadmills.  Training surface can 
therefore not be included as a risk factor for AT at this stage. 
1.5.1 (IV) ENVIRONMENTAL CONDITIONS 
Exercise in extreme heat or cold, humidity, strong wind and at altitude have all been listed 
as risk factors for developing AT.132,197,239  However, with the exception of cold weather 
training, little evidence exists to support these as independent risk factors, and they may 
actually exert their effect on risk of developing AT via the associated alterations in exercise 
intensity.  A prospective study of 1500 military recruits reported a significant effect of 
training season on the incidence of AT, with more recruits developing AT in winter 















with paratenonitis, the authors hypothesized that cold weather adversely affected the 
viscosity of the muccopolysaccharide lubrication of the paratenon during exercise.  There is 
therefore strong evidence to support cold weather training as a risk factor for AT however, 
as there is only one study reporting this association, the level of certainty is low. 
1.5.1 (V) FOOTWEAR 
The issue of footwear as a risk factor for injury comes in two separate debates: (i) whether 
barefoot/minimalist running is more beneficial than shod running and, (ii) if different types 
of footwear in shod running will affect injury incidence.   
The recent trend for runners to change to barefoot or minimalist shoe running and its effect 
on injury risk is a hotly contested debate.  There is a lack of prospective and controlled 
research in this area to support either side of the argument.  Briefly, the argument for 
barefoot, or minimalist shoe, running is that it encourages a forefoot strike pattern which 
results in decreased impact loading and a shorter stride length compared to shod running 
which encourages a rear foot strike pattern.13,241  Current research suggests that the effect 
on injury risk largely depends on an individual’s ability to transition to a forefoot strike in 
barefoot running, however there is currently no strong evidence that barefoot running 
reduces injury risk in general, or AT in particular.13,241 
Type of footwear is also often listed as a risk factor for developing AT.132,239  Rowson et al. 
(2010)245 recently tested the effects of footwear on tendon loading in cadaveric human 
Achilles tendon.  Wearing high-top athletic shoes was found to decrease the peak tension in 
the Achilles tendon by 9.9% compared to low-top athletic shoes (P=0.0002), and well-tied 
laces decreased peak tension a further 12.8% (P=0.0006).  In addition, wearing well-tied 
high-top athletic shoes decreased the peak dorsiflexion angle by 7.2% compared to low-top 
shoes.  It is suggested that well-tied laces ensure that the shoe cannot move independently 
of the foot and, together with the high-top shoes, allow more force to be transferred to the 
shoe rather than being transferred into the foot and tendons. 
Whilst there is limited evidence that footwear, either the lack thereof or different types 
thereof, will affect the biomechanics and force distribution across the foot, there is 















different perspective, footwear orthotics and in-soles can be used to correct biomechanical 
faults or malalignments which may predispose to injury.244 
1.5.1 (VI) SMOKING 
A retrospective study of 1115 male Royal Marine recruits found a significant difference in 
smoking status prior to the training programme in injured and non-injured recruits (RR 1.7, 
95% CI:1.2-2.8; P<0.01).202  This study did not distinguish between injury mechanism or 
diagnosis but reported only on overall injury.  A similar study on 2002 army recruits, 
however, reported that recruits who had smoked at least one cigarette in the month prior 
to the start of basic training subsequently sustained more overuse injuries (P<0.01).12  
Interestingly, the proportion of recruits who suffered from “tendinitis” was higher in the 
smokers when compared to the non-smokers, although this observation was not statistically 
significant.  Contrary to this result, a cross-sectional study of medical risk factors for AT 
reported less smokers in patients with chronic AT when compared to healthy athletes (OR 
0.2, 95% CI:0.1-0.4; P=0.001).157  
There are substantial confounding factors to consider when investigating the influence of 
smoking on injury risk.  In particular, runners and active individuals are more likely to adhere 
to a healthy lifestyle which does not include smoking, whereas smoking may be an 
indication of a less healthy lifestyle which could be associated with other potential risk 
factors such as inactivity or risk taking behaviour.12  In summary, there is limited evidence of 
low certainty that smoking, or a history of smoking, is a risk factor for injury, but not 
specifically AT.  There is no evidence that directly supports smoking as an independent risk 
factor for AT. 
1.5.1 (VII) MEDICATIONS 
(a) Statins 
Statins are 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors used as a therapy 
for lowering serum cholesterol and low density lipoprotein levels.187  A 2008 retrospective 
meta-analysis reported 96 cases of statin-attributed tendinous manifestations which 















attributed to statin use based on a combination of (i) a temporal relationship between the 
onset of symptoms and initiation of statin therapy, (ii) improvement in symptoms after 
cessation of statin therapy and (iii) recurrence of symptoms after statin therapy was 
reinstated.  Specific diagnoses were “tendinitis” (65.6%) and tendon rupture (34.4%), and 
the Achilles tendon was the most frequent site of injury accounting for 52.1% of the 96 
cases.  Furthermore, a 2001 case report presented four patients who specifically developed 
tendinopathy after statin treatment.48     
The mechanisms for statin toxicity in tendons are still not clear although several hypotheses 
have been suggested.  As cholesterol is an important component of cell membranes, Marie 
et al. (2008)187 suggest that statins may result in the destabilisation of cell membranes.  In 
addition, statins may decrease levels of regulatory proteins within the tendon, and increase 
levels of apoptosis.187    It has subsequently been reported that statins inhibit MMP-9 and 
enhance the activity of TIMP-1 in macrophages which would influence tendon remodelling 
and repair.29,229,262  Furthermore, the effects of statins on prostaglandin E2, which is involved 
in the development of tendinopathy due to repetitive loading, and leukotriene B4 activity 
have been implicated in statin-induced tendinopathy.55,262  Although a rare complication, 
there is limited evidence to suggest statin use as a risk factor for AT with a moderate 
certainty. 
(b) Anabolic steroids 
Anabolic androgenic steroids (AAS) are prohibited, performance enhancing drugs that are 
widely used in certain sporting codes.188  They have been linked to increased risk of 
musculotendinous injury, particularly tendon ruptures, in a number of reviews and case 
studies.132,167,171,292  In particular, case reports of very rare simultaneous bilateral quadriceps 
tendon rupture171 and bilateral avulsions of the biceps tendon292 identified AAS abuse as a 
predisposing cause.  Interestingly, another case report presented a 35-year old male with a 
history of over-the-counter oral androstenediol supplementation who suffered 
asynchronous bilateral Achilles tendon ruptures in the month following supplementation.25  
The association of AAS use with tendon injury was, however, not supported by a 
questionnaire based study of retired NFL players which found that AAS use was not 















AAS use combined with exercise in rats has been shown to result in large pathological 
changes in tendon tissue including changes in contractility and crimp morphology, collagen 
dysplasia, decreases in collagen degradation, increased synthesis of type I collagen and 
decreased tensile strength.124,167,188,218  Whilst there is substantial evidence that AAS use is 
pathological to tendon tissue in rats, and to a lesser extent humans, there is currently only 
weak evidence of low certainty to support it as a risk factor for AT.  The conduction of 
randomised controlled trials (RCT) and prospective studies on the effects of AAS use on 
injury risk is complicated by the ethical and legal issues around its use. 
(c) Oral Contraceptives and HRT 
The use of oral contraceptives (OC) and hormone/oestradiol replacement therapy 
(HRT/ERT) in women has been suggested as a risk factor for developing tendinopathy.116,306   
A cross-sectional study of 82 patients with symptomatic AT compared to two control groups 
reported a higher prevalence of both HRT (P=0.01) and OC (P=0.001) use in women with 
AT.116  Several case-control studies of healthy pre-menopausal and post-menopausal 
women have shown that circulating oestradiol (the predominant oestrogen) has significant 
effects on collagen synthesis in tendon.41,102,103,104  In particular, use of OC attenuated the 
exercise induced increase in collagen synthesis in the tendon either as a direct effect of 
circulating oestradiol, or an indirect effect of reduced levels of free IGF-1.103,104  The long 
term attenuation of endogenous plasma oestrogen in users of the monophasic OC pill was 
found to significantly decrease compliance of the Achilles tendon which may have 
implications for risk of injury.41  In addition, long term HRT in post-menopausal women 
stimulates collagen turnover at rest in a dose dependant manner and results in decreased 
stiffness of tendon during mechanical loading.102  There are currently, however, no 
prospective studies on the effect of either OC or HRT on AT incidence or risk, therefore the 
level of evidence for OC and HRT use as risk factors for AT is limited and of low certainty. 
(d) Fluoroquinolone antibiotics 
Fluoroquinolones are a class of synthetic broad spectrum antimicrobial drugs commonly 
used to treat infections in adults.46,172  They inhibit bacterial deoxyribonucleic acid (DNA) 
replication and have a significant ability to act against anaerobic bacteria.53  These drugs are 















common urinary and respiratory tract infections, as well as complicated skin 
infections.148,172,303  Fluoroquinolone associated tendinopathies were identified in the early 
1980’s and have been shown to occur at an incidence of 15-20 per 100 000 patients, 
predominantly in males.46,53,100  It should however be noted that females may be at a higher 
risk of sustaining quinolone induced tendon ruptures.303  In a nested case-control study by 
van der Linden et al. (2002),286 the adjusted relative risk of Achilles tendon disorders with 
use of fluoroquinolones was 1.9 (95% CI:1.3 to 2.6).  In patients aged 60 or over this risk 
increased to 3.2 (95% CI:2.1 to 4.9) and concomitant use of corticosteroids in this age group 
increased the risk to 6.2 (95% CI:3.0 to 12.8).  This supports the concept of “synergistic 
toxicity” in patients undergoing simultaneous fluoroquinolone and corticosteroid therapy.148  
In a review of the literature describing fluoroquinolone associated tendinopathy, Khaliq et 
al. (2003)148 found that 37.0% and 25.5% of cases followed treatment by pefloxacin and 
ciprofloxacin respectively.  The most commonly affected tendon was the Achilles, 
accounting for 89.8% of cases, 44.3% of which were bilateral injuries.  The mean latency 
period till the onset of symptoms was 17.6 ± 19.5 days, with 50% of cases occurring within 6 
days and several reports described prolonged recovery periods for the tendon injury.  Prior 
use of corticosteroids was found in 32.7% of tendinopathy cases and 52.5% of ruptures.  
These findings are consistent with initial reports.46,100,172,213.  There is consistent limited 
evidence to suggest with high certainty that fluoroquinolone treatment is a risk factor for AT 
and ATR. 
The mechanism underlying fluoroquinolone associated tendon injury is not clear but 
influences on ischaemia and vascularity, proteoglycan synthesis and matrix degradation 
have been implicated, as well as the generation of reactive oxygen species and increases in 
cytotoxicity and necrosis.46,53,148  Toxicity may be related to molecular structure as the most 
toxic fluoroquinolones share a similar structure.148  Evidence suggests that renal transplant 
patients and patients suffering from other metabolic conditions which affect renal drug 
clearance may be further predisposed to fluoroquinolone associated tendon injuries.148  
(e) Corticosteroids 
Corticosteroid, particularly glucocorticoid, injections are commonly used to treat tendon 















intratendinous corticosteroid injections.63,192,206,263,273  Systematic reviews have consistently 
concluded that there is insufficient evidence to support or refute the efficacy of 
corticosteroid injections in the treatment of tendon lesions given the potential for 
complications, including tendon rupture.63,192,206,263,273  In particular, a 2010 systematic 
review of RCTs of corticosteroid treatment for tendinopathy concluded that, although there 
was a large beneficial short-term effect, the long-term outcome was worse than that 
achieved with more conservative treatments.63  The efficacy of glucocorticoid treatment is 
in fact influenced by the underlying pathology of the tendon injury, and it will likely only be 
effective if inflammation, not degeneration, is the underlying cause.192  In addition, there is 
lack of consistency regarding the effects of glucocorticoid treatment on the biomechanical 
properties of tendon in both human and animal studies.206,254  A systematic review by 
Nichols (2005)206 reported some evidence that local injection of corticosteroids acutely 
reduced tendon strength to failure, reduced tendon stiffness and induced histological 
evidence of tendinopathy.  However, these findings were not consistent, with some studies 
reporting no deleterious effects of corticosteroid injection.  In a study on cultured rat 
tenocytes, corticosteroid (dexamethasone) treatment was found to reduce tenocyte 
number and collagen synthesis in a dose-dependent manner.254  In addition, the 
concomitant use of corticosteroids increases the risk of suffering fluoroquinolone induced 
tendinopathy (reviewed above).148,286,303  In summary, corticosteroids are catabolic, inhibit 
the synthesis of collagen and are consistently linked to tendon injury.53,132,206,208  There is 
however limited evidence of moderate certainty linking corticosteroid treatment to AT and 
ATR. 
1.5.2. INTRINSIC RISK FACTORS 
1.5.2 (I) AGE 
As medical care improves and physicians encourage cardiovascular fitness at all ages, the 
elderly population is remaining active for longer and therefore at risk of sustaining physical 
activity related soft tissue injuries.74,75  Age is often listed as an intrinsic risk factor for AT 
and ATR.53,116  However, not only the elderly are at higher risk of tendon injury, certain age 
groups are associated with a higher prevalence of AT and/or ATR.  In a retrospective study 















related ruptures in particular occurred almost exclusively between 30 and 49 years of age, 
while non-sport related ruptures peaked between 50 and 59 years of age.  These results are 
similar to those found in a Canadian population.275  The mechanism of rupture therefore 
appears to be different between younger and older patients.121,275  In a cross-sectional 
study, the highest incidence of AT in the general Dutch population was found in the 21-40 
and 41-60 year age groups.68  In particular, the incidence rate of AT was highest for females 
in the 21-40 year age group and highest for males in the 41-60 year age group.  
Interestingly, the incidence rate was substantially lower for adults over the age of 60 years, 
than for the younger age groups.  There is therefore limited evidence of low certainty that 
older adults are at higher risk of ATR and AT. 
Age related changes in tendon properties may explain the higher incidence of ATR and AT in 
older adults.  An early, but very informative, review of the ageing tendon states that the 
rate of ageing is highly individual but that tendon tissue is particularly susceptible to early 
ageing.282  Age-related cellular changes within the tendon include decreased density and 
activity of tenoblasts, although it should be noted that rabbit tendon stem cells do not lose 
their ability to repair tendon with age.74,282  Within the ECM and collagen network, ageing 
results in decreased extracellular water and muccopolysaccharide content, decreased GAG 
content and an increase in the total collagen content.282  There is a decrease in collagen 
turnover and collagen fibres increase in diameter to varying degrees.282  In particular, ageing 
affects the cross-linking profiles of collagen.78,282  Collagen cross-links are subject to non-
enzymatic glycation by the reduction of circulating sugars.23  This results in permanent 
modifications to the protein cross-links which are known as advanced glycation end 
products (AGEs) such as pentosidine.  After maturity, AGEs accumulate with age which is 
indicative of decreased collagen turnover.  The amount of permanent cross-linking increases 
with age up till maturity (approximately 30 years of age) and then gradually decreases.23,66,78  
Cross-linking affects the physical properties of collagen fibres, and therefore tendon, and an 
increase in permanent cross-links results in increased stiffness of the tendon as well as a 
decrease in maximum strain and load.23,75,282  In addition, the Achilles tendon has little 
ability to adapt to mechanical loading after maturity and therefore accumulates 
microtrauma.269  Considered in conjunction with the age-related decline in mechanical 















however be noted that it has been suggested that these changes are not intrinsically age-
related, but rather a secondary response to tendon injury and microtrauma.23 
1.5.2 (II) SEX 
In two retrospective studies on the epidemiology of ATR, males were three to four times 
more likely to suffer ATR than females.121,275  Suchak et al. (2005)275 reviewed the incidence 
of ATR and found the male to female ratio to be between 1.7 and 6.3, but predominantly 
higher than 3.0, and male sex is repeatedly reported as a risk factor for both ATR and 
AT.116,131,132,157  In a cross-sectional study of 298 healthy participants, asymptomatic Achilles 
tendon pathology was found at a higher prevalence in males (13%) compared to females 
(5%)(P=0.007, χ2 7.189).94  However, a retrospective study of AT in the general Dutch 
population found that total incidence rates for males and females were not different,68 and 
a prospective clinical trial of 648 runners found no association between gender and risk of 
developing AT.113    Females have, however, been found to be at higher risk for other 
connective tissue injuries.153,201  In particular, females were found to have a higher incidence 
of sports related ACL ruptures when injuries from male-only sports were excluded.201  
Nevertheless, there is limited evidence of low certainty that male sex is a risk factor for AT. 
Oestrogen is suggested to play an important role in the homeostasis of female connective 
tissue and oestrogen receptors have been identified in human tendons.106  A cross-sectional 
study of six males and six females found that oestradiol attenuates the exercise induced 
increase in collagen synthesis, and that collagen fibres from male tendon had a higher 
ultimate stress (P<0.05).181  As previously described, several studies on the effects of oral 
contraceptives and HRT on collagen and tendon properties suggested that synthetic 
oestradiol inhibits collagen synthesis in response to exercise, but increases collagen 
synthesis at rest in post-menopausal women.41,102,103,104 The seemingly contradictory 
evidence for the effects of oestrogen (particularly oestradiol) on tendon properties has been 
succinctly summarised by Kjaer and Hansen (2008).153  They suggest that endogenous 
oestrogen has a homeostatic effect on collagen synthesis by stimulating collagen synthesis 
at rest but attenuating any exercise-induced increase.  This is corroborated by evidence that 
the Achilles tendons of trained women have a smaller cross-sectional area when compared 















predominantly in overall suppression of collagen synthesis.  This results in women having a 
slower adaptive response to mechanical loading but may allow them to more robustly 
withstand periods of inactivity and detrimental perturbations.   
1.5.2 (III) ADIPOSITY 
A cross-sectional study of 82 patients with asymptomatic AT compared to two control 
groups reported a higher prevalence of obesity in both males (P=0.001) and females 
(P=0.025) with AT.116  In a systematic review of the relationship between adiposity and AT, 
exactly half of the included studies (n=28) showed a positive association while the other 14 
studies reported no significant association between adiposity and AT.96  Two possible 
mechanisms for this tentative association are suggested, (i) a mechanical and (ii) a systemic 
hypothesis.96  The mechanical hypothesis proposes that tendons, particularly weight bearing 
tendons, are exposed to higher loads in heavier individuals and this results in tendinopathy.  
It should, however, be noted that similar distributions of positive and negative associations 
with adiposity were found in studies on upper and lower extremity tendinopathy when one 
would expect this relationship to be more evident in weight-bearing tendons of the lower 
extremity.  It is therefore clear that mechanical loading does not fully account for the 
association between adiposity and tendinopathy.  The systemic hypothesis proposes that 
bioactive peptides released from adipose tissue may influence the integrity of tendon 
directly, or indirectly by altering the metabolic milieu.  This review did however report a 
significantly higher number of positive associations found in studies on clinical patients and 
case-control studies in which patients are recruited from specialist centres after referral, 
often because they are not responding to treatment.  It is therefore possible that the 
association between adiposity and AT observed in these studies may actually reflect 
increased adiposity as a consequence of tendinopathy, or adiposity as a factor limiting 
recovery.  In order to address the confounding issue of pain leading to inactivity and weight 
gain, Gaida et al. (2010)94 recently investigated fat distribution in asymptomatic tendon 
pathology in a large cross-sectional study of otherwise healthy Swedish and Australian 
participants.  Men with asymptomatic tendon pathology were found to have a more central 
distribution of fat, while women with asymptomatic tendon pathology were found to have a 
more peripheral distribution of fat.  The highest prevalence of asymptomatic tendon 















than 83cm.  There is therefore limited evidence of moderate certainty that adiposity, and 
particularly fat distribution, is a risk factor for AT. 
1.5.2 (IV) PREVIOUS INJURY 
A retrospective follow up of 168 patients with ATR reported an increased risk of an acute 
rupture of the contralateral tendon within four years compared to the general population 
(OR 176, 95% CI:70-282; P<0.001).16  In a cross sectional matched pair analysis, 37% of 
patients with an acute ATR were reported to have a positive history of chronic AT before the 
rupture,157 and 41% of patients diagnosed with acute/subchronic AT suffered from 
symptoms on the contralateral side within eight years.215  A recent prospective clinical trial 
on the prognostic value of power Doppler ultrasound in 634 asymptomatic runners found 
that pre-existing healed Achilles tendon disorders were a significant risk factor for the 
development of mid-portion AT within one year (OR 3.8, 95% CI:1.7-8.5; P=0.0014).113  In 
addition, a prospective study of 54 Danish soccer players showed a significantly higher 
prevalence (n=5; 45%) of symptomatic AT at the end of the season in those who had 
asymptomatic tendinopathic features on ultrasound at the beginning of the season (n=11) 
(P<0.05).88  Although the subject numbers may have been small in this study, considered in 
conjunction with the other evidence, there is strong evidence of a high certainty that 
previous injury of the Achilles tendon is an independent risk factor for AT, and probably 
ATR. 
1.5.2 (V) DECREASED BLOOD SUPPLY TO TENDON 
Ischaemia and hypoxia have previously been suggested as risk factors for AT and ATR.132,145  
However, a case-control study of laser Doppler flowmetry in chronic AT reported a higher 
blood flow in symptomatic tendons than in controls, with both groups displaying a similar 
reduction in blood flow to the Achilles tendon in response to exercise.18  In addition, a 
recent prospective clinical trial screened 634 asymptomatic runners with power Doppler 
ultrasound and found that the presence of intratendinous microvessels, indicative of 
neovascularisation, was a significant risk factor for developing mid-portion AT within a year 
(OR 6.9, 95% CI:2.6-18.8; P=0.0001).113  Blood flow in the tendon is decreased during 
exercise and certain areas are therefore exposed to hypoxia which may result in reperfusion 















injury sustained following contraction may enhance the production of reactive oxygen 
species and lead to oxidative damage in the tendon.145,176  The Achilles tendon may be 
particularly prone to this as the tendon spirals by approximately 90° during use, causing a 
“wringing” of the tendon and vascular constriction.280  Although several case studies have 
reported the occurrence of ATR following ischaemia,126,264 there is no further evidence that 
ischaemia or hypoxia are risk factors for AT or ATR.  There is however strong evidence of 
moderate certainty that neovascularisation observed during power Doppler ultrasound is an 
independent risk factor for AT.  
1.5.2 (VI) TENDON TEMPERATURE 
Tendons are not perfectly elastic and some energy is lost as heat (hysteresis) during 
exercise.  Blood supply to the tendon is not sufficient to dissipate the heat generated and 
the temperature of the tendon therefore increases.31  Wilson et al. (1994)302 recorded peak 
intra-tendinous temperatures of 43-45°C in equine SDFT during a sustained gallop and it was 
suggested that this exercise induced hyperthermia may result in tendon degeneration.302  
However, these temperatures were found to be unlikely to result in cell death in cultured 
equine SDFT fibroblasts.31  Tendon fibroblasts were in fact found to be more resistant to 
hyperthermia than other fibroblast lines, although repeated exposure to hyperthermic 
conditions may compromise cell functioning.31  Farris et al. (2011)80 collected ultrasound, 
kinetic and kinematic data from 12 males and used a mathematical model similar to that 
used by Wilson et al. (1994)302 to predict the core temperature of human Achilles tendon 
during treadmill running.  A conservative estimate of a core temperature of 41.4°C during 
running was calculated.  It should, however, be noted that hysteresis and stiffness, both 
variables that influence the calculation, were highly variable between individuals and were 
significantly negatively correlated.  It is therefore possible that differences in mechanical 
tendon properties may predispose some individuals to greater thermal damage.80  However, 
there are currently no studies directly linking tendon hyperthermia with AT. 
1.5.2 (VII) BIOMECHANICAL FACTORS 
The list of lower limb malalignments and biomechanical factors that have been suggested as 
risk factors for AT and other musculoskeletal disorders is long.  The malalignments include 















hypopronation, tibia vara, genu valgum and varum, a high- or low-riding patella and femoral 
neck anteversion.145,293  Other factors include leg length discrepancy, muscle weakness and 
imbalances, decreased flexibility and joint laxity.145 
During gait, the foot strikes the ground in a supinated position, pronates and then supinates 
again at toe-off.  During pronation, the foot is everted, abducted and dorsiflexed, while 
during supination the foot is inverted, adducted and plantar-flexed.127  This results in a 
“bowstring” or “whipping” action which creates shear forces across the Achilles tendon 
during gait.191,250  Hyperpronation may result from forefoot varus, leg length discrepancy, 
lax ligaments or muscular imbalances in the gastrocnemius and soleus muscles, and results 
in an exacerbated “whipping” action during gait.145  At midstance the foot is pronated and 
the knee extended which results in contradictory rotational forces across the Achilles 
tendon.250  If the foot then remains in a pronated position it may result in wringing of the 
tendon.191  This theory was however, not supported by a recent systematic review of 
prospective cohorts and case-control studies investigating the biomechanical factors 
associated with AT.203 
The subtalar joint in the ankle is responsible for both the inversion/eversion and 
pronation/supination movements of the foot, while the ankle joint is responsible for 
plantar- and dorsiflexion.  It has been suggested that excessive loading of the Achilles 
tendon with inversion or eversion of the subtalar joint, such as in hyperpronation, may 
result in injury.169  In support of this, a prospective study of 449 US Navy SEALs reported that 
a tight gastrocnemius muscle (RR 3.57, 95% CI:1.01-12.68; P<0.05) and increased hindfoot 
inversion (RR 2.79, 95% CI:0.91-8.55; P<0.001) were significantly associated with risk of 
developing AT.147  Furthermore, a case-control study showed that runners with AT have a 
higher ankle eversion than seen in controls (P<0.05).246  As the Achilles tendon antagonises 
pronation at heel strike and is the predominant plantar-flexor during the toe-off phase, 
stresses across the Achilles tendon are correlated to the orientation of the subtalar joint 
axis.235,250  A retrospective analysis of the spatial orientation of the subtalar joint axis in 
runners showed that runners with chronic AT had a more oblique deviation angle of the 
subtalar joint axis at maximal dorsiflexion (P=0.002), and this may result in more wringing of 















sectional investigation of the tibiocalcaneal axis in 1394 feet and found that varus 
malalignment (-14° to 0°) of the hindfoot was present in 78.3% of feet with AT compared to 
34.3% of control feet (P<0.001).  This corroborates the retrospective findings of Kvist et al. 
(1994)162 in which forefoot varus was reported to be associated with Achilles tendon 
overuse injuries.162 
Flexibility and range of motion (ROM) have been associated with patellar 
tendinopathy,185,287 and decreased ROM during passive dorsiflexion of the ankle and 
subtalar joints is also implicated as a predisposing factor for AT.162  In a prospective study of 
69 well matched military recruits, lower plantar flexor muscle strength and a higher ROM 
during dorsiflexion were found to be significant risk factors for AT overuse injury.182  In 
contrast, athletes with a lower ROM in dorsiflexion were found to absorb landing loads with 
a more everted and extended plantarflexor muscle-tendon unit, which may increase the risk 
of overuse injuries such as AT.299  A cross sectional study of biomechanical variables in 
runners with AT found a decreased ROM at knee flexion from heel strike to midstance.20 
Recently, Wyndow et al. (2012)305 have suggested that altered neuromotor control of the 
triceps surae is a feature of AT.  They reported significant differences in the activation of the 
triceps surae in runners with AT compared to controls, with earlier soleus muscle offset 
relative to lateral gastrocnemius offset.305  This corroborates a cross sectional study of 
biomechanical variables in runners with AT which found decreased muscle activity in the 
lower extremity of these runners.20   
A 10 week prospective cohort study on well-matched novice runners showed that a 
decrease in the anterior displacement of the centre of force (P=0.015) and a more lateral 
force distribution at forefoot flat (P=0.016) were significant risk factors for Achilles tendon 
overuse injuries.289  The authors suggest that the decrease in forward transfer of the centre 
of force results in less propulsion being generated during the late stance and therefore 
higher tensile forces are required during the toe-off stance. 
A 2011 systematic review of two prospective cohorts and seven case-control investigations 
of biomechanical factors specifically associated with AT concluded that individuals with AT 















abduction, (iii) reduced ankle joint dorsiflexion velocity, (iv) reduced knee flexion during the 
gait cycle, (v) altered plantar pressures and ground reaction forces, (vi) a reduced tibial 
external rotation moment and (vii) altered timing and amplitude of activity in lower limb 
muscles.203  In summary, the studies reviewed above present strong evidence of low 
certainty that a more lateral force distribution across the foot is a risk factor for AT, limited 
evidence of moderate certainty that varus malalignment is a risk factor for AT and strong 
evidence of moderate certainty that increased eversion and inversion of the foot is a risk 
factor for AT.  There is limited evidence of low certainty that reductions in muscle activity in 
the lower extremity, and changes in the relative timing of lower limb muscle activity are risk 
factors for AT.  There is also strong evidence of low certainty that ROM and decreased 
flexibility of the gastrocnemius muscle are risk factors for AT.         
1.5.2 (VIII) SYSTEMIC DISEASE 
It has been stated that approximately 2% of Achilles tendon disorders arise as complications 
of systemic disease.132  Several systemic diseases have been suggested as risk factors for AT 
and ATR including diabetes mellitus, compromised renal function, hyperlipidemia, 
hypercholesterolemia, hyperuricaemia, Alkaptonuria, gout, rheumatoid arthritis, adrenal 
disorders, thyroid disorders (hyperparathyroidism), amyloidosis and chronic lung 
disease.4,53,172,197,233,239  In addition, there are several severe inherited disorders of 
connective tissue such as Ehlers-Danlos syndrome, Marfans syndrome and osteogenesis 
imperfecta which have joint hypermobility and other musculoskeletal manifestations as 
symptoms.184   
Diabetes mellitus has been shown to result in degeneration and decreased vascularity in 
tendons.4  The high availability of plasma glucose in diabetes results in the increased 
accumulation of AGEs and permanent cross-links in collagen fibres.4,239  A case-control study 
of induced diabetes in rats showed that sustained hyperglycaemia resulted in altered 
structural properties of tendon and an increased incidence of mid-portion patellar tendon 
rupture.87 
Patients with chronic painful AT also show evidence of dyslipidemia with lipid profiles 















was reported to result in increased stiffness in the supraspinatus tendon in several species, 
and chronic hypercholesterolemia in rats is associated with detrimental changes in tendon 
biomechanics.26,27  A case-control study showed an association between hyperlipidemia and 
Achilles tendon pathology such as tendon xanthomas and “tendinitis”.155  Tendon 
xanthomas are common in familial hypercholesterolemia and are attributed to the 
accumulation and oxidisation of low density lipoprotein in tendon.4  However, tendon 
degeneration in non-familial hypercholesterolemia is not well understood and it has been 
suggested that microscopic cholesterol accumulation in tendon may initiate a chronic low-
grade inflammatory response.4  In addition, a case-control study showed that patients with 
ATR had significantly more unfavourable lipid profiles, and higher serum lipid concentrations 
than a control group.214  
The evidence for diabetes mellitus and hypercholesterolemia as risk factors for AT is 
therefore limited, and of low and moderate certainty respectively.  When considered with 
the evidence for adiposity and fat distribution as risk factors for AT, this indicates that 
tendinopathy may be a significant feature of the metabolic syndrome.   
1.5.2 (IX) BLOOD GROUP 
In 1989 Jozsa et al.139 reported an apparent association between ATR and the O blood group 
in a Hungarian population.  This result was corroborated by some146,158 but not all 
studies.16,170,179  The ABO blood group system is the most commonly used blood grouping 
system as nearly all individuals express the H surface antigen on their red blood cells.  The 
two alleles of the ABO gene, situated on the telomeric end of the long arm of chromosome 
9, encode the A- and B-glycosyltransferases.307  These enzymes catalyse the final step in the 
biosynthesis of the A and B blood group antigens by transferring different sugars to the 
acceptor H antigen.307  It has been suggested that these transferases may not only 
determine the structure of glycoprotein antigens, but also the structure of glycoproteins 
within the ECM.139,158  However, it has also been proposed that other genes closely linked to 
the ABO gene on chromosome 9 may be more likely to be associated with AT.146,158  In 















1.5.2 (X) GENETIC PREDISPOSITION 
It has long been hypothesized that genetic predisposition may influence risk of developing 
chronic tendon disorders.133,145  Subsequent findings have confirmed that a familial 
predisposition, and therefore genetic predisposition, exists in the risk of developing soft 
tissue injuries.  In particular, the relative risk of sustaining rotator cuff tears in siblings of 
patients with full thickness tears was higher than that in the control population of patients 
spouses (RR 2.42, 95% CI:1.77-3.31).107  More recently, in a cross-sectional match paired 
analysis of medical risk factors for AT and ATR, the only significant risk factor to emerge was 
a positive family history of chronic AT.157 
In addition to family history, several DNA sequence variants have been associated with risk 
of developing AT and ATR.  Mokone et al. (2006)199 and September et al. (2009)255 
investigated the association of a polymorphism within the COL5A1 gene, which encodes the 
α1 chain of type V collagen and is mapped to the same locus as the ABO gene on 
chromosome 9 (9q34), with Achilles tendinopathy in South African and Australian 
populations.  A BstUI restriction fragment length polymorphism (RFLP) within the 3’-
untranslated region (UTR) of the COL5A1 gene (rs12722, C>T) was significantly associated 
with AT in both of these groups.  Specifically, individuals with a CC genotype at this locus 
were at a significantly lower risk of developing chronic AT than individuals with either a CT 
or TT genotype in both the South African (OR 0.38, 95% CI:0.18-0.77; P=0.008) and 
Australian (OR 0.42, 95% CI:0.20-0.86; P=0.017) group.  The rs12722 single nucleotide 
polymorphism (SNP) has also been associated with ACL tears in females, ultra-endurance 
running performance, exercise associated muscle cramping and ROM, a possible risk factor 
for tendinopathy.40,56,209,227 Recently, three more SNPs in the 3’-UTR of the COL5A1 gene, 
rs71746744, rs16399 and rs1134170, have also been independently associated with chronic 
AT in South African and Australian participants.6  The associated polymorphisms within 
COL5A1 have been mapped to a functional region of the 3’-UTR of this gene and are 
suggested to play a role in the stability of COL5A1 mRNA.164  In particular, two functional 
forms of COL5A1 3’-UTRs cloned from controls and AT subjects were identified.164  The C- 
and T-forms were predominantly identified in the controls and AT participants respectively 
and the luciferase activity of the C-form was significantly lower than that of the T-form (69.0 















3’-UTR is significantly more stable than that of the C-form.  In addition, there is a functional 
micro RNA (miRNA) binding site for Hsa-miR-608 within the COL5A1 3’-UTR and the 
rs4919510 SNP within the MIR608 gene, encoding Hsa-miR-608, has also been shown to be 
independently associated with chronic AT.6 
Collins and Posthumus (2011)57 hypothesized that the COL5A1 rs12722 TT genotype results 
in increased type V collagen based on the increased stability of COL5A1 mRNA in the 
presence of the T-allele (Figure 1.9).  Increased type V collagen results in a decreased mean 
fibril diameter and an increased fibril density, which leads to changes in the biomechanical 
properties of the tissues.  They further hypothesize that these changes result in: (i) a 
reduced tensile strength and therefore higher risk of musculotendinous injuries, and (ii) 
increased creep inhibition and/or stiffness which improves running economy and endurance 
running performance.57 
The α-chains of the type V collagen fibril are encoded by the COL5A1, COL5A2 and COL5A3 
genes.  In addition, type III collagen (encoded by the COL3A1 gene) interacts with type I and 
type V collagen in the ECM.  Although the association of other collagen genes with AT has 
been investigated,228,259 to date genetic variation in the COL5A2, COL5A3 and COL3A1 genes 
has not been investigated in AT.  Polymorphisms within the COL1A1, COL12A1 and COL14A1 
genes were shown not to associate with chronic AT.228,259  The Sp1 binding site 
polymorphism, rs1800012, within the COL1A1 gene and an AluI RFLP within the COL12A1 
gene were, however, reported to be associated with ACL ruptures.225,226 
In addition to the association of several collagen gene polymorphisms with AT, 
polymorphisms within genes encoding glycoproteins and matrix associated enzymes have 
also been implicated in AT.  The TNC gene, encoding the glycoprotein tenascin-C (TN-C), is 
also situated on the long arm of chromosome nine and contains a GT dinucleotide repeat 
polymorphism in intron 17.197  Alleles with 12 or 14 repeats were found to be significantly 
over represented, and alleles with 13 or 17 repeats were under represented, in patients 
with Achilles tendon injury compared to healthy controls.  Polymorphisms within genes 
encoding other glycoproteins of the ECM, including the thrombospondin family of five 
















Figure 1.9: Collins and Posthumus’ hypothesis of the relationship between COL5A1 
rs12722 genotype and exercise related phenotypes 
A schematic summary of the relationship between (i) COL5A1 genotype (black boxes), (ii) connective 
tissue biochemical and mechanical properties (white boxes), (iii) flexibility, (iv) disease or injury risk, 
and (v) physical activity. The left panel illustrates the effects of disease-causing COL5A1 mutations on 
decreased type V collagen production, abnormal fibrillogenesis, and generalized joint hypermobility. 
These mutations cause Ehlers-Danlos syndrome (EDS), which has been shown to have a detrimental 
effect on the habitual level of physical activity within these patients. A mixture of large and small 
irregular fibrils in EDS is shown. The scenarios illustrated in the middle and right panels described the 
normal interindividual biological variation. The middle panel represents the wild-type COL5A1 gene 
and phenotypes. It is proposed that larger regularly shaped fibrils are produced from the wild-type 
gene, which is stronger and more compliant. These fibrils are associated with increased joint range of 
motion (ROM) decreased risk for specific musculoskeletal soft tissue injuries, and slower endurance 
running performance. The right panel illustrates the effect of functional common polymorphisms 
within the COL5A1 gene on increased type V collagen production. Smaller regularly shaped weaker 
fibrils are produced during fibrillogenesis. These fibrils, which are proposed to have an increased 
stiffness and/or creep inhibition, are associated with reduced joint ROM, increased risk for specific 
musculoskeletal soft tissue injuries, and faster endurance running performance 
 

















 In this same South African population, three polymorphisms within the MMP3 gene for 
matrix metalloproteinase-3 have been associated with AT.231  The GG genotype of rs679620, 
CC genotype of rs591058 and the AA genotype of rs650108 were all associated with AT, and 
the ATG haplotype for these three polymorphisms was significantly under-represented in 
the AT group (P=0.038).  Furthermore, rs679620 within this MMP3 gene interacts with the 
COL5A1 rs12722 polymorphism to modify the risk of tendinopathy.  In addition, the CC 
genotype of rs4789932 within the TIMP2 gene, which encodes tissue inhibitor 
metalloproteinase-2, has been reported to be under-represented in a control group when 
compared to participants with AT (P=0.016).76 
Several polymorphisms within genes encoding components of cellular pathways have also 
been shown to be associated with AT.  In particular, individuals with a TT genotype of the 
rs143383 polymorphism within the growth/differentiation factor-5 gene, GDF5, were found 
to have double the risk of developing AT compared to controls in a South African and 
Australian population.224  Several sequence variants within caspase (CASP8) and interleukin 
(IL-6, IL1β, IL-1RN) genes involved in the apoptosis and cell signalling pathways have also 
been implicated in AT.205,257  
As the studies outlined above are all case-control genetic association studies, they 
constitute only limited evidence.  However, given the repeatability and number of studies, 
the evidence for genetic variation as a risk factor for AT is of high certainty.  It is interesting 
to note that there are no genome-wide association studies (GWAS) on tendinopathy.  This 
may reflect the relative immaturity of the field of tendinopathy genomics as GWAS require 
very large cohorts in order to be successful.186,313  As the field and, subsequently, 
collaborations and research groups grow, larger cohorts may allow for a GWAS approach to 
tendinopathy genomics.  This will be discussed further in chapter 6.  It is however clear that 
genetic predisposition is a risk factor in the multi-factorial condition of AT.  It is likely that 
tendinopathy occurs at the milder end of a spectrum of connective tissue disorders ranging 
from complex, multifactorial conditions in which the genetic contribution is small, to severe 
















Figure 1.10: Level of evidence and level of certainty of risk factors for Achilles 
tendinopathy 
 
1.6. SUMMARY AND CONCLUSIONS OF THE LITERATURE REVIEW 
The incidence rates of Achilles tendon rupture and Achilles tendinopathy are both 
increasing.  Although there are a number of models to explain the aetiology and mechanism 
of AT, the exact aetiology has not been elucidated.  There is however a trend towards more 
integrated models and hypotheses which better explain the symptoms associated with AT, 
and the progression of the condition.  The intrinsic and extrinsic risk factors associated with 
AT have been reviewed in this chapter and it is clear that AT is a multifactorial condition.  
From the evidence based review of each risk factor, it is also clear that more research is 
required to fully elucidate the risk factors which influence risk of AT.  In particular, more 















associated with AT with more certainty.  The risk factors which emerged from this review 
with the strongest evidence and highest degree of certainty were previous Achilles tendon 
injury, neovascularisation of the tendon, genetic variation, treatment with fluoroquinolone 
antibiotics and middle- and long-distance running. 
The certainty for the existence of a genetic predisposition towards AT is increasing as more 
studies are published reporting the association of gene sequence variants with risk of AT.  In 
addition, the increasing number of genes that are reported to be associated with AT 
emphasises the polygenic nature of genetic susceptibility to AT.  It is therefore vital that the 
full spectrum of polymorphisms which influence risk of AT is uncovered.   
1.7.  AIMS AND OBJECTIVES OF THE THESIS 
The primary aim of this thesis was to further identify specific genetic elements predisposing 
individuals to risk of AT using a candidate gene, case-control genetic association approach, 
and to propose the biological mechanisms underlying this genetic risk.  Candidate genes 
(COMP, THBS2, COL27A1, TNC, COL5A2, COL5A3 and COL3A1) were selected based on their 
chromosomal location and/or the biological function of their encoded proteins within the 
ECM.   
The objectives of the specific studies which addressed this primary aim of the thesis were: 
 To test the association of sequence variants within the COMP and THBS2 candidate 
genes with risk of AT in participants from South Africa and Australia (Chapter 2) 
 To test the association of several sequence variants spanning a 780.9kb region which 
includes the COL27A1 and TNC genes, and a potential haplotype consisting of two or 
more of these SNPs, with AT in participants from South Africa and Australia (Chapter 
3) 
 To investigate the association of polymorphisms within the COL5A2, COL5A3 and 
COL3A1 genes with AT in participants from South Africa and Australia (Chapter 4) 
 To investigate interactions between polymorphisms within the COL5A2, COL5A3 and 
















 To test the gene-gene interactions between polymorphisms within genes encoding 
components of the collagen fibril and components of cell-signalling pathways within 
the ECM in the modulation of risk of AT (Chapter 5) 
The secondary aim of this thesis was to develop and test preliminary models assessing 
genetic risk of developing AT.  The objectives of the specific studies which addressed this 
secondary aim of the thesis were: 
 To investigate the relative contribution of polymorphisms within genes encoding 
components of the collagen fibril and components of cell-signalling pathways within 
the ECM to overall genetic risk in a polygenic risk model (Chapter 5) 
 To develop and evaluate a preliminary, clinically relevant genetic risk assessment 
model for AT using (i) polymorphisms that have previously been independently 
associated with AT in two populations, and (ii) polymorphisms with a definitive AT 
risk genotype that were implicated in this thesis in a haplotype or gene-gene 































CHAPTER 2: VARIANTS WITHIN THE COMP AND THBS2 GENES ARE NOT 
ASSOCIATED WITH ACHILLES TENDINOPATHY 
This chapter has been submitted for publication in a condensed format as: 
Saunders, C.J., Van Der Merwe, L., Cook, J., Handley, C.J., Collins, M., & September, A.V. 
Variants within the COMP and THBS2 genes are not associated with Achilles tendinopathy in 
a case-control study of South African and Australian populations. Journal of Sports Sciences. 
In press. 
2.1. INTRODUCTION 
As reviewed in chapter one, the Achilles tendon is exposed to high mechanical forces during 
exercise and is often a site of injury in both athletes and the general population.68,132  The 
pathology of AT has been well characterised with clearly documented clinical and imaging 
diagnostic criteria (Table 1.2),69,128,141 however the exact aetiology of the condition remains 
undefined.  The heritable factors contributing to risk of developing AT have been extensively 
reviewed in chapter two, and include polymorphisms in several genes coding for structural 
and associated proteins of the extracellular matrix.197,199,205,224,231,247,255,257  
In this study we investigated two further candidate genes, THBS2 and COMP, which code for 
thrombospondin 2 (TSP-2) and cartilage oligomeric matrix protein/thrombospondin 5 
(COMP; TSP-5) respectively.  The thrombospondins are calcium binding glycoproteins that 
can be divided into two subfamilies with distinct biological roles.7,36  TSP-1 and TSP-2 (Group 
A) are matricellular proteins that form homotrimers and modulate cell functions and cell-
matrix interactions,36 while TSP-3 to TSP-5 (Group B) are structural proteins of the 
extracellular matrix and form homopentamers.7,36,37  The thrombospondin proteins have 
five domains (Figure 2.1).44  The NH2-terminal domain is a globular β-sandwich present in all 
thrombospondins except COMP.  It provides a structural framework and contains several 
binding sites for various ligands.  These binding sites may allow the protein to anchor to 
proteoglycans at this NH2-terminal while leaving the rest of the protein free to interact with 















present in all thrombospondins and is susceptible to proteolytic activity.  The von 
Willebrand factor type C (vWFC) domain is present only in group A thrombospondins, and 
has anti-angiogenic activity.  Three thrombospondin type-1 repeats (TSR) are also only 
found in group A thrombospondins.  These repeats are normally extracellular and function 
in cell attachment, the inhibition of angiogenesis and protein-glycosaminoglycan 
interactions.  All thrombospondins contain a highly conserved signature protein domain at 
the COOH-terminal and a number of disease associated polymorphisms have been mapped 
to this domain.44  This domain includes three or more epidermal growth factor (EGF) like 
repeats, a calcium-binding wire of 13 calcium binding repeats, and a COOH-terminal lectin-
like module.   
 
Figure 2.1: Protein structure of the thrombospondin family 
Members of the thrombospondin (TSP) family have a multimodular structure. TSP1 and TSP2 are 
composed of an N-terminal heparin-binding domain (large green circle), a procollagen homology 
domain (dark-blue oval), three type I repeats (green circles), three epidermal growth factor (EGF)-like 
type II repeats (orange diamonds), seven calcium-binding type III repeats (pale blue rectangles) and a 
C-terminal globular domain (blue circle). By contrast, TSP3, TSP4 and TSP5/COMP contain distinct N-
terminal domains (light-blue, red, purple circles), four EGF-like repeats, seven type III repeats and a 
similar C-terminal globular domain. ‘S’ indicates the position of the cysteine residues involved in 
multimerization. Sequence homology increases from the N- to the C-termini of these proteins 
















TSP-2, in particular, is involved in the healing response in connective tissues and plays a 
significant role in cell-matrix interactions.7,36,37  It has an anti-angiogenic effect during the 
late-proliferative and remodelling phase of wound healing.36  In addition, investigation of 
THBS2 null mice has implicated this protein in the regulation of collagen fibrillogenesis and 
fibril diameter.  THBS2 null mice display a highly variable phenotype which includes skin 
fragility, lax tendons and increased vascularity.163  It has been postulated that TSP-2 is a 
clearance factor for matrix metalloproteinase-2 (MMP-2) and that the increased levels of 
MMP-2 in THBS2 null mice may contribute to the observed defects in collagen 
fibrillogenesis.36,37  Two SNP’s within the THBS2 gene, rs6422747 and rs9283850, have 
previously been associated with lumbar disc herniation, a multifactorial musculoskeletal 
condition, in a Japanese population.112     
COMP interacts with type I and type III collagens and plays an important role in matrix 
assembly and the repair of injured tissues.108,223,243,272  It is expressed in bovine and equine 
tendons, particularly in growing tendons and in response to mechanical load.71,269,271  Recent 
investigation has identified a mechano-responsive element in the 3kb proximal promoter of 
the human COMP gene.14  In numerous studies of equine tendons, Smith et al.269,270,271 have 
shown that COMP levels are correlated to ultimate tensile stress and stiffness of tendon 
tissue and suggest that the appropriate expression of COMP is necessary for the formation 
of a functional ECM and the structural integrity of tendons.  Additionally, serum COMP has 
been inversely associated with joint hypermobility,50 a suggested risk factor for AT.20,185,287  
Genetic variants clustered in the conserved calcium binding domains and carboxy terminal 
of the COMP protein have repeatedly been associated with skeletal dysplasia’s.7,108,122  In 
addition, the C-allele of the rs730079 SNP within the 5’UTR of this gene was previously 
associated with osteoarthritis of the knee in a Caucasian male population.284   
The observations above, together with the biological roles of these proteins, suggest that 
both COMP and THSB2 are good candidate genes for association with risk of developing AT.  
The aim of this study was, therefore, to test the association of sequence variants within the 
















2.2. MATERIALS AND METHODS 
2.2.1. PARTICIPANTS 
The two groups described below were used in the studies presented in chapter’s two to five.  
Only participants who were of self-reported European Caucasian ancestry were included in 
order to avoid the effects of population stratification.  Participants were given an 
information sheet regarding the study and then required to sign an Informed Consent Form 
in accordance with the Declaration of Helsinki [Appendix A].  Once recruited, participants 
were required to complete a detailed questionnaire recording personal particulars, medical 
history and injury history [Appendix A].  Participants were allocated a unique coding number 
to ensure anonymity of DNA samples and confidentiality of all recorded information.79  
Sample sizes were determined using QUANTO version 0.5 (Figure 2.2).97,98  The South 
African group included 131 physically active control (SA-CON) participants without any 
history of tendon or ligament pathology, as well as 94 physically active affected participants 
(SA-TEN) clinically diagnosed with chronic Achilles tendinopathy (AT).  The SA-TEN 
participants were invited to participate through the medical practice at the Sports Science 
Institute of South Africa, Cape Town, South Africa.  The presence of gradual progressive pain 
over the posterior lower leg for more than six months (n=94) together with at least one of 
the following clinical criteria was used to diagnose chronic AT: (i) early morning pain (n=32), 
(ii) early morning stiffness (n=53), (iii) history of swelling over the Achilles tendon area 
(n=36), (iv) tenderness to palpation over the Achilles tendon (n=74), (v) palpable nodular 
thickening over the affected Achilles (n=28), and/or (vi) a positive shift test (movement of 
the nodular area with plantar-/dorsi-flexion)(n=22).141,250  The diagnosis of each participant 
was reviewed by the same clinician (Appendix A), and was confirmed using soft tissue 
ultrasound in a sub-group of 36 participants.   
The Australian group included 209 apparently healthy control (AUS-CON) participants 
without any history of tendon or ligament pathology, as well as 85 affected participants 
(AUS-TEN) clinically diagnosed with chronic AT.  The AUS-TEN participants were recruited by 
the Musculoskeletal Research Centre at La Trobe University in Melbourne, Australia.  The 
diagnosis was made using similar clinical criteria to those described for the SA-TEN group, 















CON participants were also examined under ultrasound and were confirmed not to have any 
evidence of asymptomatic AT.  The same sports physiotherapist confirmed the diagnosis for 
all AUS participants.   
Participants who had a self-reported history of treatment with either fluoroquinolone 
antibiotics or local corticosteroid injections were excluded from the study to reduce 
confounding.  In addition, participants who had previously suffered, or were currently 
suffering from any connective tissue disorders or other systemic diseases associated with AT 
were also excluded from the study.  These included EDS, rheumatoid arthritis, benign joint 
hypermobility syndrome, diabetes mellitus, familial hypercholesterolaemia, systemic lupus 
erythematosus, hyperparathyroidism and renal insufficiency.     
 
 
Figure 2.2: QUANTO determined sample sizes 
Sample sizes were determined at a 10% prevalence of AT, with 80% statistical power. Number of 
controls was determined in a 2:1 ratio with cases. MAF: Minor allele frequency 
2.2.2. DNA EXTRACTION 
Approximately 4.5ml of venous blood was collected from each participant into an 
ethylenediaminetetraacetic acid (EDTA) vacutainer tube by venipuncture of a forearm vein.  















(1999)165 and modified by Mokone et al. (2005)197  Briefly, blood samples were transferred 
to sterile 15ml polypropylene tubes to which 2 volumes of TKM-1 buffer (10mM Tris-HCl pH 
7.6, 10mM KCl, 10mM MgCl2, 2mM EDTA) containing 2.5% Nonidet P-40 was added to lyse 
the red blood cells.  After incubation at room temperature for 10 minutes, the white blood 
cells were pelleted by centrifugation at 1200Xg and washed at least twice with one volume 
of TKM-1 buffer.  The pellets were resuspended in 800μl of TKM-2 buffer (10mM Tris-HCl pH 
7.6, 10mM KCl, 10mM MgCl2, 0.4M NaCl2, 2mM EDTA) containing 50μl of 10% SDS solution, 
and incubated at 55°C for 10 minutes or until the pellet was dissolved.  One hundred and 
fifty (150) μl of 5M NaClO4 and 500μl of chloroform were added to each sample and mixed 
by vortexing for 15-20 seconds.  The samples were then transferred to sterile 1.5ml 
microfuge tubes and centrifuged at 2000Xg for 5 minutes at room temperature to 
precipitate the protein.  The supernatants were transferred to new, sterile microfuge tubes 
containing 1ml of absolute ethanol and centrifuged at 2000Xg for 5 minutes at room 
temperature to precipitate the DNA.  The supernatants were removed and the pellets were 
air dried and resuspended in 100μl of 1X TE buffer (10mM Tris-Cl, 1mM EDTA, pH 8.0) 
before incubation at 65°C for 15 minutes.  DNA from the Australian participants was 
extracted as per the manufacturer’s recommendations using a sequenced extraction 
technique (FlexiGene DNA Kit, Qiagen P/L, Valencia, California, USA).255  The DNA was 
stored at 4°C until subsequent genotyping. 
2.2.3. VARIANT SELECTION 
Lists of SNPs within the COMP and THBS2 genes were generated using the National Centre 
for Biotechnology Information’s (NCBI) SNP database available at 
http://www.ncbi.nlm.nih.gov/snp/ and were interrogated using the Ensembl Genome 
Browser (http://www.ensembl.org/index.html) and Genome Variation Server 
(GVS)(http://gvs.gs.washington.edu/GVS137/).283  Three SNPs within the THBS2 gene 
(chr6q27) were selected for investigation (Figure 2.3).  SNPs rs9283850 (Intron 9), 
rs6422747 (Intron 14) and rs9505888 (Intron 17) are all A>G substitutions and were selected 
based on their heterozygosity score (>35%), minor allele frequency (>20%), linkage and 
previous association with other clinical phenotypes.112  The rs9505888 polymorphism was 
selected based on its linkage disequilibrium (LD) with rs6422747.  In addition, all three SNP’s 















are in high LD and these SNPs should therefore provide moderate coverage of this 38,3kb 
gene.  Two SNPs within the COMP gene (chr19p13.11), rs730079 (-1417C>G) and 
rs28494505 (Intron 18, A>G), were investigated based on their heterozygosity score (>35%), 
minor allele frequency (>20%) and previous association with clinical phenotypes (Figure 
2.4).284  The rs28494505 polymorphism was selected based on its location within the highly 
conserved COOH-terminal domain of the COMP protein and its identification as a Tag 
SNP.283  
2.2.4. GENOTYPING 
Polymorphisms rs9505888, rs6422747 and rs28494505 were amplified using standard 
polymerase chain reaction (PCR) and genotyped using restriction fragment length 
polymorphism (RFLP) techniques. Unless otherwise specified, PCR reactions were carried 
out in a solution containing 200ng DNA template, 1X reaction buffer, 2.0mM Mg2+, 2.5mM 
each of dATP, dCTP, dTTP and dGTP, 20pmol each of the forward and reverse primers and 
0.5 units of either Taq DNA polymerase (New England Biolabs® Inc., Ipswich, Massachusetts, 
USA) or SuperTherm Taq DNA polymerase (Hoffmann-La-Roche, US) using an XP Thermal 
Cycler Block (Bioer Technology Co., Middlesex, UK).  Reaction buffer was specific to the Taq 
used.  Thermo-Pol® reaction buffer (New England Biolabs® Inc., Ipswich, Massachusetts, 
USA) consisted of 10mM KCl, 10mM (NH4)SO4, 20mM Tris-HCl, 2mM MgSO4 and 0.1% Triton 
X-100 at pH8.8.   SuperTherm reaction buffer (Hoffmann-La-Roche, US) was provided with 
the SuperTherm Taq DNA polymerase and used as per manufacturer’s instructions.  PCR 
reactions were initiated with a five minute denaturing cycle at 94˚C, followed by 35 cycles 
consisting of 30 seconds denaturation at 94˚C, 30 seconds annealing at variant specific 
temperatures and 40 seconds extension at 72˚C with a final five minute extension step at 
72˚C.  Variant specific oligonucleotide primer sequences, reaction conditions and amplicon 
sizes are listed in Appendix B.  PCR amplicons of polymorphisms rs9505888, rs6422747 and 
rs28494505 were digested overnight with BstUI, MfeI and MspI restriction endonucleases 
respectively.  Restriction fragments were resolved, together with a 100 base pairs (bp) size 
standard (Promega Corporation, Madison, Wisconsin, USA), by 6% polyacrylamide gel 
electrophoresis (PAGE) at 120V for 2 hours and visualised under UV light after staining with 















Polymorphisms rs9283850 and rs730079, as well as a subset of samples for rs28494505, 
were genotyped using inventoried TaqMan® SNP Genotyping Assays (Applied Biosystems™) 
that were amplified and distinguished using the StepOnePlus™ Real-Time PCR System 
(Applied Biosystems™).  Briefly, real-time PCR reactions were performed in a final volume of 
8µl and included approximately 20ng DNA, TaqMan® Assay Mix and TaqMan® Genotyping 
Master Mix (2X).  TaqMan® Assay Mix consisted of sequence specific forward and reverse 
primers to amplify the polymorphic sequence, and two MGB probes labelled with VIC® and 
FAMTM dyes to detect allele 1 and allele 2 respectively.  Real-time PCR cycling started with 
an initial hold step at 95°C for 10 minutes followed by 40 cycles of 92°C for 15 seconds, and 
60°C for 1 minute.  Fluorescence signal for each MGB probe was used to discriminate alleles 
and genotypes using the StepOnePlus™ Real-Time PCR System software [Appendix B].  For 
quality control purposes, a number of positive controls of known genotype and DNA-free 
controls were randomly included on every 96-well PCR plate.  In addition, a subset of 
samples (approximately 12%) was genotyped twice using the same methodology to ensure 
genotyping was consistent.  
It should be noted that the DNA from the AUS and SA samples was extracted in different 
laboratories and therefore suspended in different buffers.  It is suspected that a reagent 
used either in the DNA extraction process, or in the suspension buffer of the AUS DNA 
samples interferes with PCR in certain samples.  In order to avoid genotyping errors, 
samples that failed twice to amplify during PCR for a particular SNP were considered as 
unsuccessfully genotyped and no further attempts were made to genotype them at that 
SNP locus.  Samples that consistently failed to amplify during PCR were excluded in further 
studies.  The number of successfully genotyped samples for each SNP investigated in this 
















Figure 2.3: Thrombospondin 2 
(A) Shaded bands indicate cytogenetic banding patterns for chromosome 6. Chromosomal banding position of THBS2 gene is indicated with an arrow (B) 
Genomic location and intron/exon structure of THBS2 including previously cited variants #Significant association with lumbar disc herniation [Hirose et al. 
(2008)112] Solid bars represent numbered exons separated by introns (solid lines). Variants in bold are included in the present study. (C) TSP-2 protein domain 
architecture. EGF: Epidermal growth factor; TSR: Thrombospondin repeat; vWC: von Willebrand factor type-C; THBS-N: Thrombospondin amino terminal 
















Figure 2.4: Cartilage oligomeric matrix protein 
(A) Shaded bands indicate cytogenetic banding patterns for chromosome 19. Chromosomal banding position of COMP gene is indicated with an arrow (B) 
Genomic location & intron/exon structure of COMP *Associated with osteoarthritis (Valdes et al. (2007))284 #Associated with PSACH & MED [Delot et al. 
(1999)70] Solid bars represent numbered exons separated by introns (solid lines).  Variants in bold are included in the present study (C) COMP protein domain 
architecture. UTR: Untranslated region; EGF: Epidermal growth factor; THBS-N: Thrombospondin N-terminal domain [Compiled from www.ensembl.org and 
















Table 2.1: The number and proportion of recruited participants successfully genotyped for 
each of the THBS2 and COMP polymorphisms 
Total number of 
participants 
Number and proportion of participants genotyped 
rs28494505 rs730079 rs9505888 rs6422747 rs9283850 
AUS-CON 209 165 79% 205 98% 185 89% 200 96% 203 97% 
AUS-TEN 85 62 73% 83 98% 75 88% 82 96% 79 93% 
TOTAL 294 227 77% 288 98% 260 88% 282 96% 282 96% 
SA-CON 131 131 100% 131 100% 130 99% 130 99% 130 99% 
SA-TEN 94 94 100% 93 99% 93 99% 93 99% 93 99% 
TOTAL 225 225 100% 224 99% 223 99% 223 99% 223 99% 
 
2.2.5. STATISTICAL ANALYSES 
The programming environment R,230 and R package, genetics,296 was used to estimate 
genotype and allele frequencies and exact Hardy-Weinberg equilibrium (HWE) probabilities.  
Age and sex were considered potential confounders and were, therefore, corrected for in 
the logistic regression model of the association of genotypes and alleles with AT.  No 
adjustments were made for multiple testing because it has been suggested that these 
corrections, such as Bonferroni, markedly overcorrect for an inflated false-positive rate and 
unnecessarily reduce power in genetic association studies where background LD exists 
between SNPs.207,220 
Genotype effects on age, height, weight, body mass index (BMI) and sex were determined 
by a one-way analysis of variance (ANOVA) using STATISTICA version 10 (StatSoft Inc., Tulsa, 
















2.3.1. DESCRIPTIVE CHARACTERISTICS 
The physiological characteristics of the SA-CON, SA-TEN, AUS-CON, AUS-TEN and the 
combined groups are given in Table 2.2.  There were no significant differences between age 
at recruitment (CON) and age at injury (TEN) in either the AUS (P=0.268), SA (P=0.167) or 
combined (SA & AUS) (P=0.099) groups.  There was no significant difference in the sex 
distribution between SA-CON and SA-TEN (P=0.163), however the AUS-CON and combined 
CON groups contained proportionally less males than the AUS-TEN (P<0.001) and combined 
TEN (P<0.001) groups respectively.  There was no difference in height between the SA-CON 
and SA-TEN groups (P=0.212), however the AUS-TEN and combined TEN groups were 
significantly taller than the AUS-CON (P=0.046) and combined CON (P=0.006) groups 
respectively.  When adjusted for sex, this difference in height was no longer significant 
between either the AUS (P=0.468) or combined (P=0.337) groups.  The AUS-TEN, SA-TEN 
and combined TEN participants weighed more at recruitment than the AUS-CON (P<0.001), 
SA-CON (P<0.001) and combined CON (P<0.001) participants respectively.  Consequently, 
the AUS-TEN, SA-TEN and combined TEN participants had a higher BMI than the AUS-CON 
(P<0.001), SA-CON (P<0.001) and combined CON (P<0.001) participants respectively.  When 
adjusted for age at recruitment, height and sex, there was no significant difference in weight 
between the AUS-CON and AUS-TEN (P=0.682), nor the combined CON and combined TEN 
(P=0.077) groups.  However, the SA-TEN group was still heavier than the SA-CON after 
adjustment (P<0.001).  It should be noted that the TEN groups could not be adjusted for age 
at injury as weight was measured at recruitment and not at time of injury.  After adjusting 
for age at recruitment and sex, BMI was no longer different between the two AUS (P=0.661) 
or combined (P=0.095) groups, but was still different between SA-CON and SA-TEN 
(P<0.001).  The proportion of participants born in Australia (born “here”) was significantly 
different between the AUS-CON (84.9%) and AUS-TEN (78.6%) groups (P=0.047), but there 
was no difference in the proportion of participants born in South Africa (born “here”) 















The sporting and medical history of the SA participants has been analysed and reported 
previously.197,198,199,255  Briefly, the majority of both SA-CON (75.9%) and SA-TEN (58.7%) 
participants were active runners.  SA-CON and SA-TEN participants had a similar number of 
years running history (SA-CON: 8.0 ± 8.0 years (n=129) vs SA-TEN: 9.0 ± 10.3 years (n=75); 
P=0.423), but SA-CON participants ran for more hours per week in the two years prior to 
recruitment (SA-CON: 3.3±2.9 hours, n=125) than the SA-TEN participants ran in the two 
years prior to injury (SA-TEN: 2.5±2.8 hours, n=66)(P=0.046).  There was a significant 
difference in the number of years spent playing high-impact sports between the SA-CON 
and SA-TEN groups (SA-CON: 16.5±16.1 years (n=129) vs SA-TEN: 31.1±29.5 years (n=75); 
P<0.001) but not for the number of hours per week spent playing high-impact sports in the 
two years prior to injury (SA-TEN: 4.4±5.2 hours, n=75) or recruitment (SA-CON: 5.1±4.8 
hours, n=129)(P=0.321). The proportion of current (SA-CON: 3.2% vs SA-TEN: 5.4%) and ex-
smokers (SA-CON: 21.4% vs SA-TEN: 25.7%) was not significantly different between the two 
groups (P=0.480).  The physical activity and smoking history of the Australian participants 
was not documented and this is recognised as a limitation to this study.   
The majority of SA-TEN participants suffered from mid-portion AT (71.0%) with a small 
proportion suffering from AT in the distal (27.4%) and upper third of the tendon (1.7%).  This 
distribution was similar in the AUS-TEN participants in which 91.8% of participants suffered 
from mid-portion AT and only 5.9% of participants suffered from AT in the distal tendon.  
There was no difference in the distribution of AT between right (AUS: 24.7%; SA: 26.7%) or 
left (AUS: 23.5%; SA: 27.9%) legs, however, a large proportion of TEN participants suffered 
from bilateral AT (AUS: 51.8%; SA: 45.6%). 
2.3.2. GENOTYPE AND ALLELE FREQUENCIES 
Genotype and minor allele frequency distributions for each of the polymorphisms, together 
with the HWE P-values, are shown in Table 2.3.  The frequency distributions of the SNPs 
tested in this study were found to differ significantly between the South African and 
Australian participant groups at the rs28494505 (P<0.001) and rs6422747 loci (P=0.024). The 
participants from the two groups were therefore summarised separately.  All genotype 
distributions were in HWE except at the rs28494505 locus that deviated significantly in the 















observed for this polymorphism in the AUS samples (Table 2.1).  There were no significant 
genotype effects on age, weight, height, BMI or sex (Table 2.4).  After adjusting for the 
potential confounder’s age, sex and born “here”, there were no significant differences in 
















Table 2.2: Descriptive characteristics of the Australian and South African participants 
 
AUSTRALIA SOUTH AFRICA COMBINED 
















































































































COUNTRY OF BIRTH 
(% Born “here”) 
 
84.9 (174) 78.6 (66) 0.047 81.7 (107) 82.2 (74) 0.304 n/a n/a n/a 
Values are means ± SD (age, height, weight, BMI) or frequencies (sex, country of birth) with n in parentheses. Height, weight & BMI measured at 
recruitment. Combined: AUS and SA participants; Age: Age at injury (TEN) or recruitment (CON); Country of birth: proportion of participants born in Australia 
(AUS) or South Africa (SA) 

















Table 2.3: Genotype and minor allele frequency distributions of the sequence variants 
investigated within the COMP and THBS2 genes in control (CON) and Achilles 
tendinopathy (TEN) groups of Australian (AUS) and South African (SA) populations 
 
CON TEN P-Values 
 
AUS SA AUS SA Country Group 
COMP:      
rs28494505 
     N 165 131 62 94 
  
A/A 0.80 0.54 0.68 0.62 <0.001 0.994 
A/G 0.17 0.43 0.26 0.36   
G/G 0.03 0.03 0.06 0.02   
G 0.12 0.24 0.19 0.2 <0.001 0.919 
HWE 0.043 0.097 0.212 0.345 
  
rs730079 
     
N 205 131 83 93   
G/G 0.34 0.38 0.39 0.35 0.687 0.727 
G/C 0.50 0.43 0.45 0.47   
C/C 0.16 0.19 0.17 0.17   
C 0.41 0.40 0.39 0.41 0.978 0.455 
HWE 0.773 0.206 0.644 0.832   
THBS2: 
rs9505888       
N 185 130 75 93   
G/G 0.26 0.33 0.32 0.32 0.602 0.244 
G/A 0.55 0.52 0.44 0.47   
A/A 0.19 0.15 0.24 0.20   
A 0.46 0.41 0.46 0.44 0.315 0.533 
HWE 0.236 0.467 0.354 0.679   
rs6422747 
     
N 200 130 82 93   
A/A 0.42 0.34 0.34 0.35 0.024 0.645 
A/G 0.51 0.43 0.50 0.47   
G/G 0.08 0.23 0.16 0.17   
G 0.33 0.45 0.41 0.41 0.055 0.480 
HWE 0.058 0.156 0.823 0.832   
rs9283850 
     
N 203 130 79 93   
A/A 0.28 0.28 0.25 0.25 0.965 0.604 
A/G 0.43 0.48 0.53 0.46   
G/G 0.29 0.23 0.22 0.29   
G 0.50 0.47 0.48 0.52 0.889 0.632 
HWE 0.068 0.728 0.655 0.533   
P-values are for the difference between countries and between diagnostic groups respectively, 
adjusted for each other, age at injury/recruitment, sex and whether or not a person was investigated 
in his/her country of birth. The genotype P-value is calculated using a 2-degrees of freedom test, with 
genotypes as categories and the allelic P-value is calculated using an additive allelic model.  HWE 
gives exact P-values from tests of Hardy–Weinberg equilibrium.  N is number of samples genotyped  

















Table 2.4: Genotype effects of COMP and THBS2 polymorphisms on physiological 
characteristics of participants 
POLYMORPHISM 
P-VALUES 
AGE AGE INJURED HEIGHT WEIGHT BMI SEX 
rs28494505 0.177 0.450 0.445 0.855 0.722 0.446 
rs730079 0.457 0.370 0.996 0.992 0.857 0.663 
rs9505888 0.486 0.296 0.343 0.094 0.073 0.121 
rs6422747 0.233 0.098 0.442 0.711 0.778 0.061 
rs9283850 0.939 0.934 0.844 0.381 0.313 0.285 
 Age: Age at recruitment (CON & TEN); Age Injured: Age at recruitment (CON) & age at diagnosis 
(TEN);  P-values for age, age injured, height, weight and BMI are determined by one-way ANOVA; P-
value for sex is determined by Pearsons χ2 analysis 
 
Pairwise linkage disequilibrium (LD) using D’ was calculated between the two COMP 
polymorphisms, and between the three THBS2 polymorphisms, and is presented in Table 
2.5.  LD is the non-random inheritance of alleles at two or more genomic loci.  D’ is 
calculated by comparing the frequency of haplotypes of polymorphisms with the product of 
the individual allele frequencies.  If they are equal, D’ will be equal to zero and will indicate 
that these polymorphisms are not in LD.  If they differ, D’ will not equal zero and will 
indicate that these polymorphisms are in LD.  The closer the D’ value is to one, the tighter 
the LD.  Pairwise LD analysis between the two COMP polymorphisms indicates that 
rs730079 and rs28494505 are in tight LD within this Australian group, but only moderately 
so in this South African group.  The same analysis between the three THBS2 polymorphisms 
indicates that the rs6422747 and rs9505888 polymorphisms are in moderate LD in both 



















Table 2.5: Pairwise linkage disequilibrium (LD) between polymorphisms using D’ 
GROUP 
COMP Polymorphisms THBS2 Polymorphisms 
 rs730079  rs6422747 rs9283850 
AUS CON rs28494505 0.77 
rs9505888 0.59 0.36 
rs6422747 n/a 0.20 
AUS TEN rs28494505 1.00 
rs9505888 0.32 0.06 
rs6422747 n/a 0.08 
SA CON rs28494505 0.38 
rs9505888 0.30 0.43 
rs6422747 n/a 0.19 
SA TEN rs28494505 0.52 
rs9505888 0.52 0.23 
rs6422747 n/a 0.21 
 
2.4. DISCUSSION 
The primary finding of this study is that no association of the selected polymorphisms within 
the COMP and THBS2 candidate genes with Achilles tendinopathy (AT) was detected in 
either of the two groups studied.  Although this study was only sufficiently powered to 
detect large effects on risk of developing AT (OR>2),97,98 and was therefore unlikely to 
detect any risk variant with a small effect, it should be noted that there was no tendency 
towards association with AT for any of the polymorphisms investigated.  We cannot exclude 
the possibility that other polymorphisms within these genes are associated with AT, 
however, all the SNPs investigated in this study were identified as Tag SNPs and it is, 
therefore, unlikely that any SNPs tightly linked to these would show a significant effect on 
risk of AT.  Both THBS2 (38,3kb) and COMP (8,5kb) are small genes and the Tag SNPs 
selected span 11,6kb and 9,9kb respectively, therefore giving moderate coverage of both 
genes.          
Previous work in this area has shown that genetic variants in genes encoding structural 
components of the collagen fibril often have large effects on risk of developing AT 
(OR>2).197,199,231  Furthermore, rare disease-causing mutations within genes encoding these 















disorders including pseudoachondroplasia, multiple epiphyseal dysplasia, osteogenesis 
imperfecta and Ehlers-Danlos syndrome.108,122,183,193,222,268  Based on these observations it 
has been suggested that there is limited redundancy within the biological mechanisms 
leading to collagen fibrillogenesis, and that common polymorphisms in the associated genes 
may have large effects on risk of developing mild connective tissue pathology, such as AT.236 
In particular, the carboxy terminal signature domain of all thrombospondins, which contains 
the EGF-like repeats, type III calcium binding repeats and a carboxy terminal lectin-like 
globule, is highly conserved between the five members of this protein family.7,44  Within the 
COMP gene, mutations in this signature domain result in a spectrum of clinical 
manifestations from mild to severe skeletal dysplasia’s.44,122  There is evidence to suggest 
that variations in this domain alter protein structure and folding, and disrupt calcium 
binding. 49,108,120,161,177  As suggested above, it is therefore possible that the biological role of 
COMP is non-redundant, and that sequence variants which have even a minor effect on 
transcription, translation or protein structure and function will result in at least a mild 
inherited clinical dysplasia.  Taking into account the high sequence conservation of both the 
COMP and THBS2 genes between species, it remains possible that rare sequence variants 
(minor allele frequency 0.1-3.0%) within these genes may be associated with a large effect 
on risk of AT.34,212  Such rare polymorphisms often have a larger effect on risk as well as 
greater penetrance, making them good targets for prophylactic treatments.34  For example, 
the rare TT genotype (<5% in Caucasian populations) of the functional Sp1-binding site 
polymorphism (rs1800012; G>T) within intron 1 of the COL1A1 gene is associated with 
reduced risk of acute soft tissue ruptures.58,81,152,225  Associations of common multifactorial 
diseases with rare polymorphisms are unlikely to be found by either genome wide 
association studies or case-control association studies such as the current study, and further 
work would therefore be necessary to test this hypothesis. 34 
This study, and those presented in chapters four to six, have a number of limitations.  Firstly, 
the TEN participants were significantly heavier at recruitment than the CON participants.  
Given the possible association between adiposity and AT (reviewed in chapter one), this is 
recognised as a limitation to this study, as well as those presented in chapter’s three to five.  















participants reported weight gain due to a decrease in physical activity after developing AT.  
In support of this, Gaida et al.94 state that 40% of participants with AT reported an average 
of 5kg weight gain after onset of symptoms.  In the AUS participants, this difference may 
also be explained by the higher frequency of males in the AUS-TEN group as the difference 
was no longer significant when adjusted for age at recruitment, sex and height.  Secondly, 
another limitation to the studies presented in this thesis is the lack of physical activity and 
smoking data for the Australian participants.  Lastly, the low genotype call rate for some 
polymorphisms in the AUS participants is a limitation.  In this particular study, the genotype 
call rate was low for rs28494505 in the AUS participants (77%).  As discussed in the 
description of the genotyping techniques, this may be due to chemical interference with 
PCR in the AUS DNA samples.  This low genotype call rate is reflected in the deviation from 
HWE in the AUS-CON participants, and the difference in genotype frequencies between the 
SA and AUS groups at this locus.  HWE is a measure of Mendelian inheritance and in a large, 
randomly mating population, alleles which are not subjected to any selective pressures will 
distribute according to the principles of HWE.105  Deviations from HWE at any particular 
locus result from selective pressure and non-random mating within a population, but may 
also indicate technical problems such as genotyping errors and assay non-specificity.119,168  
In the studies presented in this thesis, deviations from HWE may be explained by (i) the 
selection of participants and, (ii) possible genotyping errors.  In the first instance, the 
inclusion and exclusion criteria adhered to during recruitment of participant’s results in a 
study sample that is not a true reflection of the general population as a whole, but rather 
represents two small a d specific samples of this population.  The TEN participants, in 
particular, are a highly selected group but the exclusion criteria also result in selection of the 
CON participants.  In the second instance, it is recognised that genotyping errors may have 
occurred.  However, several steps were taken in all studies included in this thesis to ensure 
that potential contamination and genotyping errors would be detected.  These steps are 
described in the methods section of each study but include repeat genotyping of subsets of 
samples as well as the inclusion of positive (known genotype) and DNA-free controls.  It can, 
therefore, be reasonably assumed that genotyping errors are not the cause of deviations 
















In conclusion, this study did not identify an association between the common sequence 
variants investigated and increased risk of AT.  However, it remains possible that other 
sequence variants (rare or common) within the COMP and THBS2 genes may be associated 































CHAPTER 3: HAPLOTYPE ANALYSIS OF COL27A1 & TNC CANDIDATE GENES AS 
RISK FACTORS FOR ACHILLES TENDINOPATHY 
This chapter has been published in a condensed format as: 
Saunders, C.J., Van Der Merwe, L., Posthumus, M., Cook, J., Handley, C.J., Collins, M., & 
September, A.V. Investigation of variants within the COL27A1 and TNC genes and Achilles 
tendinopathy in two populations. Journal of Orthopaedic Research. 2013. 31(4), 632–637 
3.1. INTRODUCTION 
As reviewed in chapter one of this thesis, genetic susceptibility has been shown to be a 
significant intrinsic risk factor for the development of AT.  This thesis aims to identify 
particular candidate genes that may harbour variants contributing to this genetic 
susceptibility.  Initial research in this area linked the ABO gene, involved in determining 
blood type, on the long arm of chromosome 9 (9q34.2) with risk of developing AT139,146,158 
but this association was not repeated in all studies.170,179  This suggested that another gene 
in close proximity to the ABO gene could be associated with AT instead.  As discussed in 
chapter one, Mokone et al. (2009)199 and September et al. (2009)255 reported an association 
between the rs12722 SNP, also known as the BstUI RFLP, within the 3’-UTR of the COL5A1 
gene with chronic AT in participants from South Africa and Australia.  The COL5A1 gene 
encodes the α1 chain of type V collagen and is mapped to the same locus as the ABO gene 
on the long arm of chromosome 9 (9q34)(Figure 3.1).  This rs12722 polymorphism has 
recently been fine mapped to a functional region within the 3’-UTR of COL5A1 and is 
implicated in maintaining the stability of COL5A1 mRNA.6,164  In addition, three more 
polymorphisms within the 3’-UTR and a polymorphism within a microRNA gene (MIR608) 
which binds to this region have been independently associated with chronic AT, and are 


















Figure 3.1: Ideogram schematic representation of human chromosome 9 
The centromere is the structural region of the chromosome that binds with the nuclear spindle at 
mitosis and meiosis. The telomere refers to each end region of the chromosome, which consists of 
tandem repeats of simple DNA sequences. The chromosome is comprised of a short arm (p) and a 
long arm (q). The dark and light areas reflect the unique banding pattern of chromosome 9 when 
stained using cytogenetic techniques. The nomenclature of each band is indicated on the right side of 
the chromosome. A segment corresponding to the telomeric end of the long arm of chromosome 9 
(9q32–q34), which encompasses the 155 kb COL27A1, 20 kb tenascin C (TN-C), 20 kb ABO and 201 kb 
COL5A1 genes, is also shown. The ve tical lines represent the relative position of each gene, while the 
arrows indicate the direction of their transcription. COL27A1 encodes type XXVII collagen; TNC 
encodes TN-C; ABO encodes the ABO transferases; and COL5A1 encodes the pro-α1(V) chain of type V 
collagen. Mb, megabase 
[Figure and caption reprinted from September et al. (2007)260 with permission from BMJ Publishing 
Group Ltd.] 
 
Mokone et al. (2005)197 also investigated a polymorphism within the TNC gene which 
encodes tenascin-C (TN-C) and is mapped to a region 19,6Mbp upstream of COL5A1.  A 
guanine-thymine (GT) dinucleotide repeat polymorphism within intron 17 of the TNC gene 
was shown to be significantly associated with Achilles tendon injuries (ATI).  In particular, 
alleles containing 12 and 14 GT repeats were over-represented in the ATI group (2=21.6, 
P<0.001), and alleles containing 13 and 17 GT repeats were under-represented in the ATI 















containing 13 and 17 GT repeats were 6.2 fold less likely to develop ATI.  However, the 
possibility that this original association, between the GT dinucleotide repeat polymorphism 
within the TNC gene and AT, was actually due to the association of a polymorphism within a 
neighbouring gene could not be excluded.  Given the large genomic distance between the 
TNC and COL5A1 genes (Figure 3.1), it is unlikely that the association observed with the GT 
dinucleotide repeat polymorphism in TNC reflects that observed in the COL5A1 gene.  
Interestingly, the COL27A1 gene, which encodes the α1 chain of type XXVII collagen, has 
been mapped to chromosome 9q32-33, 708kbp upstream of TNC.35,216  It was therefore 
decided to further explore the chromosomal region which included the TNC and COL27A1 
genes in order to potentially define a smaller genetic interval associated with AT.  
The tenascins (TN) are a family of six glycoproteins – TN-N, TN-R, TN-X, TN-W, TN-Y and TN-
C.136,204  Tenascin-C (TN-C) is a symmetrical hexameric ECM glycoprotein (Figure 3.2 and 3.4) 
and its structure, function and regulation is expertly reviewed by Jones and Jones (2000).136  
Briefly, each TN-C subunit ranges between 190 and 300kDa in size and contains an NH2-
terminal tenascin assembly (TA) domain at which subunit polypeptide chains are disulphide-
linked to form a six-armed hexabrachion.  Adjacent to the TA domain is a thin and rigid 
portion of the arm containing several EGF-like repeats.  These repeats are approximately 31 
amino acids in length and are important in facilitating intrachain disulphide bonds.  This 
region also has counter-adhesive properties that are particularly important during neuronal 
development.  The distal portion of the arm is thick and flexible and contains a variable 
number of fibronectin type III (FNIII) domains.  These FNIII domains are highly elastic, bind 
several ECM proteins, glycosaminoglycans as well as cell surface receptors, and are 
particularly susceptible to proteolytic degradation.10,136,210   The variable number of these 
FNIII domains in tenascin-C subunits is a result of alternative mRNA splicing and this may 
play an important role in the diversity of functions fulfilled by the tenascin-C protein.136,137  
At the COOH-terminus, several polypeptide loops form a fibrinogen globe which binds Ca2+ 
and influences interactions with other proteins.135  These domains are highly conserved and 
are therefore likely to fulfil essential roles.77  TN-C is expressed transiently and in a highly 
constrained manner in embryonic tissues, and during wound healing and tissue remodelling 
in adult tissues.136,137  Its expression is regulated by a number of factors, including several 















that are exposed to high tensile and compressive stress during the transmission of 
mechanical forces and there is evidence that TN-C expression is mechanosensitive.129,130,136  
In particular, Jarvinen et al.130 showed that TN-C expression was down regulated in the OTJ 
of the rat quadriceps tendon following three weeks of immobilisation, increased slightly 
after free remobilisation and increased significantly after intensified remobilisation.  This 
suggests that TN-C expression in the OTJ is regulated by mechanical strain in a dose-
dependent manner.  Similar results were found in the MTJ of the rat Achilles tendon and 
gastrocnemius muscle, as well as the Achilles tendon itself, where mechanical loading was 
again shown to regulate TN-C expression in a dose-dependent manner.129  TN-C expression 
has also been reported to increase significantly in tendinopathy.133,221  
In close proximity to the TNC gene, is the COL27A1 gene (chr9q32) (Figure 3.3) encoding the 
highly conserved α1 chain of type XXVII collagen.  Boot-Handford et al. (2003)35 
hypothesized that mutations in the conserved regions of this gene are likely to be the cause 
of heritable conditions in man although the authors identified no candidate diseases based 
on the chromosomal location of this gene.  The human COL27A1 gene is approximately 
156kbp in length and consists of 61 exons where exons 1 and 2 code for the signal peptide, 
exon 3 codes for the remainder of the N-terminal non-collagenous domain, exons 4 through 
55 encode the highly conserved collagenous domains while the C-terminal noncollagenous 
domain is encoded by exons 56-61.35,216  Type XXVII collagen is expressed in many tissues 
but particularly in developing cartilage,35,216 and is up-regulated in tendinopathy (2.5 fold, 
P<0.005).133 
The aim of this study was, therefore, to test the association of several sequence variants 
spanning a 780.9kbp region which includes the COL27A1 and TNC genes, and a potential 
haplotype consisting of two or more of these SNPs, with Achilles tendinopathy in two 
















Figure 3.2: Tenascin C 
(A) Shaded bands indicate cytogenetic banding patterns for chromosome 9. Chromosomal banding position of COL27A1 and TNC genes are indicated with 
arrows (B) Genomic location and intron/exon structure of TNC including previously cited variants. *Associated with rhinoconjunctivitis [Orsmarck-Pietras et 
al. (2008)211] #Included in haplotype associated with adult asthma [Matsuda et al. (2005)190] $Associated with Achilles tendon injuries [Mokone et al. 
(2005)197] Solid bars represent numbered exons separated by introns (solid lines).  Variants in bold are included in the present study (C) TN-C protein domain 
















Figure 3.3: The α1 chain of type XXVII collagen  
(A) Shaded bands indicate cytogenetic banding patterns for chromosome 9. Chromosomal banding position of COL27A1 and TNC genes are indicated with 
arrows (B) Genomic location & intron/exon structure of COL27A1 including previously cited variants. *Potential clinical source #Associated with height 
[Gudbjartsson et al. (2008)101] Solid bars represent numbered exons separated by introns (solid lines). Variants in bold are included in the present study (C) 
Collagen XVII α1 chain protein domain architecture [Compiled from www.ensembl.org, Boot-Handford et al. (2003)35 and Pace et al. (2003)216; Reprinted 
















Figure 3.4: Tenascin-C hexabrachion  
FNIII: Fibronectin type III; EGF: Epidermal growth factor; TA: Tenascin Assembly                                          
[Adapted from Jones et al. (2000)136] 
 
3.2. MATERIALS AND METHODS 
3.2.1. PARTICIPANTS 
The SA-TEN (n=94), SA-CON (n=131), AUS-TEN (n=85) and AUS-CON (n=209) groups 
described in chapter two were used in this study.  Participant characteristics are presented 
in Table 2.2 and described in 2.3.1. 
3.2.2. VARIANT SELECTION 
Lists of SNPs within the COL27A1 and TNC genes were generated using the NCBI SNP 
database available at http://www.ncbi.nlm.nih.gov/snp/ and were interrogated using the 
Ensembl Genome Browser (http://www.ensembl.org/index.html) and Genome Variation 
Server (GVS)(http://gvs.gs.washington.edu/GVS137/).283  SNPs were selected for analysis 
based on their location, reported minor allele frequency (>0.20), reported heterozygosity 
(>0.35), biological significance and previously reported associations with other multi-
factorial conditions.  Four SNPs within the highly conserved collagenous domains of the 
COL27A1 gene were therefore selected for investigation.  Rs4143245 is a synonymous T>C 
substitution in exon 36 while rs1249744 (A>G), rs753085 (G>A) and rs946053 (T>G) are all 
intronic.  The latter SNP, rs946053, is in intron 41 and has previously been associated with 















Three SNPs in close proximity to the GT dinucleotide repeat polymorphism within intron 17 
of the TNC gene were also selected for investigation.  A non-synonymous G>C substitution 
in exon 24 of the TNC gene, rs13321, results in a change from a glutamic acid residue to a 
glutamine residue at position 2008 in the TN-C protein (Glu2008Gln), and has been 
associated with rhinoconjunctivitis in children.211  Another non-synonymous SNP in exon 17, 
rs2104772 (T>A), results in a change from a leucine to an isoleucine residue at position 1677 
(Leu1677Ile) and is associated with both adult asthma and childhood rhinoconjunctivitis, 
while rs1330363 (C>T) is in intron 15 and has previously been associated with childhood 
rhinoconjunctivitis190,211  
3.2.3. ALLELIC DISCRIMINATION 
SA-CON, SA-TEN, AUS-CON and AUS-TEN participants were genotyped for all seven 
polymorphisms.  Standard PCR and RFLP techniques were used to amplify and genotype 
polymorphisms rs4143245, rs946053, rs13321, rs2104772 and rs1330363.  Unless otherwise 
specified, PCR reactions were carried out in a solution containing 200ng DNA template, 1X 
reaction buffer, 2.0mM Mg2+, 2.5mM each of dATP, dCTP, dTTP and dGTP, 20pmol each of 
the forward and reverse primers and 0.5 units of either Taq DNA polymerase (New England 
Biolabs® Inc., Ipswich, Massachusetts, USA) or SuperTherm Taq DNA polymerase 
(Hoffmann-La-Roche, US) using an XP Thermal Cycler Block (Bioer Technology Co., 
Middlesex, UK).  Reaction buffer was specific to the Taq used.  Thermo-Pol® reaction buffer 
(New England Biolabs® Inc., Ipswich, Massachusetts, USA) consisted of 10mM KCl, 10mM 
(NH4)SO4, 20mM Tris-HCl, 2mM MgSO4 and 0.1% Triton X-100 at pH8.8.   SuperTherm 
reaction buffer (Hoffmann-La-Roche, US) was provided with the SuperTherm Taq DNA 
polymerase and used as per manufacturer’s instructions.  PCR reactions were initiated with 
a five minute denaturing cycle at 94˚C, followed by 35 cycles consisting of 30 seconds 
denaturation at 94˚C, 30 seconds annealing at variant specific temperatures and 40 seconds 
extension at 72˚C with a final five minute extension step at 72˚C.  Variant specific 
oligonucleotide primer sequences, reaction conditions and amplicon sizes are listed in 
Appendix B.  PCR amplicons of polymorphisms rs4143245, rs946053, rs13321, rs2104772 
and rs1330363 were digested overnight for 15 hours with XhoI, BglI, BbvCI, MseI and 















Tetra-primer amplification refractory mutation system (T-ARMS) PCR as described by Ye et 
al308 was used to genotype polymorphisms rs1249744 and rs753085.  Unless otherwise 
specified, PCR reactions were carried out in a solution containing 200ng DNA template, 1X 
reaction buffer, 2.0mM Mg2+, 2.5mM each of dATP, dCTP, dTTP and dGTP, 20pmol each of 
the forward and reverse primers and 0.5 units of either Taq DNA polymerase (New England 
Biolabs® Inc., Ipswich, Massachusetts, USA) or SuperTherm Taq DNA polymerase 
(Hoffmann-La-Roche, US) using an XP Thermal Cycler Block (Bioer Technology Co., 
Middlesex, UK).  Reaction buffer was specific to the Taq used.  Thermo-Pol® reaction buffer 
(New England Biolabs® Inc., Ipswich, Massachusetts, USA) consisted of 10mM KCl, 10mM 
(NH4)SO4, 20mM Tris-HCl, 2mM MgSO4 and 0.1% Triton X-100 at pH8.8.   SuperTherm 
reaction buffer (Hoffmann-La-Roche, US) was provided with the SuperTherm Taq DNA 
polymerase and used as per manufacturer’s instructions.  PCR reactions were initiated with 
a five minute denaturing cycle at 95˚C, followed by an initial five cycles consisting of 25 
seconds denaturation at 95˚C, 45 seconds annealing at 70˚C and 30 seconds extension at 
72˚C.  This was followed by 27 cycles consisting of 25 seconds denaturation at 95˚C, 45 
seconds annealing at variant specific temperatures and 30 seconds extension at 72˚C with a 
final 10 minute extension step at 72˚C.  Variant specific oligonucleotide primer sequences, 
reaction conditions and amplicon sizes are listed in Appendix B.  Genotyping accuracy was 
confirmed by allele specific PCR in a subset of samples, and a small subset of samples were 
genotyped twice.  A number of known genotype positive controls and DNA-free controls 
were included on each 96-well PCR plate.  The number and proportion of successfully 
genotyped samples is presented in Table 3.1.       
All PCR amplicons and restriction fragments were mixed with SYBER Gold nucleic acid gel 
stain (Invitrogen Molecular Probes, Oregon, USA) and, together with a 100bp DNA size 
standard (Promega Corporation, Madison, Wisconsin, USA), separated by electrophoresis on 
2% agarose (100V for 35 minutes) and 6% PAGE (120V for 2 hours) gels respectively.  All gels 
were photographed under UV light using a photodocumentation system (Uvitec Limited, 















3.2.4. STATISTICAL ANALYSIS 
The programming environment R230 and R packages were used for all analyses.  The R 
package, Genetics,296 was used to estimate genotype and allele frequencies and HWE 
probabilities.  Logistic regression was used to compare genotype, allele and allele-
combination frequencies between the TEN and CON groups, as well as SA and AUS groups.  
Results with a P-value of less than 0.05 were accepted as significant.  As the genotype 
frequencies did not differ significantly between either AUS-TEN and SA-TEN or AUS-CON and 
SA-CON, the two populations were combined for further analyses.  All analyses were 
corrected for potential confounding by including age, sex, and group (SA or AUS) in the 
models as fixed effects.  Haplotype frequencies were inferred for both the SA and AUS 
groups using the R package, haplo.stats.,249,266 and were based on the genotype data of all 
seven polymorphisms.  No adjustments were made for multiple testing because it has been 
suggested that these corrections, such as Bonferroni, markedly overcorrect for an inflated 
false-positive rate and unnecessarily reduce power in genetic association studies where 
background LD exists between SNPs.207,220 
Genotype effects on age, height, weight, BMI and sex were determined by a one-way 
analysis of variance (ANOVA) using STATISTICA version 10 (StatSoft Inc., Tulsa, OK, USA).   
Statistical significance was accepted when P<0.05. 
3.2.5. PRE-MRNA STRUCTURE MODELLING 
Sfold software72,73 (http://sfold.wadsworth.org accessed May 2012) was used to predict 
differences in pre-mRNA secondary structure in ancestral versus minor alleles for rs946053, 
rs13321 and rs2104772. Briefly, the Sfold algorithm generates statistically representative 
samples from the ensemble of secondary structures in proportion to their Boltzmann 
weights.72,73  The centroid structure is that which has the minimum base-pair distance to all 
the structures in a given set and most accurately represents the tendency of a set of 
structures, either in a free energy cluster (cluster centroid) or the entire Boltzmann 
weighted ensemble of structures (ensemble centroid).  In this study, the ten cluster 
centroids and the ensemble centroid were examined for differences between the ancestral 
and minor allelic forms of these three polymorphisms.  In particular, structures were 



















Table 3.1: Number and proportion of recruited participants successfully genotyped for the seven polymorphisms investigated in this study 
Total number of participants 
Number and proportion of participants genotyped 
rs4143245 rs1249744 rs753085 rs946053 rs13321 rs2104772 rs1330363 
AUS-CON 209 194 93% 205 98% 206 99% 198 95% 200 96% 195 93% 158 76% 
AUS-TEN 85 77 91% 84 99% 83 98% 80 94% 79 93% 84 99% 64 75% 
TOTAL 294 271 92% 289 98% 289 98% 278 95% 279 95% 279 95% 222 76% 
SA-CON 131 130 99% 130 99% 128 98% 131 100% 129 98% 127 97% 129 98% 
SA-TEN 94 93 99% 94 100% 93 99% 91 97% 94 100% 90 96% 91 97% 















comparing folding and structural elements (e.g. hairpin loops), and single-strandedness.  In 
general, proteins regulating splice site selection preferentially recognise single-stranded 
rather than double-stranded pre-mRNA,111 and folding of pre-mRNA, based on base-pairing 
and hydrophobic interactions, results in occlusion or exposure of cis-acting regulatory 
elements which effect accessibility of regulatory proteins.43  Secondary pre-mRNA structures 
are, therefore, important in determining splicing outcome.43,111  Increased accessibility is 
assumed where pre-mRNA is single-stranded and/or presented in a protruding hairpin loop.  
Decreased accessibility is assumed where pre-mRNA is double stranded and/or folded in 
such a way as to be hidden by other secondary structures. 
3.2.6. FUNCTIONAL ANALYSIS OF VARIANTS 
The online software programmes SIFT,160 PolyPhen-28 and FastSNP310 were used to predict 
functional effects of the three SNPs implicated by the haplotype analysis (rs946053, rs13321 
and rs2104772).    The FASTSNP310 analysis tool was used to identify any putative 
transcription factor binding sites and regulatory elements in close proximity to the SNPs and 
predict a risk for deleterious effects of that SNP.   
3.3. RESULTS 
3.3.1. GENOTYPE AND ALLELE FREQUENCIES 
Genotype and allele frequency distributions for each of the polymorphisms, together with 
HWE probabilities, are shown in Tables 3.2 and 3.3.  The relationship between the 
genotypes and AT was tested and found not to differ significantly between the SA and AUS 
groups. Data from the population groups was, therefore, combined for all further analyses.  
Age, sex and country group were considered confounders (Table 2.2) and were adjusted for 
in all analyses by including them in the models. 
After adjusting for the confounders age, sex and country group there were no significant 
differences in either genotype or allele frequencies between the CON and TEN groups at the 
rs4143245, rs1249744, rs753085, rs946053 and rs13321 loci. However, a significant 

















Table 3.2: Genotype and minor allele frequency distributions of the sequence variants 
investigated within the COL27A1 gene in control (CON) and Achilles tendinopathy (TEN) 
groups of South African (SA) and Australian (AUS) populations 
 
CON TEN P-Values 
 
AUS SA AUS SA Country Group 
COL27A1:      
rs4143245 
     N 194 130 77 93 
  
T/T 0.39 0.44 0.44 0.42 0.601 0.610 
T/C 0.49 0.45 0.38 0.47   
C/C 0.12 0.12 0.18 0.11   
C 0.37 0.34 0.37 0.34 0.314 0.933 
HWE 0.538 1.000 0.092 0.818 
  
rs1249744 
     
N 205 130 84 94   
A/A 0.55 0.54 0.46 0.40 0.340 0.106 
A/G 0.37 0.36 0.45 0.47   
G/G 0.08 0.10 0.08 0.13   
G 0.27 0.28 0.31 0.36 0.159 0.084 
HWE 0.476 0.276 0.798 1.000   
rs753085 
     
N 206 128 83 91   
C/C 0.56 0.54 0.54 0.43 0.186 0.199 
C/T 0.33 0.34 0.39 0.47   
T/T 0.11 0.13 0.07 0.10   
T 0.27 0.29 0.27 0.34 0.083 0.440 
HWE 0.013 0.034 1.000 0.644   
rs946053 
     
N 198 131 80 93   
G/G 0.23 0.24 0.23 0.38 0.149 0.248 
G/T 0.56 0.56 0.58 0.48   
T/T 0.22 0.21 0.20 0.14   
T 0.49 0.48 0.49 0.38 0.074 0.096 
HWE 0.155 0.223 0.262 1.000   
P-values are for the difference between countries and between diagnostic groups respectively, 
adjusted for each other, age, sex and whether or not a person was investigated in his/her country of 
birth. The genotype P-value is calculated using a 2-degrees of freedom test, with genotypes as 
categories and the allelic P-value is calculated using an additive allelic model.  HWE gives exact P-
values from tests of Hardy–Weinberg equilibrium.  N is number of samples genotyped. Bold P-values 
















significantly less frequently in TEN than CON (OR 0.70, 95% CI: 0.52-0.94; P=0.017). For 
rs1330363, the G-allele was significantly more prevalent in TEN than in CON after adjusting 
for the three known confounders (OR 1.46, 95% CI: 1.06-2.03; P=0.020), although any 
association found with rs1330363 should be interpreted with caution due to the smaller 
number of Australian participants genotyped for this SNP (76%)(Table 3.1).  At the rs753085 
locus, the genotype frequency for both the AUS CON (P=0.013) and SA CON (P=0.034) 
deviated from HWE with too few heterozygotes observed (Table 3.2).  There were no 
genotype effects on age, weight, height, BMI or sex (Table 3.4). 
Table 3.3: Genotype and minor allele frequency distributions of the sequence variants 
investigated within the TNC gene in control (CON) and Achilles tendinopathy (TEN) groups 
of South African (SA) and Australian (AUS) populations 
 
CON TEN P-Values 
OR (95% CI) 
 
AUS SA AUS SA Country Group 
TNC: 
rs13321       
 
N 200 129 79 94    
C/C 0.48 0.52 0.52 0.39 0.430 0.291  
C/G 0.46 0.40 0.41 0.48    
G/G 0.06 0.08 0.08 0.13    
G 0.29 0.28 0.28 0.37 0.418 0.166  
HWE 0.123 1.000 1.000 0.828    
rs2104772 
     
 
N 195 127 84 90    
A/A 0.33 0.31 0.36 0.43 0.141 0.056  
A/T 0.49 0.45 0.54 0.40    
T/T 0.18 0.24 0.11 0.17    
T 0.43 0.46 0.38 0.37 0.398 0.017 0.70 (0.52-0.94) 
HWE 1.000 0.286 0.248 0.181    
rs1330363 
     
 
N 158 129 64 91    
A/A 0.34 0.39 0.22 0.27 0.220 0.065  
A/G 0.46 0.46 0.52 0.53    
G/G 0.20 0.16 0.27 0.20    
G 0.43 0.38 0.52 0.46 0.082 0.020 1.46 (1.06-2.03) 
HWE 0.516 0.712 1.000 0.674    
P-values are for the difference between countries and between diagnostic groups respectively, 
adjusted for each other, age, sex and whether or not a person was investigated in his/her country of 
birth. The genotype P-value is calculated using a 2-degrees of freedom test, with genotypes as 
categories and the allelic P-value is calculated using an additive allelic model.  HWE gives exact P-
values from tests of Hardy–Weinberg equilibrium.  N is number of samples genotyped. Bold P-values 



















AGE AGE INJURED HEIGHT WEIGHT BMI SEX 
rs4143245 0.546 0.879 0.914 0.435 0.317 0.554 
rs1249744 0.235 0.262 0.399 0.934 0.441 0.578 
rs753085 0.062 0.265 0.903 0.192 0.070 0.500 
rs946053 0.646 0.988 0.599 0.932 0.905 0.975 
rs13321 0.457 0.724 0.755 0.372 0.525 0.605 
rs2104772 0.558 0.125 0.986 0.616 0.246 0.569 
rs1330363 0.154 0.502 0.668 0.592 0.712 0.709 
Age: Age at recruitment; Age Injured: Age at recruitment (CON) & age at diagnosis (TEN);  P-values 
for age, age injured, height, weight and BMI are determined by one-way ANOVA; P-value for sex is 
determined by Pearsons χ2 analysis 
 
3.3.2. HAPLOTYPE ANALYSIS 
Haplotypes consisting of various combinations of the seven SNPs investigated were inferred 
and are presented in Table 3.5.  There was no significant difference between the combined 
CON and combined TEN groups in the frequency of inferred haplotypes constructed from all 
seven polymorphisms (P=0.511). However, significant differences in haplotype frequencies 
were noted between the CON and TEN groups, after adjusting for the confounders, when 
the inferred haplotypes were constructed from the following six polymorphisms: rs4143245; 
rs1249744; rs753085; rs946953; rs13321 and rs2104772 (P=0.029). Similarly, significant 
differences in the haplotype distributions were noted when haplotypes were constructed 
using the most distal COL27A1 polymorphism, rs946053, and the two proximal TNC 
polymorphisms, rs13321 and rs2104772 (P=0.026).  
Table 3.6, Table 3.7 and Figure 3.5. show the inferred frequencies of each combination of 
alleles in the implicated six and three SNP haplotypes.  In the six SNP haplotype, the TACTCT 
haplotype occurs at the highest combined frequency and is therefore used as the reference 
haplotype.  In the three SNP haplotype the GCA haplotype occurs at the highest combined 















frequently observed in the TEN group (27%) compared to the CON group (18%) and was 
therefore significantly associated with an increased risk of AT (P=0.019).  Three haplotypes 
showed significantly lower odds of TEN versus the GCA haplotype [(GCT: OR 0.35, 95% CI: 
0.17-0.70)(TCA: OR 0.38, 95% CI: 0.18-0.81)(TGT: OR 0.09, 95% CI: 0.01-0.85)].  This 
association is reflected in the association of a six SNP haplotype starting with rs4143245 
with AT, in which the TACTCT haplotype allele occurs at a significantly higher frequency 
amongst controls (CON: 0.11 vs TEN: 0.08, P=0.024)(Table 3.6).  
 
 
Table 3.5: The probability of differences in the frequency of inferred haplotypes between 




NUMBER OF POLYMORPHISMS (P) 
2 3 4 5 6 7 
COL27A1 
rs4143245 9:117033022T>C 0.276 0.293 0.387 0.245 0.029 0.511 
rs1249744 9:117043352A>G 0.208 0.434 0.797 0.175 0.513  
rs753085 9:117045447G>A 0.398 0.633 0.122 0.448  
rs946053 9:117049891T>G 0.185 0.026 0.134  
TNC 
rs13321 9:117792583C>G 0.091 0.323  
rs2104772 9:117808785T>A 0.114  
rs1330363 9:117813990C>T  
Polymorphisms listed indicate the first polymorphism of the haplotype and ‘number of 
polymorphisms’ indicates the total number of adjacent polymorphisms included in that haplotype 
analysis. Pairs of haplotypes were inferred and tested for association with group (CON vs. TEN) 

















Table 3.6: Inferred allele frequencies for a six SNP haplotype including rs4143245-
rs1249744-rs753085-rs946053-rs13321-rs2104772 
ALLELE CON TEN P ODDS RATIO (95% CI) 
TACTCT 0.11 0.08 0.024 1 P 
TGTGCT 0.08 0.06 0.781 1.55 (0.49-4.89) 0.459 
TACGCA 0.07 0.11 0.733 2.22 (0.69-7.16) 0.183 
TGTGCA 0.07 0.09 0.242 2.13 (0.78-5.83) 0.141 
CACTCT 0.06 0.09 0.462 2.04 (0.65-6.40) 0.222 
CACTCA 0.07 0.05 0.151 0.79 (0.22-2.76) 0.707 
TACTCA 0.06 0.04 0.815 1.88 (0.47-7.49) 0.373 
TACGGA 0.07 0.03 0.959 1.39 (0.44-4.41) 0.579 
CACTGA 0.06 0.03 0.770 1.32 (0.34-5.06) 0.686 
TGTGGA 0.05 0.05 0.337 2.23 (0.66-7.51) 0.196 
TACTGA 0.02 0.07 0.605 2.72 (0.75-9.94) 0.131 
CACGCA 0.04 0.03 0.147 2.87 (0.86-9.57) 0.087 
CACGCT 0.04 0.03 0.314 0.69 (0.07-6.80) 0.751 
TACGCT 0.04 0.02 0.106 0.83 (0.15-4.60) 0.827 
CACTGT 0.02 0.02 0.977 1.09 (0.01-103.79) 0.970 
TACTGT 0.02 0.00 0.227 0.37 (0.01-16.24) 0.607 
CACGGA 0.00 0.05 0.005 67.01 (0.15-30687.31) 0.179 
Values are inferred haplotype frequencies and P-value for a test of equality of those frequencies.  
















Table 3.7: Inferred allele frequencies for a three SNP haplotype including rs946053-
rs13321-rs2104772 
ALLELE CON TEN P ODDS RATIO (95% CI) 
GCA 0.18 0.27 0.019 1 P 
TCT 0.19 0.20 0.083 0.64 (0.37-1.10) 0.106 
GCT 0.18 0.10 0.061 0.35 (0.17-0.70) 0.003 
TCA 0.15 0.10 0.324 0.38 (0.18-0.81) 0.013 
GGA 0.12 0.14 0.107 0.73 (0.36-1.50) 0.390 
TGA 0.10 0.12 0.394 0.92 (0.49-1.73) 0.792 
TGT 0.04 0.01 0.246 0.09 (0.01-0.85) 0.036 
GGT 0.02 0.06 0.403 1.65 (0.52-5.22) 0.394 
Values are inferred haplotype frequencies and P-value for a test of equality of those frequencies.  
Odds ratios of AT are calculated versus the GCA reference allele. Bold P-values are <0.05 
 
 
Figure 3.5: Inferred allele frequencies for a three SNP haplotype containing rs946053-
rs13321-rs2104772 















3.3.3. PREDICTED FUNCTIONAL EFFECTS OF SELECTED SNPS 
Bioinformatics tools were used to investigate the functional effects of the SNPs implicated 
by the three SNP haplotype (rs946053; rs13321; rs2104772) and revealed several potentially 
functional elements that overlap this region.  These are summarised in Table 3.8 and 
described in detail below.    
Rs946053 (G>T) is intronic and therefore not listed on either the SIFT160 or PolyPhen-28 
database.  FASTSNP310 reports a very low to low predicted risk associated with this SNP, 
despite the elimination of a c-Myc transcription factor binding site in the presence of the 
minor T-allele.  In addition, for the majority of Sfold72,73 predicted pre-mRNA secondary 
structures generated from the 457bp DNA sequence surrounding this SNP, including the 
ensemble centroid, the G-allele is predicted to result in a more single stranded pre-mRNA 
conformational structure immediately surrounding the SNP compared to the ancestral T-
allele (Figure 3.6).  This suggests that the c-Myc binding site, which is abolished in the 
presence of the minor T-allele, is normally highly exposed.   
Rs13321 (G>C) involves a non-synonymous amino acid substitution (Glu2008Gln) which is 
predicted to be tolerated (SIFT160) and benign (PolyPhen-28).  Furthermore, FASTSNP310 
predicts a low to medium risk associated with this sequence variant which falls within, but 
does not abolish, a GATA transcription factor binding site.  The Sfold72,73 predicted pre-
mRNA secondary structure for this polymorphism suggests that this transcription factor 
binding site is exposed by unfolding when the G-allele is present.  FASTSNP310 also predicts a 
splicing regulation effect with the different allelic forms of this SNP.  An exonic splicing 
enhancer (ESE) and an exonic splicing silencer (ESS) occur 7bp and 15bp downstream of the 
SNP respectively.  Analysis of the Sfold predicted centroid structures suggests that the ESE is 
more accessible, and the ESS is less accessible, in the secondary pre-mRNA structure of the 
C-allele compared to the G-allele.  This is, however, not evident in the representative 
ensemble centroid (Figure 3.7).   Although this configuration is not mirrored in the ensemble 
centroid structure, the majority of cluster centroid structures generated using the G-allele 
sequence predict the ESS to be more exposed in a single-stranded hairpin loop, while the 
















Rs2104772 (T>A) also involves a non-synonymous amino acid substitution (Leu1677Ile) 
which is predicted to be tolerated (SIFT160) and benign (PolyPhen-28).  FASTSNP reports a 
low to medium risk associated with this missense SNP, but does not predict any change in 
transcription factor binding sites or ESE and ESS elements.  In addition, analysis of the Sfold 
predicted pre-mRNA secondary structures reveals very similar centroid structures when 
comparing the A- and T-alleles (Figure 3.8).   
In summary, (i) rs946053 (G>T) lays within a putative c-Myc transcription factor binding site 
which is eliminated in the presence of the T-allele; (ii) rs13321 (G>C) lays within a putative 
GATA transcription factor binding site, and putative splicing regulatory elements are found 
7bp and 15bp downstream of this SNP; but (iii) no predicted functional effects were 
identified for the sequence region overlapping rs2104772 (T>A). 
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Figure 3.7: The ensemble (left) and cluster 1 (right) centroids of Sfold predicted pre-mRNA secondary structures for the sequence 
surrounding rs13321 is both the G- and C-alleles 















Figure 3.8: The ensemble centroid Sfold predicted pre-mRNA secondary structures for the sequence surrounding rs2104772 in both the A- 
and T-alleles
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3.3.4. LINKAGE DISEQUILIBRIUM 
Figure 3.9 shows the D’ and r estimates for LD between all seven SNPs included in this study, 
based on the genotype data.  Variant pairs that are in tight LD are indicated in light yellow 
while pairs that are not in LD are indicated with dark red.  The TNC SNPs rs13321, rs2104772 
and rs1330363 are in tight LD in the TEN groups and, to a lesser degree, in the CON groups.  
Similarly, the COL27A1 SNPs rs4143245, rs1249744, rs753085 and rs946053 are in tight LD 
in both TEN groups and AUS-CON, and moderate LD in the SA-CON group.    
 
Figure 3.9: Heatmaps showing linkage disequilibrium (LD) estimates between seven 
polymorphisms within the COL27A1 and TNC genes in each of the groups investigated 
LD based on D’ and r estimates.  Light yellow indicates SNP pairs in tight LD, red indicates SNP pairs 
















The primary finding of this study is that the GCA haplotype, consisting of the COL27A1 
rs946053 (T>G), TNC rs13321 (G>C) and TNC rs2104772 (T>A) SNPs, is significantly 
associated with AT in a South African and Australian population.  Mokone et al. (2005)197 
previously described the association between a GT dinucleotide microsatellite marker within 
the TNC gene and ATI.  As microsatellite markers have a long range effect, the possibility 
that this polymorphism was in LD with another neighbouring risk polymorphism could not 
be excluded.  The aims of this case-control genetic association study were therefore, (i) to 
test this association in samples representative of two populations (SA and AUS) and, (ii) to 
narrow the interval containing the potential risk allele by conducting genetic analysis of the 
region containing both candidate genes, COL27A1 and TNC, using SNPs instead of the long 
range microsatellite marker used in the original study.  
The results of this genetic analysis of the combined SA and AUS groups further implicates 
the TNC gene region, as well as the COL27A1 gene region, in increased risk of developing AT.  
In particular, the T-allele of rs2104772 was associated with a 0.7 fold reduced risk of 
developing AT (95% CI:0.52-0.94) and the G-allele of rs1330363 was associated with a 1.46 
fold reduced risk of developing AT (95% CI:1.06-2.03).  The identification of a risk haplotype 
(GCA) implicates the genetic interval spanning SNPs rs946053, rs13321 and rs2104772 with 
increased risk of AT.  It is interesting to note that the GT dinucleotide microsatellite 
(GenBank accession number: Z11654), previously associated with AT in the initial South 
African ATI group,197 localises to intron 17 while rs13321 and rs2104772 localise to exons 24 
and 17 respectively.  Although rs1330363 was independently associated with AT, it was not 
implicated in the haplotype analysis.  This is most likely due to the lower number of AUS 
participants successfully genotyped for this SNP, which is a limitation to the study.  The 
reason for the lower genotype call rate (76%) for this SNP is the same as that described for 
rs28494505 in chapter two. 
The observed allele and haplotype associations with AT suggest that either (i) the SNPs 
implicated are in LD with a true risk polymorphism within, close to or between the TNC or 
COL27A1 genes, or (ii) one or a combination of these SNPs exerts a biological effect and is a 















shown to be associated with other multi-factorial phenotypes.  Although there were no 
genotype effects of rs946053, nor any of the other SNPs investigated in this study, on 
height, the COL27A1 rs946053 SNP has previously been associated with human height.101  
The TNC SNPs rs13321 and rs2104772 were associated with rhinoconjunctivitis in children 
from the PARSIFAL study,211 and rs2104772 is associated with adult asthma in a Japanese 
population.190  Considered in conjunction with the bioinformatics analysis conducted in this 
study, this suggests that the implicated haplotype harbours potentially functional regulatory 
elements.   
The T-allele of rs946053 is predicted to abolish a c-Myc binding site.  This oncogenic protein 
is a global regulator of transcription with an extensive target gene network.65  In particular, 
it represses transcription of many collagen genes as well as genes involved in cell adhesion 
and cell growth arrest, possibly by interfering with activators of gene expression.65     In the 
ancestral G-allele, this binding site is situated in a stretch of pre-mRNA that is predicted to 
be single stranded and, therefore, easily accessible for binding.  Despite the location of this 
binding site in the distal region of the COL27A1 gene, its abolishment when the T-allele is 
present may result in less transcriptional repression and inappropriate expression of the α1 
chain of type XXVII collagen 
Of particular interest is the functional modelling of the sequence surrounding rs13321.  This 
polymorphism occurs in the region encoding the fibrinogen globe domain of the TN-C 
protein.  This highly conserved globe is formed by several polypeptide loops and binds Ca2+ 
thereby influencing TN-Cs interaction with other proteins.77,136  The G>C substitution at 
rs13321 results in an amino acid change from a Glutamic acid (Glu) residue in the G-allele to 
its uncharged amide derivative Glutamine (Gln) at position 2008.  This may affect the folding 
of the protein in this domain and, subsequently, the interaction of TN-C with its associated 
proteins.211  In addition, rs13321 falls within, but does not abolish, a GATA transcription 
factor binding site.  The GATA family of transcription factors bind to the (G/A)GATA(A/T) 
sequence motif and interact with other transcriptional regulators to influence 
haematopoiesis, cell differentiation and cell proliferation.99  In particular, GATA-6 has been 
shown to repress TNC expression through response elements in the promoter,99 and this 















predicted pre-mRNA secondary structure for the sequence surrounding this binding site and 
rs13321 suggests that the GATA transcription factor binding site is more accessible in the C-
allele.  In addition, this polymorphism results in considerable changes in the predicted 
secondary structure  of the pre-mRNA molecule containing both the ESE and ESS elements 
and may, therefore, have an effect on splicing regulation in two ways: (i) by affecting 
binding of splicing regulators directly through exposure or occlusion of these elements and, 
(ii) by altering the relative distance between these elements which leads to alterations in 
splice site usage and efficiency.43,111 This is noteworthy because intron/exon boundaries 
occur 51bp and 102bp up- and downstream of this polymorphism respectively.  It is 
therefore possible that the rs13321 polymorphism may subtly affect the function of the TN-
C protein in one, or all, of three ways: (i) altering its’ interaction with other proteins at the 
fibrinogen globe, (ii) altering transcriptional regulation, and subsequent expression, by a 
GATA transcription factor, or (iii) altering splicing regulation in the region of the SNP.   
Rs2104772 and the GT dinucleotide repeat polymorphism both occur in the DNA sequence 
coding for the fibronectin type III (FnIII) repeat domains of the TN-C protein.  These domains 
confer elasticity and are highly susceptible to protein degradation during remodelling of TN-
C containing matrices.136  The T>A substitution in rs2104772 does not result in any 
noteworthy changes in the predicted pre-mRNA secondary structure, however it does result 
in an amino acid change from Leucine to Isoleucine (Leu1677Ile) within the alternatively 
spliced FnIII-D domain.  Matsuda et al.190 previously suggested that Ile1677 results in steric 
hindrance with Phe1636 and, consequently, instability of the beta-sheet and alterations in 
the molecular elasticity of this domain.  As TN-C is upregulated in wound healing, tissue 
remodelling,137 tendinopathy133,221 as well as in response to increased load,129 it is 
reasonable to hypothesize that it plays a vital role in the adaptation of tendon tissue during 
the initial reactive and the tendon disrepair phases of tendinopathy.62  Subtle alterations in 
its protein interactions, transcription levels and elastic properties may result in an 
inappropriate healing response during the early stages of reactive tendinopathy and 
predispose the tendon to early progression towards advanced stages of tendinopathy. 
The majority of limitations to this study have already been discussed in chapter two.  These 















and the lack of physical activity and smoking data for the Australian participants.  As with 
rs28494505 in chapter two, there was a low genotype call rate (76%) for rs1330363 within 
the TNC gene in this study which is recognised as a limitation to this study.  For this reason, 
the finding that the G-allele of this SNP was significantly associated with AT should be 
interpreted with caution.  Although not necessarily a limitation to this study, it should be 
noted that the S-fold predicted changes in pre-mRNA secondary structure are generated 
using a short stretch of DNA (<500bp) surrounding each SNP and do not take the cellular 
milieu into account.  Notwithstanding, it is of value to note that a simple base-pair 
substitution can result in considerable changes in pre-mRNA secondary structures. 
3.5. CONCLUSION 
In conclusion, the main finding of this study is the further implication of the genomic region 
containing the TNC and COL27A1 genes in influencing risk of Achilles tendinopathy.  This 
study maps the potential risk allele to a 759kbp region containing the GCA haplotype 
(rs946053; rs13321; rs2104772), as well as the 3’-end of the COL27A1 gene (exons 42-61, 
3’UTR) and the 5’-end of the TNC gene (5’UTR, exons 1-17).  The region implicated by this 
haplotype may have functional effects on the transcription, structure and properties of TN-C 
and the α1 chain of type XXVII collagen.  One can further hypothesize that these effects on 
protein properties may modify subsequent protein-protein interactions, or other protein-
environment interactions thereby compromising wound healing, tissue remodelling and 
adaptation.  Further research is required to replicate this finding in an independent study 
and to explore the functional significance of this interval spanning the two genes.  
Understanding the functional mechanisms underlying genetic associations is important in 
elucidating disease mechanisms underlying AT.  Only once we fully understand the disease 

















CHAPTER 4: COLLAGENS OF THE EXTRACELLULAR MATRIX AND ACHILLES 
TENDINOPATHY 
4.1. INTRODUCTION 
The predominant protein in the extracellular matrix (ECM) of tendons is collagen.  In 
particular, type I collagen fibrils are the basis of the hierarchical structure of tendons and 
determine the mechanical strength of tendon tissue.78,115,234  Type V collagen is a minor 
fibrillar collagen that is co-expressed with type I collagen fibrils and regulates both the size 
and shape of these heterotypic fibrils during development and growth.32,123,297  The triple 
helical domain of type V collagen monomers lays within the type I collagen fibrils with the 
NH2-terminal domain exposed, and this exposed NH2-terminal domain is responsible for the 
regulation of type I collagen fibril diameter by type V collagen.32  In particular, the presence 
of increasing amounts of type V collagen results in progressively decreasing diameters of 
type I collagen fibrils, while reductions in type V collagen result in abnormally large fibrils 
being deposited into the matrix.32  Type V collagen predominantly exists as heterotrimers of 
two α1(V) and one α2(V) chain of type V collagen, however homotrimers of the α3(V) chain 
of type V collagen have also been reported.32,123  As described in chapter one, Mokone et al. 
(2006)199 and September et al. (2009)255 previously reported an association of the BstUI 
RFLP (rs12722) within the 3’-UTR of the COL5A1 gene, which encodes α1(V), with chronic AT 
in both a South African and Australian group.  In particular, the CC genotype of this SNP was 
associated with a significantly decreased risk of developing AT.  Recent investigation of this 
3’-UTR within the COL5A1 gene found further polymorphisms to be associated with AT, 
which were suggested to alter the predicted secondary structure of the 3’-UTR and regulate 
mRNA stability.6,164  In particular, the alleles associated with AT appear to increase the 
stability of COL5A1 3’-UTR mRNA.164  The α2(V) chain is encoded by the COL5A2 gene which 
has been mapped to chromosome 2q32.  The α3(V) chain is encoded by the COL5A3 gene 
which is expressed in the developing tendons and ligaments of murine embryos and has 
been mapped to chromosome 19p13.2.123  Like COL5A1, mutations within the COL5A2 gene 
have also been associated with various forms of EDS and abnormal fibrillogenesis.32,193,238  















of classical EDS in which these COL5A1 and COL5A2 gene variants have been excluded.123  
This emphasizes the importance of type V collagen fibrils in the ECM of connective tissue.  
Type III collagen is a major fibrillar collagen and is important in the healing process of 
tendons.173  It is laid down early in the repair process and rapidly forms disulphide cross-
links which stabilise the newly synthesized matrix of the repair site.52  These cross-links are 
easily degraded which allows for rapid growth and remodelling of tissue.52  However, type III 
collagen fibres are thinner than type I collagen fibres and their presence therefore causes a 
decrease in the tensile strength of the tissue.78  This is particularly relevant in AT where 
degeneration of tendon tissue leads to a chronic healing response and results in a slow 
accumulation of type III collagen.78  Type III collagen exists as a homotrimer of three α1(III) 
chains,268 encoded by the COL3A1 gene which lays in tail-to-tail orientation 22kbp apart 
from COL5A2.285  A missense polymorphism (rs1800255) in exon 30 of this gene has 
previously been associated with other connective tissue disorders such as pelvic organ 
prolapse and floppy mitral valve/mitral valve prolapse.51,54,134,156 
The primary aim of this study was, therefore, to investigate the association of 
polymorphisms within the COL3A1, COL5A2 and COL5A3 genes with AT in South African and 
Australian groups.  A second aim was to investigate interactions between these 
















4.2. MATERIALS AND METHODS 
4.2.1. PARTICIPANTS 
The SA-TEN (n=94), SA-CON (n=131), AUS-TEN (n=85) and AUS-CON (n=209) groups 
described in chapter two were used in this study.  Participant characteristics are presented 
in Table 2.2 and described in 2.3.1. 
4.2.2. VARIANT SELECTION 
Lists of SNPs within the COL5A3, COL5A2 and COL3A1 genes were generated using the NCBI 
SNP database available at http://www.ncbi.nlm.nih.gov/snp/ and were interrogated using 
the Ensembl Genome Browser (http://www.ensembl.org/index.html) and the Genome 
Variation Server (GVS)(http://gvs.gs.washington.edu/GVS137/).283 SNPs were selected for 
analysis based on their location within conserved regions of the genes, reported minor allele 
frequency (>0.20), reported heterozygosity (>0.35), biological significance and previously 
reported associations with other multi-factorial conditions.   
Three SNPs within the COL5A3 gene were investigated (Figure 4.1).  The synonymous 
453C>A transversion in exon 4 (rs2303099) does not change the alanine residue at position 
151, the synonymous 1425C>G transversion in exon 14 (rs1559186) also does not change 
the leucine residue at position 475 but is situated in a splicing regulatory region, and the 
missense 3125G>C transversion in exon 42 (rs2161468) results in a change from arginine to 
proline at position 1042 (Arg1042Pro) and is situated in a splicing regulatory region.  The 
GVS lists a high conservation score for SNPs rs2161468 (0.6130) and rs2303099 (0.8150), 
and in addition lists all three SNPs as Tag SNPs.283  
Three SNPs within the COL3A1 gene were selected for investigation (Figure 4.2).  The two 
SNPs in intron 1 (rs2056156; 80-1018T>C) and intron 2 (rs3106796; 282+85A>G) are situated 
within regulatory regions, and the 2092G>A missense polymorphism (rs1800255) in exon 30 
results in a change from an alanine to a threonine residue at position 698 (A698T).  It should 
be noted that this SNP is often referred to as the “exon 31 polymorphism”,54,134 however 
the Ensembl Genome Browser localises this SNP to exon 30.  In addition, all three SNP’s are 















Two SNPs in COL5A2 were also investigated (rs13031549; 97+13418A>C)(rs4667264; 
97+34516G>C)(Figure 4.3), both of which are in intron 1.  The rs4667264 SNP has a high 
conservation score (0.3310) listed on the GVS.283     
4.2.3. ALLELIC DISCRIMINATION 
SA-CON, SA-TEN, AUS-CON and AUS-TEN participants were genotyped for all eight 
polymorphisms.  Standard PCR based RFLP techniques were used to amplify and genotype 
rs1559186.  PCR reactions were carried out in a solution containing 200ng DNA template, 1X 
reaction buffer, 1.5mM Mg2+, 2.5mM each of dATP, dCTP, dTTP and dGTP, 20pmol each of 
the forward and reverse primers and 0.5 units of either Taq DNA polymerase (New England 
Biolabs® Inc., Ipswich, Massachusetts, USA) or SuperTherm Taq DNA polymerase 
(Hoffmann-La-Roche, US) using an XP Thermal Cycler Block (Bioer Technology Co., 
Middlesex, UK).  Reaction buffer was specific to the Taq used.  Thermo-Pol® reaction buffer 
(New England Biolabs® Inc., Ipswich, Massachusetts, USA) consisted of 10mM KCl, 10mM 
(NH4)SO4, 20mM Tris-HCl, 2mM MgSO4 and 0.1% Triton X-100 at pH8.8.   SuperTherm 
reaction buffer (Hoffmann-La-Roche, US) was provided with the SuperTherm Taq DNA 
polymerase and used as per manufacturer’s instructions.  PCR reactions were initiated with 
a five minute denaturing cycle at 94˚C, followed by 35 cycles consisting of 30 seconds 
denaturation at 94˚C, 30 seconds annealing at 58˚C and 40 seconds extension at 72˚C with a 
final five minute extension step at 72˚C.  The oligonucleotide primer sequences, reaction 
conditions and amplicon sizes are listed in Appendix B.  PCR amplicons were digested 
overnight for 15 hours with the PvuII restriction endonuclease as per manufacturer’s 
guidelines.  PCR amplicons and restriction fragments were mixed with SYBER Gold nucleic 
acid gel stain (Invitrogen Molecular Probes, Oregon, USA) and, together with a 100bp DNA 
size standard (Promega Corporation, Madison, Wisconsin, USA), separated by 
electrophoresis on 2% agarose (100V for 35 minutes) and 6% PAGE (120V for 2 hours) gels 
respectively.  All gels were photographed under UV light using a photodocumentation 
















Figure 4.1: The alpha -3 chain of type V collagen 
(A) Shaded bands indicate cytogenetic banding patterns for chromosome 19. Chromosomal banding position of COL5A3 gene is indicated with a n arrow (B) 
Genomic location and intron/exon structure of COL5A3. Solid bars represent numbered exons separated by introns (solid lines).  Variants in bold are included 
in the present study. (C) The α3 chain of type V collagen protein domain architecture. NC: Non-collagenous; VAR: Variable domain; PARP: Proline/arginine 

















Figure 4.2: The alpha-1 chain of type III collagen 
(A) Shaded bands indicate cytogenetic banding patterns for chromosome 9. Chromosomal banding position of COL3A1 and COL5A2 genes are indicated with 
arrows (B) Genomic location and intron/exon structure of COL3A1. Solid bars represent numbered exons separated by intron (solid lines).  Variants in bold 
are included in the present study.*Associated with pelvic organ prolapse.51,134,156 #Associated with floppy mitral valve/mitral valve prolapse.54 (C) The α1 
chain of type III collagen protein domain architecture NC: Non-collagenous; vWFC: von Willebrand factor type C [Compiled from www.ensembl.org and 
















Figure 4.3: The alpha-2 chain of type V collagen 
(A) Shaded bands indicate cytogenetic banding patterns for chromosome 9. Chromosomal banding position of COL3A1 and COL5A2 genes are indicated with 
arrows (B) Genomic location and intron/exon structure of COL5A2. Solid bars represent numbered exons separated by intron (solid lines).  Variants in bold 
are included in the present study. (C) The α2 chain of type V collagen protein domain architectecture. NC: Non-collagenous; vWFC: von Willebrand factor 















All remaining polymorphisms (rs2303099, rs2161468, rs13031549, rs4667264, rs2056156, 
rs3106796, and rs1800255) were genotyped using inventoried TaqMan® SNP Genotyping 
Assays (Applied Biosystems™) that were amplified and distinguished using the 
StepOnePlus™ Real-Time PCR System (Applied Biosystems™).  Briefly, real-time PCR 
reactions were performed in a final volume of 8µl and included 20ng DNA, TaqMan® Assay 
Mix and TaqMan® Genotyping Master Mix (2X).  TaqMan® Assay Mix consisted of sequence 
specific forward and reverse primers to amplify the polymorphic sequence, and two MGB 
probes labelled with VIC® and FAMTM dyes to detect allele 1 and allele 2 respectively.  Real-
time PCR cycling started with an initial hold step at 95°C for 10 minutes followed by 40 
cycles of 92°C for 15 seconds, and 60°C for 1 minute.  Fluorescence signal for each MGB 
probe was used to discriminate alleles and genotypes using the StepO ePlus™ Real-Time 
PCR System software [Appendix B].  For quality control purposes, a number of positive 
controls of known genotype and DNA-free controls were randomly included on every 96-
well PCR plate.  In addition, a subset of samples were genotyped twice to ensure genotyping 
was consistent.  The number and proportion of successfully genotyped participants for each 
of the polymorphisms is presented in Table 4.1.  Below normal genotype call rates were 
observed for the AUS samples at the rs1559186 (88%), rs2303099 (78%) and rs13031549 
(86%) loci. 
4.2.4. STATISTICAL ANALYSIS 
The programming environment R230 and R packages were used for all analyses.  The R 
package, Genetics,296 was used to estimate genotype and allele frequencies and HWE 
probabilities.  Logistic regression was used to compare genotype, allele and allele-
combination frequencies between the TEN and CON groups, as well as SA and AUS groups.  
Results with a P-value of less than 0.05 were accepted as significant.  Haplotype frequencies 
were inferred for both the SA and AUS groups using the R package, haplo.stats.,249,266 and 
were based on the genotype data of the polymorphisms within each gene.  All analyses 
were corrected for potential confounding by including age, sex, and group (SA or AUS) in the 
models as fixed effects.  No adjustments were made for multiple testing because it has been 
suggested that these corrections, such as Bonferroni, markedly overcorrect for an inflated 















background LD exists between SNPs.207,220  Genotype effects on age, height, weight, BMI 
and sex were determined by a one-way analysis of variance (ANOVA) using STATISTICA 




















Table 4.1: Number and proportion of recruited participants successfully genotyped for the eight polymorphisms investigated in this study 
Total number of participants 
Number of participants genotyped 
rs2161468 rs1559186 rs2303099 rs2056156 rs3106796 rs1800255 rs4467264 rs13031549 
AUS-CON 209 204 98% 181 87% 153 73% 190 91% 193 92% 194 93% 204 98% 176 84% 
AUS-TEN 85 80 94% 78 92% 76 89% 77 91% 80 94% 79 93% 81 95% 78 92% 
TOTAL 294 284 97% 259 88% 229 78% 267 91% 273 93% 273 93% 285 97% 254 86% 
SA-CON 131 131 100% 130 99% 131 100% 130 99% 130 99% 129 98% 130 99% 128 98% 
SA-TEN 94 93 99% 93 99% 93 99% 92 98% 91 97% 90 96% 93 99% 91 97% 
TOTAL 225 224 99% 223 99% 224 99% 222 99% 221 98% 219 97% 223 99% 219 97% 
















4.3.1. GENOTYPE AND ALLELE FREQUENCIES 
Genotype and minor allele frequency distributions for each of the polymorphisms, together 
with the HWE P-values, are shown in Tables 4.2, 4.3 and 4.4.  The frequency distributions of 
the SNPs tested in this study were found to differ significantly between the SA and AUS 
groups at the rs2303099 (P<0.001) and rs3106796 loci (P=0.034). The participants from the 
two groups were therefore summarised separately.  All genotype distributions were in HWE 
except at the rs1559186 locus that deviated significantly in the AUS-TEN group (P=0.034).  
After adjusting for the potential confounder’s age and sex, there were no significant 
differences in either the genotype or allele frequency distributions between the CON and 
TEN groups.  There were no significant genotype effects on age, weight, height, BMI or sex 




















Table 4.2: Genotype and minor allele frequency distributions of the sequence variants 
investigated within the COL5A3 gene in control (CON) and Achilles tendinopathy (TEN) 
groups of South African (SA) and Australian (AUS) populations 
 
CON TEN P-Values 
 
AUS SA AUS SA Country Group 
COL5A3:      
rs2303099 
     N 153 131 76 93 
  
T/T 0.25 0.32 0.24 0.35 <0.001 0.890 
T/G 0.43 0.54 0.49 0.54   
G/G 0.32 0.14 0.28 0.11   
G 0.54 0.41 0.52 0.38 <0.001 0.885 
HWE 0.105 0.207 0.821 0.192 
  
rs1559186 
     
N 181 130 78 93   
C/C 0.50 0.45 0.44 0.35 0.386 0.050 
C/G 0.42 0.42 0.53 0.54   
G/G 0.08 0.13 0.04 0.11   
C 0.29 0.34 0.30 0.38 0.185 0.594 
HWE 1.000 0.558 0.034 0.192   
rs2161468 
     
N 204 131 80 93   
C/C 0.38 0.42 0.36 0.34 0.886 0.473 
C/G 0.46 0.41 0.46 0.52   
G/G 0.16 0.17 0.18 0.14   
G 0.39 0.37 0.41 0.40 0.691 0.916 
HWE 0.660 0.191 0.816 0.522   
P-values are for the difference between countries and between diagnostic groups respectively, 
adjusted for each other, age, sex and whether or not a person was investigated in his/her country of 
birth. The genotype P-value is calculated using a 2-degrees of freedom test, with genotypes as 
categories and the allelic P-value is calculated using an additive allelic model.  HWE gives exact P-
values from tests of Hardy–Weinberg equilibrium.  N is number of samples genotyped. Bold P-values 






















Table 4.3: Genotype and minor allele frequency distributions of the sequence variants 
investigated within the COL3A1 gene in control (CON) and Achilles tendinopathy (TEN) 
groups of South African (SA) and Australian (AUS) populations 
 
CON TEN P-Values 
 
AUS SA AUS SA Country Group 
COL3A1: 
rs2056156       
N 190 130 77 92   
T/T 0.31 0.25 0.26 0.25 0.347 0.928 
T/C 0.49 0.53 0.56 0.49   
C/C 0.20 0.22 0.18 0.26   
C 0.44 0.49 0.46 0.51 0.147 0.925 
HWE 0.884 0.598 0.361 0.837   
rs3106796 
     
N 193 130 80 91   
A/A 0.33 0.24 0.30 0.25 0.100 0.900 
A/G 0.48 0.52 0.51 0.48   
G/G 0.20 0.24 0.19 0.26   
G 0.44 0.50 0.44 0.51 0.034 0.825 
HWE 0.663 0.726 0.823 0.834   
rs1800255 
     
N 194 129 79 90   
G/G 0.56 0.55 0.63 0.57 0.688 0.726 
A/G 0.26 0.35 0.30 0.36   
A/A 0.08 0.10 0.06 0.08   
A 0.26 0.28 0.22 0.26 0.698 0.463 
HWE 0.453 0.183 0.334 0.579   
P-values are for the difference between countries and between diagnostic groups respectively, 
adjusted for each other, age, sex and whether or not a person was investigated in his/her country of 
birth. The genotype P-value is calculated using a 2-degrees of freedom test, with genotypes as 
categories and the allelic P-value is calculated using an additive allelic model.  HWE gives exact P-
values from tests of Hardy–Weinberg equilibrium.  N is number of samples genotyped. Bold P-values 

















Table 4.4: Genotype and minor allele frequency distributions of the sequence variants 
investigated within the COL5A2 gene in control (CON) and Achilles tendinopathy (TEN) 
groups of South African (SA) and Australian (AUS) populations 
 
CON TEN P-Values 
 
AUS SA AUS SA Country Group 
COL5A2:      
rs4667264 
     
N 204 130 81 93   
A/A 0.50 0.44 0.47 0.45 0.270 0.915 
A/G 0.38 0.48 0.44 0.44   
G/G 0.11 0.08 0.09 0.11   
G 0.30 0.32 0.31 0.33 0.629 0.820 
HWE 0.185 0.422 0.800 1.000   
rs13031549 
     
N 176 128 78 91   
G/G 0.47 0.34 0.42 0.40 0.077 0.969 
G/T 0.40 0.56 0.47 0.47   
T/T 0.13 0.09 0.10 0.13   
T 0.33 0.38 0.34 0.37 0.231 0.805 
HWE 0.236 0.037 0.801 1.000   
P-values are for the difference between countries and between diagnostic groups respectively, 
adjusted for each other, age, sex and whether or not a person was investigated in his/her country of 
birth. The genotype P-value is calculated using a 2-degrees of freedom test, with genotypes as 
categories and the allelic P-value is calculated using an additive allelic model.  HWE gives exact P-
values from tests of Hardy–Weinberg equilibrium.  N is number of samples genotyped. Bold P-values 
are  0.05 
 
Table 4.5: Genotype effects of investigated collagen gene SNP's on physiological 
characteristics of participants 
POLYMORPHISM 
P-VALUES 
AGE AGE INJURED HEIGHT WEIGHT BMI SEX 
rs2161468 0.202 0.329 0.627 0.618 0.764 0.915 
rs1559186 0.123 0.565 0.699 0.428 0.219 0.746 
rs2303099 0.190 0.124 0.521 0.395 0.417 0.105 
rs2056156 0.278 0.763 0.156 0.110 0.324 0.405 
rs3106796 0.635 0.988 0.330 0.430 0.250 0.640 
rs1800255 0.083 0.084 0.351 0.817 0.864 0.293 
rs4667264 0.561 0.914 0.949 0.665 0.726 0.678 
rs13031549 0.928 0.851 0.436 0.518 0.622 0.496 
Age: Age at recruitment; Age Injured: Age at recruitment (CON) & age at diagnosis (TEN);  P-values 
for age, age injured, height, weight and BMI are determined by one-way ANOVA; P-value for sex is 















4.3.2. HAPLOTYPE ANALYSIS 
There were no inferred haplotypes significantly associated with AT within any of the 
COL5A3, COL3A1 and COL5A2 genes, nor within the combined COL3A1 and COL5A2 genes 
(Table 4.6).  The most common haplotypes within the COL5A3 gene (rs2161468-rs1559186-
rs2303099) were CCT and CCG in both the CON and TEN groups, however the distribution of 
all the haplotypes differed significantly between countries (P=0.002).  Similarly, there was a 
significant difference in the distribution of haplotypes between SA and AUS within the 
COL3A1 gene (P=0.025), with the most commonly occurring haplotype being CGG 
(rs2056156-rs3106796-rs1800255).  The predominant haplotype within the COL5A2 gene 
was GG (rs4667264-rs13031549) and there were no differences in the distribution of 
haplotypes between either country (P=0.626) or group (P=0.682).  In the combined COL3A1 
and COL5A2 haplotypes, the CGGGG haplotype occurred at the highest frequency.  
Furthermore, there was a significant difference in the distribution of these haplotypes 
between country groups (P=0.040). 
4.3.3. INTERACTIONS WITH COL5A1 RS12722 
The probability of gene-gene interactions between any of the eight SNP’s investigated and 
the COL5A1 rs12722 polymorphism in modulating AT risk is shown in Table 4.7.  There were 
no significant interactions, nor trends towards significance, between any of these SNPs and 

















Table 4.6: Inferred haplotype frequencies for SNPs within the COL5A3, COL3A1 and 
COL5A2 genes, as well as the combined COL3A1 and COL5A2 haplotype 
 
CON TEN P-Values 
 
AUS SA AUS SA Country Group 
COL5A3 (rs2161468-rs1559186-rs2303099): 0.002 0.895 
CCT 0.24 0.30 0.28 0.32 
  
CCG 0.29 0.23 0.26 0.17   
GGG 0.15 0.10 0.09 0.12   
GGT 0.07 0.15 0.14 0.11   
GCT 0.12 0.09 0.06 0.12   
GCG 0.05 0.03 0.11 0.05   
CGT 0.03 0.05 0.00 0.07   
CGG 0.04 0.04 0.07 0.04 
  
COL3A1 (rs2056156-rs3106796-rs1800255): 0.025 0.997 
CGG 0.42 0.48 0.43 0.49 
  
TAG 0.30 0.23 0.35 0.24   
TAA 0.25 0.27 0.20 0.25   
TGG 0.01 0.01 0.01 0.01   
CAG 0.01  0.00 0.01   
CGA 0.00 0.00 0.01 0.01   
TGA 0.01  0.00    
CAA 0.00  0.01  
  
COL5A2 (rs4667264-rs13031549): 0.626 0.682 
GG 0.66 0.63 0.66 0.63 
  
CT 0.30 0.32 0.32 0.33   
GT 0.04 0.05 0.03 0.04   
CG 0.00 0.00 0.00    
COL3A1 & COL5A2:   0.040 0.828 
CGGGG 0.29 0.32 0.28 0.34   
TAGGG 0.24 0.14 0.26 0.14   
CGGCT 0.12 0.14 0.14 0.15   
TAAGG 0.11 0.16 0.10 0.14   
TAACT 0.12 0.09 0.10 0.10   
TAGCT 0.05 0.08 0.06 0.07   
TAGGT 0.01 0.01 0.02 0.03   
CGGGT 0.01 0.02 0.00 0.00   
TAAGT 0.01 0.02 0.00 0.01   
CGAGG 0.00 0.00 0.01 0.01   
TGGCT 0.01 0.01 0.01 0.01   
CAGGG 0.01 0.00 0.00 0.01   
CAACT 0.00 0.00 0.01 0.00   
TGAGG 0.01 0.00 0.00 0.00   
Values are inferred haplotype frequencies and P-value for a test of equality of those frequencies. 
Combined COL3A1 and COL5A2 haplotypes that were not observed in any of the groups were 



































The primary finding of this case-control genetic association study is that there were no 
independent associations between any of the eight SNP’s investigated within the COL5A3, 
COL3A1 and COL5A2 genes and AT in a South African or Australian group.  The hypothesis 
driven selection of the candidate genes was based on their biological function within the 
ECM of tendons.  Furthermore, the selection of the eight SNPs investigated in this study was 
also hypothesis driven and based on the heterozygosity, location, conservation, and 
biological significance of these SNPs.  Despite this, only rs1559186 within the COL5A3 gene 
tended towards an association with AT (P=0.050).  As discussed in chapter two, this study 
was only sufficiently powered to detect large effects on risk of developing AT (OR>2.0).  It is 
therefore possible that the rs1559186 SNP may have a small effect on risk of developing AT 
that is unlikely to be detected in the current study.  This is corroborated by the observation 
that the distribution of genotype frequencies in rs1559186 deviates from HWE in the AUS-
TEN group (P=0.034), as this may be expected if one of these alleles or genotypes confers a 
harmful or protective effect.  As in chapter two, the current study does not exclude the 















smaller effects - within these three genes are associated with AT.34,175  However, it should 
be noted that many rare polymorphisms within the COL3A1 and COL5A2 genes have been 
shown to cause the severe connective tissue disorder, Ehlers-Danlos syndrome.193,238,268  It is 
therefore possible that biologically significant variants within these highly conserved genes 
are more likely to result in severe clinical conditions, rather than common diseases, because 
of the limited redundancy within the collagen protein network.  It is perhaps more likely 
that common polymorphisms with a smaller effect would be associated with the common 
condition of AT.175     
The α2(V) chain forms heterotrimers with two α1(V) chains, while three α3(V) chains form 
homotrimers in type V collagen fibrils.  In addition, both type V collagen and type III collagen 
(α1(III)3) are involved in determining the diameter and tensile strength of type I collagen 
fibrils.  For these reasons, it was decided to further explore gene-gene interactions between 
any of the eight selected collagen gene SNPs and the rs12722 SNP in COL5A1 in modulating 
the risk of AT.  There were, however, no significant interactions, nor trends towards 
significance, between rs12722 and any of the eight SNPs investigated, including rs1559186.  
We can therefore conclude that any interactions between these genes at these SNP loci do 
not significantly contribute to the risk of AT.  These results would further suggest that even 
if rs1559186 does have a small effect on the risk of developing AT, it is independent of the 
effect that rs12722 exerts.  The COL5A1 rs12722 polymorphism and the polymorphisms in 
the IL-1RN, IL-6 and IL-1β genes have collectively been implicated in modulating risk of AT 
via a proposed cell-signalling pathway.257  It is therefore reasonable to hypothesise that 
other collagen genes, such as those investigated in this study, may also interact with these 
interleukin genes in this pathway.  This hypothesis will be investigated in the next chapter.   
As with other studies in this thesis, there were several limitations to this study.  These 
include the heavier weight of the TEN participants when compared to the CON participants, 
the lack of physical activity and smoking data for the Australian participants, and a small 
sample size which only results in sufficient power to detect large effects on risk of AT 
(OR>2.0).  In addition, the low genotype call rate for rs1559186 (88%), rs2303099 (78%) and 















been discussed in chapter two.  The strength of this study however, lays in the hypothesis 
driven selection of candidate genes and SNPs for investigation. 
4.5. CONCLUSION 
The eight polymorphisms investigated within the COL5A3, COL3A1 and COL5A2 genes were 































CHAPTER 5: GENE-GENE INTERACTIONS IN THE EXTRACELLULAR MATRIX AND 
RISK MODELS FOR ACHILLES TENDINOPATHY 
5.1. INTRODUCTION 
A recent study by September et al. (2011)257 used a pathway-based approach to investigate 
the association of functional sequence variants within the IL-1β (rs1143627; rs16944), IL-6 
(rs1800795) and IL-1RN (rs2234663) genes with AT.  Although, no independent associations 
were found between the polymorphisms investigated and AT, these cell-signalling pathway 
polymorphisms and the COL5A1 rs12722 polymorphism were collectively implicated in 
modulating risk of AT.  Another recent study found an association of functional 
polymorphisms within the gene encoding caspase-8, a component of the apoptosis 
signalling cascade, with increased risk of AT.205  In particular, rs1045486 and rs3834129 
within the CASP8 gene were found to be associated with AT both independently and as a 
haplotype.  Considered collectively, the evidence above suggests an interaction between 
these components of the cell-signalling pathways involved in regulating the ECM, and the 
biology of the collagen fibril in tendon.  It is therefore reasonable to hypothesize that 
polymorphisms within genes encoding other components of the ECM may also interact with 
these cell-signalling pathways in modulating the risk of AT.   
Chapter 3 of this thesis presented the association of the potentially functional GCA 
haplotype within the COL27A1 and TNC genes with AT in SA and AUS groups.  Chapter 4 of 
this thesis reported the absence of any association between polymorphisms within the 
COL5A3, COL3A1 and COL5A2 genes with AT, however a tendency towards an independent 
association with AT was reported for rs1559186 within the COL5A3 gene.  Given the 
biological role of the proteins encoded by these genes in the ECM, it was decided to 
investigate potential gene-gene interactions between these ECM genes (COL27A1, TNC, 
COL5A3, COL3A1 and COL5A2) and previously genotyped polymorphisms within genes 
encoding components of the cell-signalling pathways (IL-6, IL-1β and CASP8).199,205,255,257  
The primary aim of this study was, therefore, to test the gene-gene interactions between 















cell-signalling pathways within the ECM, and to investigate the relative contribution of these 
polymorphisms to overall genetic risk in a polygenic model. 
The number of distinct genes encoding various ECM proteins with either similar or distinct 
biological functions that have been implicated in modulating risk of AT is growing.59,258  In 
addition to the various interactions and haplotypes which have been shown to influence risk 
of AT, a number of polymorphisms within several genes have been independently 
associated with AT in both the SA and AUS populations (Figure 5.1).  As this number of 
confirmed, independent associations between polymorphisms and AT grows, and the 
biology underlying these associations is elucidated, it may become increasingly pertinent to 
incorporate genetic testing into the clinical management of athletes or individuals who 
present with other risk factors.  Therefore, the second aim of this study was to develop and 
evaluate a clinically relevant genetic risk assessment (GRA) model for AT using (i) 
polymorphisms that have previously been independently associated with AT in two 
populations (Figure 5.1), and (ii) polymorphisms with a definitive AT risk genotype that were 
implicated in this thesis in a haplotype or gene-gene interactions. 
5.2. METHODS 
5.2.1. PARTICIPANTS 
The SA-TEN (n=94), SA-CON (n=131), AUS-TEN (n=85) and AUS-CON (n=209) groups 
described in chapter two were used in this study.  Participant characteristics are presented 
in Table 2.2 and described in 2.3.1. 
5.2.2. GENOTYPING 
Genotype data for the polymorphisms investigated in chapter three and four of this thesis 
were used in this study.  These included rs4143245 (COL27A1), rs1249744 (COL27A1), 
rs753085 (COL27A1), rs946053 (COL27A1), rs13321 (TNC), rs2104772 (TNC), rs1330363 
(TNC), rs2161468 (COL5A3), rs1559186 (COL5A3), rs2303099 (COL5A3), rs2056156 
(COL3A1), rs3106796 (COL3A1), rs1800255 (COL3A1), rs4667264 (COL5A2) and rs13031549 
(COL5A2),.  Previously reported genotype data for polymorphisms rs1800795 (IL-6), 















(COL5A1), rs71746744 (COL5A1), rs16399 (COL5A1), rs1134170 (COL5A1), rs4919510 
(MIR608), rs143383 (GDF5) and rs4789932 (TIMP2) was obtained for the SA-CON, SA-TEN, 
AUS-CON and AUS-TEN participants.6,76,199,205,224,255,257 
 
 
Figure 5.1: Polymorphisms previously associated with risk of Achilles tendinopathy in two 
populations 
GDF5 rs143383: OR 1.82 (95% CI: 1.23-2.74) TT vs CC + CT;  CASP8 rs1045485: OR 0.55 (95% CI: 0.35-
0.84) GG vs CC + CG;  COL5A1 rs71746744: OR 2.0 (95% CI: 1.2-3.3) AGGG/AGGG vs del/del + 
AGGG/del;  COL5A1 rs1134170: OR 1.8 (95% CI: 1.1-2.9) TT vs AA + AT;  COL5A1 rs16399: OR 1.7 
(95% CI: 1.1-2.7) del/del vs ATCT/ATCT + ATCT/del;  COL5A1 rs12722: OR 0.42 (95% CI: 0.20-0.86) CC 
vs TT + CT;  miR608 rs4919510: OR 1.6 (95% CI: 1.1-2.5) CC vs GG + CG;  TIMP2 rs4789932: OR 1.58 
(95% CI: 1.03-2.43) CC vs TT + CT;  CASP8 rs3834129: OR 1.67 (95% CI: 1.08-2.60) del/del vs AGTAAG/ 















5.2.3. GENE-GENE INTERACTIONS AND LOGISTIC REGRESSION RISK MODELS FOR AT 
The programming environment R230 and R packages were used for all analyses.  Stepwise 
logistic regression was used to compare allele-combination frequencies between the TEN 
and CON groups and to derive risk models for AT.  Results with a P-value of less than 0.05 
were accepted as significant.  All analyses were corrected for potential confounding by 
including age, sex, and country group (SA or AUS) in the models as fixed effects.  Two risk 
models (model A and B) were derived using stepwise logistic regression and receiver 
operating characteristic (ROC) curves were constructed, using the R package Epi,45 to 
analyse the strength of each model.83  Risk model A was derived by stepwise logistic 
regression of 20 variables: age, sex, country group, born “here” and genotype date for the 
16 polymorphisms investigated within the COL27A1, TNC, COL5A1, COL5A3, COL3A1 and 
COL5A3 genes.  These were discarded one by one until the model with the optimum 
specificity and sensitivity remained.  Risk model B was derived by stepwise logistic 
regression of the same 20 variables above, as well as genotype date for the five 
polymorphisms investigated within the IL-6, IL-1β and CASP8 genes.  These were discarded 
one by one until the model with the optimum specificity and sensitivity remained.  The area 
under each ROC curve (AUC) was used to quantify the overall ability of the model to 
discriminate between the TEN and CON groups based on genotype risk.  No adjustments 
were made for multiple testing because it has been suggested that these corrections, such 
as Bonferroni, markedly overcorrect for an inflated false-positive rate and unnecessarily 
reduce power in genetic association studies where background LD exists between 
SNPs.207,220 
5.2.4. GENETIC RISK ASSESSMENT MODELS 
A stepwise approach was used to develop a series of potentially useful genetic risk 
assessment (GRA) models.  Polymorphisms that were independently associated with AT in 
both populations were included in the GRA models (Figure 5.1).  In addition, those 
polymorphisms with a clear at-risk or protective genotype that were implicated in either a 
haplotype or gene-gene interaction associated with AT were also included in the GRA 
models.  Risk (and protective) genotype scores were calculated for each participant by 















points for each of the other two genotypes.  As the COL5A1 polymorphisms rs71746744, 
rs16399 and rs1134170 are in strong LD6 and inclusion of all three polymorphisms in the 
GRA models would therefore result in bias, only rs16399 was included based on the higher 
number of participants genotyped for this polymorphism.  In each GRA model, risk (or 
protective) genotype scores for each polymorphism included in that model were summed 
for each participant.  Differences in the distribution of risk (or protective) genotype scores 
between CON and TEN participants were calculated using Pearsons Chi-square analysis 
(STATISTICA version 10, StatSoft Inc., Tulsa, OK, USA).  Two-tailed Chi-square tests were 
used to determine specific differences in risk (or protective) genotype score between CON 
and TEN participants (GraphPad Prism 5.00 for Windows, GraphPad Software, San Diego, 
California, USA). 
 
Table 5.1: List of polymorphisms and their risk genotypes included in genetic risk 







COL5A1 rs71746744 Independent AGGG/AGGG Abrahams et al.6 
COL5A1 rs16399 Independent del/del Abrahams et al.6 
COL5A1 rs1134170 Independent TT Abrahams et al.6 
miR608 rs4919510 Independent CC Abrahams et al.6 




del/del Nell et al.205 
TNC rs2104772 Haplotype AA 
Saunders et al.247 
Chapter 3 
COL27A1 rs946053 Haplotype GG 


















Table 5.2: List of polymorphisms and their protective genotypes included in genetic risk 







COL5A1 rs12722 Independent CC 
Mokone et al.199 
September et al.255 
CASP8 rs1045485 Independent CC Nell et al.205 




GG Chapter 4 
COL27A1 rs1249744 Gene-gene 
interaction 




5.3.1. PARTICIPANT CHARACTERISTICS 
Physiological characteristics for the TEN and CON groups are presented in chapter 2.3.1. 
5.3.2. GENE-GENE INTERACTIONS 
Frequencies were inferred for all allele-allele combinations between polymorphisms 
investigated in this thesis and previously genotyped polymorphisms within the cell-signalling 
pathways [Appendix C].  The distribution of these inferred allele-allele combinations was 
compared between the TEN and CON groups and the significance levels for differences in 
these combinations are shown in Table 5.3.  Several significant associations with AT risk 
were noted.  In particular, rs1249744 within the COL27A1 gene significantly interacted with 
rs1800795 within the IL-6 gene (P=0.004), rs16944 (P=0.030) and rs1143627 (P=0.046) 
within the IL-1β gene, and rs1045485 (P=0.026) and rs3834129 (P=0.034) within the CASP8 
gene to contribute to risk of AT.  The COL27A1 rs946053 polymorphism significantly 
interacted with IL-6 rs1800795 (P=0.017) and IL-1β rs16944 (P=0.043).  All three TNC 















rs2104772 polymorphism further interacted with IL-1β rs16944 (P=0.034), CASP8 rs1045485 
(P=0.033) and CASP8 rs3834129 (P=0.049), and TNC rs1330363 further interacted with 
CASP8 rs1045485 (P=0.039) and CASP8 rs3834129 (P=0.025).  The COL5A3 rs2303099 
polymorphism significantly interacted with IL-6 rs1800795 in the modulation of risk of AT 
(P=0.040).   
The frequencies of specific allele combinations in the TEN and CON groups for all 
combinations are presented in appendix C.  Briefly, the allele combinations for the 
significant interactions were generally consistent with the independent and haplotype 
associations observed for these polymorphisms.  Allele combinations which included the 
COL27A1 rs1249744 A-allele, COL27A1 rs946053 T-allele, TNC rs2104772 T-allele, TNC 
rs1330363 A-allele, IL-6 rs1800795 C-allele, rs16944 T-allele, rs1045485 C-allele and 
rs3834129 CTTACT-insertion allele occurred at a higher frequency in the CON group.  Allele 
combinations which included the COL27A1 rs1249744 G-allele, COL27A1 rs946053 G-allele, 
TNC rs2104772 A-allele, TNC rs1330363 G-allele, IL-6 rs1800795 G-allele, IL-1β rs16944 C-
allele, CASP8 rs1045485 G-allele and CASP8 rs3834129 deletion allele occurred at a higher 
frequency in the TEN group.  The only exception was the interaction between TNC rs13321 
and IL-6 rs180079, in which the distribution of allele combinations was the reverse of what 
would be expected from the haplotype association with AT presented in chapter three.  The 
TNC rs13321 C-allele combined with the IL-6 rs180079 C-allele was more frequently 
observed in the CON group (P=0.020), while the rs13321 G-allele in combination with the 


































COL27A1 rs4143245 0.064 0.298 0.626 0.266 0.410 
COL27A1 rs1249744 0.004 0.030 0.046 0.026 0.034 
COL27A1 rs753085 0.080 0.270 0.526 0.361 0.380 
COL27A1 rs946053 0.017 0.043 0.175 0.090 0.117 
TNC rs13321 0.039 0.278 0.485 0.097 0.216 
TNC rs2104772 0.004 0.034 0.090 0.033 0.049 
TNC rs1330363 0.012 0.056 0.131 0.039 0.025 
COL3A1 rs2056156 0.067 0.364 0.812 0.386 0.425 
COL3A1 rs3106796 0.064 0.290 0.769 0.368 0.461 
COL3A1 rs1800255 0.072 0.422 0.802 0.353 0.556 
COL5A2 rs4667264 0.081 0.304 0.765 0.379 0.469 
COL5A2 rs13031549 0.081 0.286 0.761 0.386 0.314 
COL5A3 rs2161468 0.086 0.434 0.776 0.347 0.408 
COL5A3 rs1559186 0.063 0.243 0.636 0.154 0.543 
COL5A3 rs2303099 0.040 0.342 0.786 0.393 0.533 
Values are P-values for interactions between the polymorphism listed on the left and the 
polymorphism listed on top in the modulation of risk of AT.  Bold P-values are <0.05 
 
 
5.3.3. LOGISTIC REGRESSION RISK MODELS FOR AT 
As described in the methods, risk model A (Figure 5.2) for AT was derived by including 20 
variables: age, sex, country group, born “here” and genotype data for 16 polymorphisms 
within the COL27A1, TNC, COL5A1, COL5A3, COL3A1 and COL5A2 genes.  These were 
discarded one by one until the model with the optimum specificity and sensitivity remained.  
This best fit risk model included the variables country (SA), age (years), sex (male), COL27A1 
rs1249744 (AG, GG), TNC rs2104772 (AT, TT), COL5A1 rs12722 (TC, TT) and COL5A3 















specificity of the risk model when including/excluding different variables was generated.  
The optimal risk model had a sensitivity of 82.4%, where sensitivity is the proportion of 
participants who have the target condition (TEN) and are assessed by the model to be at 
high risk of AT.  Specificity is the proportion of participants who do not have the target 
condition (CON) and are assessed to not be at risk of AT by the model,83 and was calculated 
to be 58.0% for this model.  The positive and negative predictive values were calculated to 
be 52.0% and 85.6% respectively.  However these two statistics are of little value in case-
control studies when the “diseased” and “not diseased” participants have been pre-
selected.  The AUC for the optimal risk model was 0.775.  
 
Figure 5.2: Receiver operating characteristic (ROC) curve of risk model A for Achilles 
tendinopathy showing sensitivity (Sens) and specificity (Spec) at the optimal cutpoint 
ROC curve determines the true positive (sensitivity) versus true negative (specificity) rate for various 
cut-offs in determining risk of Achilles tendinopathy. The straight line indicates where sensitivity = 1-
specificity and AUC = 0.5. The optimal cut-off which yields the maximum sensitivity plus specificity is 















Table 5.4: List of variables included in risk model A for Achilles tendinopathy 
Factor Level Coefficient SE P-value 
Country of birth AUS 0   
Country of birth SA 0.43 0.23 0.065 
Age Years 0.07 0.01 <0.001 
Sex Female 0   
Sex Male 0.74 0.24 0.002 
COL27A1 rs1249744 AA 0   
COL27A1 rs1249744 AG 0.54 0.24 0.024 
COL27A1 rs1249744 GG 0.22 0.42 0.600 
TNC rs2104772 AA 0   
TNC rs2104772 AT -0.39 0.25 0.122 
TNC rs2104772 TT -0.63 0.34 0.064 
COL5A1 rs12722 CC 0   
COL5A1 rs12722 CT 1.04 0.31 0.001 
COL5A1 rs12722 TT 0.43 0.34 0.197 
COL5A3 rs1559186 CC 0   
COL5A3 rs1559186 CG 0.28 0.24 0.242 
COL5A3 rs1559186 GG -0.57 0.47 0.221 
Coefficients are used to predict risk of AT, which is used to calculate points on the ROC curve.  P-
values are adjusted for other variables and assess the effect of each variable compared to its 

















Risk model B (Figure 5.3) for AT was derived by including the same 20 variables included in 
risk model A, as well as genotype data from polymorphisms within the IL-6, IL-1β and CASP8 
genes.  The best fit risk model included the variables age (years), sex (male), COL27A1 
rs946053 (GT, TT), COL5A1 rs12722 (TC, CC), COL5A3 rs1559186 (CG, GG), IL-6 rs1800795 
(GC, CC), CASP8 rs1045485 (GC, CC) and CASP8 rs3834129 (del/CTTACT, del/del) (Table 5.5).  
Figure 5.3 shows the ROC curve analysis for the optimal risk model with a specificity of 
86.5% and a sensitivity of 58.1%.  The AUC for the optimal risk model was 0.801. 
 
 
Figure 5.3: Receiver operating characteristic (ROC) curve of risk model B for Achilles 
tendinopathy showing sensitivity (Sens) and specificity (Spec) at the optimal cutpoint 
ROC curve determines the true positive (sensitivity) versus true negative (specificity) rate for various 
cut-offs in determining risk of Achilles tendinopathy. The straight line indicates where sensitivity = 1-
specificity and AUC = 0.5. The optimal cut-off which yields the maximum sensitivity plus specificity is 
















Table 5.5: List of variables included in risk model B for Achilles tendinopathy 
Factor Level Coefficient SE P-value 
Age Years 0.073 0.01 0.000 
Sex Female 0   
Sex Male 0.724 0.27 0.007 
COL27A1 rs946053 GG 0   
COL27A1 rs946053 GT -0.507 0.30 0.094 
COL27A1 rs946053 TT -1.098 0.38 0.004 
COL5A1 rs12722 TT 0   
COL5A1 rs12722 TC 0.42 0.29 0.139 
COL5A1 rs12722 CC -0.49 0.38 0.194 
COL5A3 rs1559186 CC 0   
COL5A3 rs1559186 CG 0.263 0.27 0.321 
COL5A3 rs1559186 GG -0.905 0.56 0.105 
IL6 rs1800795 GG 0   
IL6 rs1800795 GC -0.54 0.29 0.060 
IL6 rs1800795 CC -0.87 0.38 0.023 
CASP8 rs1045485 GG 0   
CASP8 rs1045485 GC -0.65 0.29 0.024 
CASP8 rs1045485 CC -0.75 1.31 0.566 
CASP8 rs3834129 CTTACT/CTTACT 0   
CASP8 rs3834129 del/CTTACT -0.265 0.32 0.402 
CASP8 rs3834129 del/del 0.708 0.36 0.048 
Coefficients are used to predict risk of AT, which is used to calculate points on the ROC curve.  P-
values are adjusted for other variables and assess the effect of each variable compared to its 

















5.3.4. GENETIC RISK ASSESSMENT (GRA) MODELS 
The previous analyses in this study show (i) that there are gene-gene interactions between 
ECM genes and cell-signalling pathway genes, and (ii) that some polymorphisms potentially 
contribute to the burden of risk of AT even if they are not independently associated with AT.  
However, the best fit risk models derived by logistic regression are complicated and, in the 
current form, difficult to interpret in a clinical setting.  The underlying principle of a 
polygenic risk profile containing several implicated loci contributing to overall genetic risk of 
AT was therefore used to develop a more clinically relevant tool.  A genetic risk assessment 
model using polymorphisms previously independently associated with risk of AT was 
developed first (Figure 5.4).  Risk genotype scores for GRA model 1 were calculated using 
genotype data from rs16399 (COL5A1), rs4919510 (miR608), rs143383 (GDF5) and 
rs3834129 (CASP8) and therefore had a maximum score of eight (Table 5.1).6,205,224  
Participants with a risk genotype score of two or less were significantly more frequently 
observed in the CON group (OR 0.28, 95% CI: 0.15-0.51; P<0.001), whereas participants with 
a risk genotype score of six or more were significantly more frequently observed in the TEN 
group (OR 4.66, 95% CI: 2.51-8.68; P<0.001)(Figure 5.4).   
 
Figure 5.4: GENETIC RISK ASSESSMENT MODEL 1 - Distribution of risk genotype scores in 
participants with Achilles tendinopathy (TEN) and controls (CON) 
Risk genotype score calculated using rs16399 (del/del), rs4919510 (CC), rs143383 (TT) and rs3834129 
(del/del) with a maximum score of 8; n=combined SA and AUS   
* 0-2 vs 4-8: χ2 18.44, P<0.001, OR 0.28 (95% CI: 0.15-0.51) 















To assess whether the addition of two further genetic variables, with clear at-risk 
genotypes, would influence the efficacy of this model, a second GRA model was developed.  
Risk genotype scores for GRA model 2 were calculated using genotype data from rs946053 
(COL27A1) and rs2104772 (TNC) only, and therefore had a maximum score of four (Table 
5.1).  Participants with a risk genotype score of four were significantly more frequently 
observed in the TEN group (OR 2.42, 95% CI: 1.35-4.32; P=0.002) (Figure 5.5).   
 
Figure 5.5: GENETIC RISK ASSESSMENT MODEL 2 - Distribution of risk genotype scores in 
participants with Achilles tendinopathy (TEN) and controls (CON) 
Risk genotype score calculated using rs946053 (GG) and rs2104772 (AA) with a maximum score of 4; 
n=combined SA and AUS   
* 0-2 vs 4: χ2 9.26, P=0.002, OR 2.42 (95% CI: 1.35-4.32) 
 
Given the differences in the distribution of risk genotype scores observed in GRA model 2, 
two further GRA models were derived which sequentially tested the effect of adding the 
two new variables to GRA model 1.  Risk genotype scores for GRA model 3 were calculated 
using genotype data from rs16399 (COL5A1), rs4919510 (miR608), rs143383 (GDF5), 
rs3834129 (CASP8) and rs2104772 (TNC), and therefore had a maximum score of ten (Table 
5.1).  Participants with a risk genotype score of eight or more were significantly more 
frequently observed in the TEN group (OR 6.88, 95% CI: 2.76-17.13; P<0.001) (Figure 5.6).  















(COL5A1), rs4919510 (miR608), rs143383 (GDF5), rs3834129 (CASP8), rs2104772 (TNC) and 
rs946053 (COL27A1), and therefore had a maximum score of 12 (Table 5.1).  Again, 
participants with a risk genotype score of eight or more were significantly more frequently 
observed in the TEN group (OR 5.89, 95% CI: 2.39-14.52; P<0.001) (Figure 5.7).  A graphical 
representation comparing the ORs of GRA models 1-4 is shown in Figure 5.8.  Taking into 
account the OR and the 95% CI for each model, GRA model 4 was chosen as the best model 
for distinguishing between TEN and CON participants.  The proportion of TEN and CON 
participants that would be classified as either at-risk or not at-risk by GRA model 4 is 
presented in Figure 5.9.  Thirty-seven percent (37%) of TEN participants are classified as at-
risk, and 90% of CON participants are classified as not at-risk by GRA model 4. 
 
 
Figure 5.6: GENETIC RISK ASSESSMENT MODEL 3 - Distribution of risk genotype scores in 
participants with Achilles tendinopathy (TEN) and controls (CON) 
Risk genotype score calculated using rs16399 (del/del), rs4919510 (CC), rs143383 (TT), rs3834129 
(del/del) and rs2104772 (AA) with a maximum score of 10; n=combined SA and AUS  
* 0-6 vs 8-10: χ2 21.02, P<0.001, OR 6.88 (95% CI: 2.76-17.13) 
















Figure 5.7: GENETIC RISK ASSESSMENT MODEL 4 - Distribution of risk genotype scores in 
participants with Achilles tendinopathy (TEN) and controls (CON) 
 Risk genotype score calculated using rs16399 (del/del), rs4919510 (CC), rs143383 (TT), rs3834129 
(del/del), rs2104772 (AA) and rs946053 (GG) with a maximum score of 12; n=combined SA and AUS   
* 0-6 vs 8-12: χ2 24.20, P<0.001, OR 5.89 (95% CI: 2.39-14.52) 
# 0-2 vs 4-12: χ2 17.67, P<0.001, OR 5.34 (95% CI: 2.55-11.17) 
 
 
Figure 5.8: Odds ratios and 95% confidence intervals of genetic risk assessment (GRA) 
models 1-4 
GRA model 1: rs16399, rs4919510, rs143383, rs3834129; GRA model 2: rs2104772, rs946053; GRA 
model 3: rs16399, rs4919510, rs143383, rs3834129, rs2104772; GRA model 4: rs16399, rs4919510, 

















Figure 5.9: The proportion of TEN and CON participants classified as at risk or not at risk of 
Achilles tendinopathy by genetic risk assessment model 4 
At risk: GRA model 4 risk genotype score ≥8; Not at risk: GRA model 4 risk genotype score ≤6; GRA 
model 4: rs16399, rs4919510, rs143383, rs3834129, rs2104772, rs946053. TEN: n=76, CON: n=146 
 
A GRA model using polymorphisms previously independently associated with protection 
against AT was also sequentially developed.  Protective genotype scores for GRA model 5 
were calculated using genotype data from rs12722 (COL5A1), rs4789932 (TIMP2) and 
rs1045485 (CASP8) and therefore had a maximum score of six (Table 5.2).76,199,205,255  
Participants with a protective genotype score of two or more were significantly more 
frequently observed in the CON group compared to the TEN group (OR 0.44, 95% CI: 0.28-
0.69; P<0.001)(Figure 5.10).  The addition of rs1559186 (COL5A3) to this model resulted in a 
larger effect with participants who had a protective genotype score of two or larger once 
more observed more frequently in the CON group (OR 0.39, 95% CI: 0.23-0.65; 
P<0.001)(Figure 5.11).  A similar result was observed when COL27A1 rs1249744 was added 
to the model (OR 0.38, 95% CI: 0.23-0.64; P<0.001), however this addition did not increase 
the effect size (Figure 5.12).  The ORs and 95% confidence intervals for each protective GRA 
model are shown in Figure 5.13.  Taking into account the OR and 95% confidence interval for 















and CON participants that would be classified as either protected or not protected by GRA 
model 6 is presented in Figure 5.14.  The large majority (83%) of CON participants were 
classified as protected, however 66% of TEN participants were also classified as protected by 




Figure 5.10: GENETIC RISK ASSESSMENT MODEL 5 - Distribution of protective genotype 
scores in participants with Achilles tendinopathy (TEN) and controls (CON) 
Protective genotype score calculated using rs1045485 (CC), rs12722 (CC) and rs4789932 (CC) with a 
maximum score of 6; n=combined SA and AUS   

















Figure 5.11: GENETIC RISK ASSESSMENT MODEL 6 - Distribution of protective genotype 
scores in participants with Achilles tendinopathy (TEN) and controls (CON) 
Protective genotype score calculated using rs1045485 (CC), rs12722 (CC), rs4789932 (CC) and 
rs1559186 (GG) with a maximum score of 8; n=combined SA and AUS   
* 0 vs 2-8: χ2 13.19, P<0.001, OR 0.39 (95% CI: 0.23-0.65) 
 
 
Figure 5.12: GENETIC RISK ASSESSMENT MODEL 7 - Distribution of protective genotype 
scores in participants with Achilles tendinopathy (TEN) and controls (CON) 
Protective genotype score calculated using rs1045485 (CC), rs12722 (CC), rs4789932 (CC), rs1559186 
(GG) and rs1249744 (AA) with a maximum score of 10; n=combined SA and AUS   
















Figure 5.13: Odds ratios and 95% confidence intervals for protective genetic risk 
assessment (GRA) models 5-7 
GRA model 5: rs1045485, rs12722, rs4789932; GRA model 6: rs1045485, rs12722, rs4789932, 
rs1559186; GRA model 7: rs1045485, rs12722, rs4789932, rs1559186, rs1249744  
 
 
Figure 5.14: The proportion of TEN and CON participants classified as protected or not 
protected against AT by genetic risk assessment model 6 
Protected: GRA model 6 protective genotype score ≥2; Not protected: GRA model 6 protective 

















The primary finding of this study is that there are significant interactions between genes 
encoding components of the ECM and genes encoding components of cell-signalling 
pathways in modulating risk of AT.  Variations in these genes may act in parallel through 
different pathways, or within the same pathway to modulate risk of AT.  In addition, the 
analysis of risk models derived from both logistic regression and risk genotype scores shows 
that polymorphisms with a small effect (OR<2.0) contribute to overall genetic risk of AT in a 
cumulative manner. 
Stepwise logistic regression analyses implicated interactions between genes encoding 
components of the ECM (COL27A1, TNC, COL5A1 and COL5A3) and genes encoding 
components of the cell-signalling pathways (IL-6, IL-1β and CASP8) in a cumulative risk 
model for AT.  September et al. (2011)257 have previously proposed pathways in which the 
IL-6 and IL-1β proteins influence the expression of type V collagen and tenocyte apoptosis 
(Figure 5.15).  Briefly, IL-1β up-regulates the expression of both itself and IL-6 as well as 
other inflammatory mediators which up-regulate the expression of MMP-1, MMP-3 and 
MMP-13.257,281  These MMPs target type V collagen for degradation.33  In addition, both IL-
1β and IL-6 specifically affect the expression of the COL5A1 gene via transforming growth 
factor β (TGF-β),143,291 and TGF-β has also been shown to regulate the expression of 
COL27A1, COL3A1 and COL5A2.30,277,290  Interestingly, TGF-β has been shown to induce 
expression of a miRNA gene (MIR455) which, in humans, is located in intron 8 of the 
COL27A1 gene, and miR455 in turn regulates TGF-β signalling.277  In addition to its effects on 
TGF-β expression IL-6, together with caspase-8, has also been shown to play a role in 
tenocyte apoptosis.196  Increased expression of both IL-6 and CASP8 is associated with 
tenocyte apoptosis and has been observed in tendinopathy.196,205,257  The evidence above 
emphasises the intricate relationship between cell-signalling pathways and their effects on 

















Figure 5.15: Proposed cell-signalling pathways which may lead to increased risk of AT 
Proposed pathways through which increased mechanical loading induces expression of IL-1β, IL-1ra 
and IL-6, which in turn may act to influence the expression of type V collagen thereby potentially 
modulating the risk of AT.33,55,143,166,279,291 IL-1β increases MMP expression by increasing expression of 
inflammatory mediators such as COX-2 and PGE2.279,281 IL-6 induces tenocyte apoptosis causing the 
production of reactive oxygen species and subsequent activation of caspases 8 and 3.196 Some of 
these interactions have been observed in chondrocytes and are assumed to be similar in tenocytes. 
Up and down arrows refer to increased or decreased expression, respectively. Boxed molecules are 
those investigated in this study. The functional alleles are given in brackets and have previously been 
shown to affect the expression of the proteins as indicated by the arrows. IL-6, interleukin-6; IL-1β, 
interleukin-1β; IL-1ra, interleukin-1 receptor antagonist; MMP, matrix metalloproteinase; TGF- β, 
transforming growth factor β 
 




In addition, the gene-gene interactions observed between TNC and the IL-6, IL-1β and CASP8 
genes lend further support to recent evidence that implicates TN-C in the innate and 
adaptive immune responses.90,194  In recent studies of inflammatory joint disease, TN-C was 
shown to be an endogenous activator of toll-like receptor (TLR) 4 which, together with TLR 
2, is the predominant TLR in recognizing damage-associated molecular patterns (DAMPs).90  
DAMPs are generated as endogenous molecules are released from the ECM and cells in 
response to stress or injury and are recognised by pattern recognition receptors such as 
TLRs.90  The recognition of DAMPs by TLRs is important during sterile immune responses 















tumorigenesis.90  TN-C in particular has been shown to have a key role in promoting the 
innate and adaptive immune responses in inflammatory joint disease.194  It is required for 
chronic, destructive joint inflammation and stimulates the synthesis of tumor necrosis factor 
alpha (TNF-α), IL-6 and interleukin-8 in macrophages, and IL-6 in synovial fibroblasts.194  In 
addition, the expression of TNC, together with COL5A1, COL5A3 and COL27A1, is 
upregulated in tendinopathy133 which, when considered with the gene-gene interactions 
noted in this study, further implicates these cellular pathways in the ECM response to load, 
adaptation and repair. 
Considering the interactions observed in this study between the genes encoding 
components of the collagen fibril and genes involved in the cell-signalling pathways, as well 
as the biological relationship between these pathways, preliminary models for predicting 
genetic risk of AT incorporating these polymorphisms were investigated.  When interpreting 
the ROC curve for the two risk models derived from stepwise logistic regression, a number 
of parameters are important.  Sensitivity is the proportion of participants who have AT (TEN) 
who are predicted to be at risk of AT by the risk model, whereas specificity is the proportion 
of participants in the CON group who are predicted to not be at risk of AT.83  The AUC 
quantifies the ability of the risk model to effectively discriminate between those participants 
with AT (TEN) and those participants without AT (CON), where an AUC of 1.00 represents 
the ideal model and an AUC of 0.50 represents a model that discriminates between TEN and 
CON no better than chance.  Risk model A is, therefore, moderately able to discriminate 
between CON and TEN participants (AUC=0.775).  Although the specificity of this model is 
low, the sensitivity is relatively high.  In particular, 82.4% of TEN participants were predicted 
to be at risk of AT by this model.  Conversely, risk model B has a higher specificity than 
sensitivity and is better able to discriminate CON and TEN participants (AUC=0.801).  It is 
important to note that in this study, the optimal risk model was assumed where both 
sensitivity and specificity were optimised.  It is however, possible to derive a risk model in 
which either sensitivity or specificity is optimised depending on the desired outcomes of the 
test.  For example, using the ROC curve plotted in Figure 5.3, it is possible to derive a risk 
model in which sensitivity is optimised to approximately 98% with a corresponding 
specificity of 30%.  This type of risk model would be able to predict risk of TEN in 98% of TEN 















Contrary to this, deriving a risk model in which specificity is optimised to approximately 95% 
would decrease the sensitivity to approximately 35%.  This more conservative model would 
only have assessed 35% of TEN participants to be at risk of AT, but would have assessed 
more CON participants to not be at risk of AT. 
The strength of risk models derived from a statistical stepwise logistic regression lays in the 
relative weighting of risk attached to each factor or variable.  Polymorphisms which have a 
larger biological effect on risk of AT will be more heavily weighted in their contribution to 
the risk model.  The results obtained from this analysis are perhaps more applicable to a 
population or group, and are effective in highlighting the biologically significant factors that 
should be considered when evaluating disease risk for a group of individuals.  However, in 
the current form, these risk models are not easy to interpret in a clinical setting.  In this era 
of personalised medicine, a clinical tool that is pertinent to individuals may be of value.  It 
was therefore decided to derive and test a risk model which may be more clinically 
appropriate and allow for easy interpretation at an individual level.  Although the GRA 
models presented in this study may be more clinically applicable, they do not currently take 
into account the relative contribution of each polymorphism as all risk genotypes are 
weighted equally.  An initial GRA model based on previously published genetic associations 
with AT observed in two populations was derived (GRA model 1).  Participants with a risk 
genotype score of six or higher in this model, had 4.7-fold higher odds of having AT 
compared to those with a score of four or less.  The COL27A1 and TNC SNPs, rs946053 and 
rs2104772, were investigated in this thesis and found to be associated with AT in a 
haplotype and significantly contributed to risk of AT in the logistic regression models of risk.  
As they had a clearly distinguishable at-risk genotype (rs946053 GG; rs2104772 AA), the 
effect of their inclusion on the efficacy of GRA model 1 was tested.  A GRA model was first 
derived using only these two SNPs (GRA model 2) and found that participants with a risk 
genotype score of four were twice as likely to have AT when compared to participants with 
a score of two or less.  These two polymorphisms were therefore consecutively added to the 
initial risk model.  When either TNC rs2104772 alone (GRA model 3) or both polymorphisms 
(GRA model 4) were included in the initial risk model, participants with a risk genotype score 















suggests that the addition of the rs2104772 and rs946053 polymorphisms to the initial 
model may strengthen its ability to assess risk of AT in these participants.   
Similarly, a GRA model derived using polymorphisms that have previously been associated 
with protection against AT was investigated (GRA model 5).  Participants with a protective 
genotype score of two or more were half as likely to have AT than participants with a score 
of zero.  The addition of the COL5A3 rs1559186 marginally improved the model (GRA model 
6), but the addition of COL27A1 rs1249744 did not improve the model further (GRA model 
7).  Analysis of the proportion of CON and TEN participants predicted to be protected or not 
protected from AT by GRA model 6 showed that 83% of CON participants were predicted to 
be protected against AT.  However, 66% of TEN participants were also predicted to be 
protected against AT.  This model is, therefore, of limited value to the clinician as a risk 
assessment tool. 
The identification of these preliminary risk models may support the inclusion of genetic risk 
testing in clinical care.  However, it should be clearly noted that only 37% of TEN 
participants were predicted to be at risk of AT using GRA model 4.  Conversely, 63% of TEN 
participants were predicted not to be at risk of AT using this model.  This result emphasises 
that genetic susceptibility is only one contributing factor in the determination of overall 
susceptibility to AT.  Using the current example, approximately 63% of the risk of AT can be 
attributed to polymorphisms other than those already identified (“missing” genes) and/or 
other risk factors.  The more polymorphisms that are incorporated into risk models, the 
more likely they are to effectively assess risk.205  In order to develop cost effective screening 
strategies, it is however important to determine the minimum number of these 
polymorphisms that can be used while still maintaining the efficacy of the model.  As more 
polymorphisms which contribute to risk of AT are identified and the accuracy of genetic risk 
assessment models improves, genetic screening tests may become important tools in the 
clinical management of athletes and at-risk individuals. However, as genetic tests are 
neither diagnostic nor predictive, they should not be conducted in isolation.  They would be 
of more value when considered in conjunction with other clinical information in athletes 
and individuals who present with other risk factors for AT including previous Achilles tendon 















As only participants who were successfully genotyped for all polymorphisms included in 
each model could be included, small sample size is recognised as a limitation to this study.  
In addition, the applicability of these results to other racial groups and geographically 
defined populations may be limited.   
5.5. CONCLUSION 
The primary finding of this study is that there are significant genetic interactions between 
genes encoding components of the ECM and genes encoding components of the cell-
signalling pathways in the modulation of AT risk.  The biological mechanisms which may 
underlie these interactions are diverse and point to an intricate homeostatic relationship 
between cell-signalling pathways and the structural integrity of the ECM collagen network.  
This study also provides proof of concept that as more polymorphisms which influence risk 
of AT, and the biological mechanisms underpinning these associations, are elucidated, 
genetic screening tests for individuals presenting with other risk factors for AT may be 
















CHAPTER 6: SUMMARY & PERSPECTIVES 
Although there are clear clinical, histological and imaging diagnostic criteria for AT, the exact 
aetiology of this condition is still unclear.  Several models have been proposed to explain the 
initiation and progression of this condition and a review of these models (Chapter 1) 
suggests that the underlying mechanism of pathology in AT is likely to be a combination of 
several mechanisms which are influenced by both intrinsic and extrinsic risk factors.   It is 
therefore clear that Achilles tendinopathy is a multi-factorial condition.  The most notable 
risk factors are a history of previous Achilles tendon injury, evidence of neovascularisation 
on examination with ultrasound, treatment with fluoroquinolone antibiotics, high running 
loads and heritable elements (reviewed in Chapter 1).  In particular, there is strong evidence 
to support genetic variation as an independent risk factor for AT.  Family history of AT has 
been identified as a significant risk factor for AT,157 and several genes encoding structural 
and associated elements of the ECM have previously been associated with risk of 
AT.6,76,164,197,199,205,224,231,255,257  Considering the number of these genes and the distinct 
pathways that they are components of, it is clear that the heritable component of AT is 
polygenic in nature and it is therefore unlikely that there is one causative gene variant for 
AT.  It is more likely that many polymorphisms with small to moderate effects collectively 
contribute to an individual’s genetic predisposition to develop AT.  The identification of the 
full array of these variants is vital in elucidating the underlying mechanisms contributing to 
AT, as well as for the development of injury prevention practices.82   
The primary aim of this thesis was therefore to identify additional genetic elements which 
predispose individuals to risk of AT and to propose the biological mechanisms underlying 
this genetic risk.  In chapters 2 to 4 of this thesis, several genes encoding components of the 
ECM were identified as good candidate genes for association with AT based on their 
chromosomal location and biological function.  A case-control, genetic association study 
approach was adopted to investigate the association of specific polymorphisms within these 
genes and AT.  The selection of polymorphisms investigated was hypothesis driven and 
based on chromosomal location, biological function, heterozygosity, minor allele frequency 















The COL5A1 gene, encoding the α1(V) chain, is the most investigated gene in AT.  A number 
of polymorphisms within the 3’-UTR of this gene have been independently associated with 
AT in two separate populations.6,199,255  These polymorphisms have been suggested to alter 
the predicted secondary structure of the 3’-UTR and, subsequently, mRNA stability.6  In 
particular, increased mRNA stability has been associated with Achilles tendinopathy when 
compared to the stability in asymptomatic controls.164  This evidence has led to the 
hypothesis that the increased stability of the COL5A1 mRNA results in an increased relative 
content of type V collagen in the collagen fibril, and leads to a collagen fibre that contains 
smaller, more densely packed collagen fibrils (Figure 6.1).57,236  The subsequent changes in 
the mechanical properties of tendon tissue may lead to an increased susceptibility to 
injury.57,236  It is therefore clear that the role of type V collagen in fibrillogenesis is strongly 
involved in the pathogenesis of tendinopathy.  Type V collagen predominantly exists as a 
heterotrimer of two α1(V) and one α2(V) chains, but also exists as a homotrimer of three 
α3(V) chains.  It is therefore reasonable to hypothesise that the COL5A2 and COL5A3 genes, 
which encode the α2(V) and α3(V) chains respectively, may play a role in the pathogenesis 
of tendinopathy.  As with COL5A1, polymorphisms within the COL5A2 gene have been 
associated with EDS and abnormal fibrillogenesis, and the COL5A3 gene has also been 
suggested as a suitable candidate locus for investigation in EDS.32,123,198,238  Despite this, the 
polymorphisms investigated in the COL5A3 (rs2303099; rs1559186; rs2161468), COL5A2 
(rs13031549; rs4667264) and neighbouring COL3A1 (rs2056156; rs3106796; rs1800255) 
genes were found not to be significantly associated with risk of AT in the SA and AUS 
participants.  There was, however, a trend towards association with AT for the COL5A3 
rs1559186 polymorphism.  In summary, the hypothesis for the selection of these genes as 
candidate genes in this thesis remains strong.  It may therefore be of value to interrogate 
these genetic loci further with whole gene sequencing, using next generation sequencing 
technologies together with bioinformatics analyses to uncover potential functional variants 
















Figure 6.1: Ribbans and Collins'236 hypothesis of the mechanism through which the 
COL5A1 polymorphisms affect risk of AT 
1) Four polymorphisms within the mRNA are independently associated with tendinopathy; 2) These 
polymorphisms appear to alter the predicted secondary structure of the 3’-UTR; 3) The secondary 
structure regulates mRNA stability and by implication type V collagen production; 4) Type V collagen 
regulates fibrillogenesis and thus the mechanical properties of tendons; 5) The healthy tendon 
contains larger less densely packed fibrils while the injured tendon contains smaller more densely 
packed fibrils.57 [Figure and caption reprinted from RIbbans et al. (2013)236] 
 
Similarly, the selection of the polymorphisms within the COMP and THBS2 genes for 
investigation was also hypothesis driven.  COMP (TSP-5) is a mechanosensitive, structural 
glycoprotein that plays a role in matrix assembly and tissue repair, and rs730079 has 
previously been associated with osteoarthritis.14,108,223,243,272,284  TSP-2 is implicated in the 
healing response, MMP homeostasis, cell-matrix interactions as well as the regulation of 
collagen fibrillogenesis and fibril diameter, and both rs6422747 and rs9283850 have been 
associated with other multifactorial musculoskeletal conditions.7,36,37,112,163  However, the 















rs6422747; rs9283850) genes were also found not to associate with risk of AT in the AUS 
and SA participants investigated.  Notwithstanding, whole gene sequencing of COMP and 
THBS2, as well as the COL5A3, COL5A2 and COL3A1 genes, should be considered as viable 
methods to conclusively test whether polymorphisms within these genes are associated 
with AT. 
An additional novel finding of this thesis which addressed the primary aim was the 
association of the GCA haplotype, constructed from the COL27A1 rs946053 (T>G), TNC 
rs13321 (G>C) and TNC rs2104772 (T>A) SNPs, with AT in the Australian and South African 
groups.  This finding implicates the 759kbp region containing the 3’-end of the COL27A1 
gene and the 5’-end of the TNC gene in influencing risk of AT.  Functional analysis of this 
region suggests that genetic variation within this haplotype may have functional effects on 
mRNA transcription, as well as the structure and properties of the TN-C and α1(XXVII) 
proteins.  This potentially results in modified protein-protein and protein-environment 
interactions and, subsequently, compromised wound healing, tissue remodelling and 
adaptation (Chapter 3).  Future research prospects include genome sequencing of this 
region in order to identify more functional variants and/or signature molecular motifs which 
may predispose to AT. 
As briefly discussed in chapter 1, the ultimate objective of injury research at any level is the 
development and implementation of clinically relevant and practical injury prevention 
strategies.  A six stage framework proposed by Finch (2006)82 describes an approach for 
translating research into injury prevention practice (TRIPP).  Briefly, stage 1 requires high-
quality injury surveillance in order to establish the extent of the problem.  Stage 2 requires a 
multidisciplinary research approach to establish the aetiology and mechanisms of injury as 
well as the factors associated with increased risk and severity of injury.  The findings which 
fulfil the primary objective of this thesis contribute towards the increasing body of 
knowledge at this stage of the TRIPP framework.  Findings from these genetic association 
studies also start to unveil the underlying molecular mechanisms in tendinopathy as seen in 















Stage 3 of the TRIPP framework is the identification and development of appropriate injury 
prevention strategies using a multidisciplinary approach.82  Whilst AT is recognised as a 
multifactorial condition of which genetic variation is only one component contributing to 
overall risk, tools which gauge the extent of genetic risk of AT for individuals will be of value 
to sports clinicians.  The secondary aim of this thesis was therefore to develop and test 
preliminary models assessing genetic risk of developing AT in order to start addressing stage 
3 of the TRIPP framework.  This secondary aim was addressed in chapter 5 of this thesis. 
September et al. (2011)257 reported the interaction of sequence variants within the COL5A1, 
IL-6, IL-1β and IL-1RN genes in the modulation of risk of AT using a pathway-based 
approach.  Another study reported the independent and haplotype association of sequence 
variants within the CASP8 gene, encoding a component of the apoptosis pathway, with 
AT.205  It was therefore hypothesized that polymorphisms within genes encoding other 
components of the ECM may also interact with these cell-signalling pathways in the 
modulation of risk of AT.  In chapter 5, two approaches were used to develop models which 
assessed genetic risk of AT.  The first, stepwise logistic regression with ROC curve analysis, 
optimised both sensitivity and specificity of the model by sequentially adding factors to the 
models.  Two separate, biologically plausible, risk models were developed which identified 
the polymorphisms contributing, and their relative contribution, to overall genetic risk of 
AT.  The best fit risk model with the largest area under the curve included the variables age 
(years), sex (male), COL27A1 rs946053 (GT,TT), COL5A1 rs12722 (TC,CC), COL5A3 rs1559186 
(CG,GG), IL-6 rs1800795 (GC,CC), CASP8 rs1045485 (GC,CC) and CASP8 rs3834129 
(del/CTTACT,del/del), and had sensitivity and specificity indicators of 58.1% and 86.5% 
respectively.  These risk models are valuable in that they indicate the relative contribution 
of each factor to the risk of AT assessed by that model, and highlight the biologically 
significant factors which should be considered when assessing risk.  The risk models 
developed in chapter 5 emphasise the interactions between genes encoding components of 
the collagen fibril and genes involved in the cell-signalling pathways in modulating risk of AT.  
In addition, they emphasise the fact that the ability of risk models to effectively assess risk is 















The risk models described above are of value at a population level but are not easy to 
interpret in a clinical setting.  Therefore, the underlying principles were used to develop a 
series of genetic risk assessment (GRA) models which may be more relevant in the provision 
of personal medical care.  The GRA models included polymorphisms that (i) have previously 
been associated with AT in two independent populations and, (ii) have a definitive risk 
genotype that was implicated in a haplotype or gene-gene interactions associated with AT.  
A genetic risk assessment model which included risk genotype scores for polymorphisms 
rs16399 (COL5A1), rs4919510 (MIR608), rs143383 (GDF5), rs3834129 (CASP8), rs2104772 
(TNC) and rs946053 (COL27A1) was developed and accurately assessed 90% of CON 
participants as not at-risk of AT but only accurately assessed 37% of TEN participants as at-
risk of AT (OR 5.89, 95% CI:2.39-14.52; P<0.001).  Although these preliminary GRA models 
are not fully implementable in a clinical setting, they provide proof of concept that genetic 
screening tests for AT are of value as a clinical tool. 
Stages 4, 5 and 6 of the TRIPP framework centre around the evaluation of the injury 
prevention strategies under ideal conditions, understanding factors which influence the 
implementation of these measures and evaluating the effectiveness of the strategy in real-
world conditions.82  It is, therefore, worthwhile discussing some of the ethical and practical 
considerations which may influence the implementation and effectiveness of genetic 
screening tests. 
It is important for clinicians and patients to understand the limitations of genetic screening 
tests, as well as issues of validity.  Before polymorphisms that have been associated with 
risk of AT are included in genetic screening tests, the associations should have been 
repeated in at least one other independent population.1,47  In addition, the association 
should be shown to be biologically plausible through investigation of the mechanisms 
underlying the association.  For example, the initial association of the rs12722 SNP in 
COL5A1 with AT in a South African population has been replicated in an independent 
Australian population and, together with other polymorphisms, has been mapped to a 
functional region of the 3’-UTR and suggested to play a role in the stability of COL5A1 















It is particularly important to emphasise that predisposition does not equal 
predetermination.  Polygenic profiling tests are not predictive and can only identify relative 
risk of disease/injury.236,256  While some rare genetic mutations are causative and result in 
severe or lethal phenotypes without the involvement of environmental factors, milder non-
lethal phenotypes are often a result of environmental exposure interacting with genetic risk 
factors (Figure 6.2).236  Although there is an increasing number of sequence variants shown 
to be associated with AT, it is still not fully understood how these polymorphisms interact 
with environmental risk factors to either mask or modify risk of AT, nor the extent to which 
environmental factors modulate genetic risk through epigenetics.59,236,256  This point is 
particularly pertinent when considering the ethical implications of genetic screening tests.  It 
is imperative that these tests are interpreted by trained geneticists and that qualified 
genetic counsellors are involved in the process.  As the identification of genetic risk factors 
increases and our understanding of personal genomics grows, so too does the potential for 
genetic discrimination.  Genetic testing for sports performance and predisposition to 
concussion is already commercially available,2,3 and has the potential to be considered in 
the selection and contracting of athletes to sports teams.  In addition, there is potential for 
medical insurance companies to start considering genetic predisposition to disease/injury in 
a similar light to pre-existing conditions and therefore adjusting risk estimates and medical 
cover accordingly.15 
Notwithstanding these limitations, genetic screening tests may ultimately allow for better 
prescription of exercise and preventative measures as well as treatment of AT.  The 
feasibility of gene therapy has been shown in animal tendon studies and could be used to 
manipulate the healing environment of genetically “compromised” tendons.110,312  Future 
challenges include identifying the most appropriate gene targets and refining the timing and 
mechanism of delivery to the affected tissue.110  As is the case with many advances in 
medical treatment, the potential for abuse of these therapies is present.  The World Anti-
doping agency (WADA) prohibits “the transfer of polymers of nucleic acids or nucleic acid 
analogues” and “the use of normal or genetically modified cells” as methods of gene doping 
















Figure 6.2: The gene-environment continuum described by Ribbans and Collins (2013)236 
The heat bars indicate the effect of genotype and environmental exposure on the phenotype.  Black 
shading represents the largest effect while the clear shading represents minimal or no effect.  The 
black and dark grey boxes represent the most severe phenotypes and are caused by rare genetic 
mutations with minimal or no environmental exposure.  Common orthopaedic injuries are caused by 
environmental exposure interacting with the individual’s genetic background (middle box). [Figure 
and caption reprinted from RIbbans et al. (2013)236] 
 
for the treatment of overuse injuries evolve, these therapies may be both legitimately used 
and abused by athletes partaking in high-load repetitive sports such as marathon running, 
rowing, canoeing and swimming to both improve recovery and increase resistance to injury 
during training.  Currently, these prohibited methods are difficult to detect without baseline 
genetic profiling of athletes. 
The studies included in this thesis have a number of limitations.  Firstly, the sample size 
provides statistical power to detect associations of polymorphisms with AT that have an 
effect where OR>2.  However, previous research in this area has shown that genetic variants 















risk of developing AT.197,199,231  Future studies with larger cohorts are required to repeat 
these findings, as well as many of the previously published associations with AT, in 
independent populations.  Secondly, the TEN participants were significantly heavier than the 
CON participants at recruitment.  Although weight of TEN participants at time of injury could 
not be obtained, several TEN participants reported weight gain due to a decrease in physical 
activity after injury.  In addition, the lack of physical activity and smoking data for the 
Australian participants is recognised as a limitation to this study.  Lastly, due to the effects 
of population stratification and differences in genotype distribution, the applicability of 
these findings to other racial groups and geographically defined populations may be limited. 
6.1. FUTURE DIRECTIONS 
Future research in this field should exploit a multi-disciplinary approach to fully elucidate 
the role of genetic variation in Achilles tendinopathy.  As mentioned previously in this 
chapter, it is likely that many polymorphisms with small to moderate effects collectively 
contribute to an individual’s genetic predisposition to AT, and the identification of many 
more of these variants is vital in building a model to describe this genetic predisposition.82  
The studies presented in this thesis and those published to date have only been sufficiently 
powered to identify polymorphisms with a moderate effect due to the experimental sample 
size.  As the field of tendinopathy genomics grows and collaborations lead to larger cohorts, 
it may become possible to explore a GWAS approach to define further genomic regions 
which are associated with AT.186  Although GWAS are not always of value in detecting rare 
variants because of their exclusion in the currently available commercial arrays, they are 
likely to detect common variants with small effects, as well as copy number variations in 
newer GWAS chips.186  Whilst GWAS in tendinopathy have value to add to the field, the 
value of candidate-gene association studies should not be underestimated as GWAS are 
based purely on statistical computation and do not take biological plausibility into 
account.186  As larger study populations become available, it is also important to investigate 
the repeatability of reported associations with AT in independent populations, which will 
















In addition to undertaking a purely genetic approach, an integrated approach to 
investigating AT using techniques from molecular and cell biology, biochemistry, 
bioinformatics and genetics is necessary.  A particularly interesting area of expansion for this 
field lies in the investigation of epigenetic modulation of gene expression profiles due to 
gene-environment interactions.59,236,256  More specifically, alterations in the methylation 
profiles of CpG sites within genes encoding proteins of the extracellular matrix and cell-
signalling pathways should be investigated.59,242 
Currently, only the associated variants within the 3’-UTR of the COL5A1 gene have been 
investigated at a functional level.6,164  Future research should therefore focus on elucidating 
the molecular mechanisms underlying other reported genetic associations with AT.  A 
suggested approach is the combination of next generation sequencing of genomic regions of 
interest to identify rare and/or functional variants which are likely to be associated with AT, 
with subsequent bioinformatic analysis to identify signature molecular elements within 
these regions.  Furthermore, functional molecular research will help to elucidate and 
confirm the biological pathways and mechanisms which underpin the ECM response to load, 
adaptation and healing, as well as the role of genetic variation in this process. 
Lastly, large prospective cohort studies are required to assess the ability of genetic 
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4. PARTICIPANT QUESTIONNAIRE 
  
Department of Human Biology 
UCT/ MRC RESEARCH U NIT FOR E XERCISE S CIENCE & S PORTS M EDICINE 
Faculty of Health Sciences , University of Cape Tow n 
Private Bag, Rondebosch 7700, South Afr ica 
Tel: + 27 21 6504561 
Fax: + 27 21 686 7530 
GENETIC BASIS OF TENDON INJURY QUESTIONNAIRES 





E-m ail address Phone (day time) 
Date of birth YYYY / M M I 0 0 Cell 
Height (em) Gender Male 0 Female 0 
Weight (kg) 
Ethnic group Black/A frican 0 W hite 0 Indian 0 
(On ly Required and 
Used fO( Research 
0 0 0 Purposes) Mixed Ancestry (Co loured) Asian Other 
Ancestry: Tribal 
0 or national Father Unknow n 
background 
(e9 Xhosa , Dutch, 
0 ZUIU 'n~erman, Mother Unknow n 
Italian 
Country of Birth Nationality 
Dominant Hand Left 0 Right 0 Both 0 Dominant Leg Left 0 Right 0 Both 0 
Yes (Current) 0 j Yes (Ex smoker) 0 I No, never 0 
Smoker If yes, Number of years I lf stopped, w hen 
If yes, number per day 
Do you know your Yes 0 A 0 BO AB 0 00 
blood group? No 0 Rh Pos 0 Rh Neg 0 
Genetic Basis of Tendon Injury Questionna ires 
The University of Cape Town is committed to policies of equal opportunity and affirmative action 
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5. DIAGNOSTIC CRITERIA FOR ACHILLES TENDINOPATHY (TEN) PARTICIPANTS 
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(B) ALLELIC DISCRIMINATION METHODOLOGY 
1. PCR CONDITIONS FOR COMP & THBS2 POLYMORPHISMS INVESTIGATED IN CHAPTER 
TWO 
dbSNP:   rs9283850 
CHROMOSOMAL POSITION:  6:169637456 
BASE PAIR CHANGE:  R; A>G 
MINOR ALLELE FREQUENCY:  44.8% 




Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™) 
     Assay ID C____180588_10 
 
 
Figure B.1: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 















dbSNP:   rs6422747 
CHROMOSOMAL POSITION:  6:169629783 
BASE PAIR CHANGE:  R; A>G 
MINOR ALLELE FREQUENCY:  48.1% 










Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 55˚C 
Mg
2+




Amplicon size 527bp 
RESTRICTION CONDITIONS: 
Nuclease MfeI 
Cutting site  C’AATT_G 
Reaction Buffer New England Biolabs® Inc. Buffer 4 
Incubation temperature 37˚C 
Fragment sizes 
A allele - 527bp 
G allele - 405 and 122bp 
 
 
Figure B.2: A typical 6% PAGE image 
discriminating restriction fragments 
from individuals who are 
homozygous AA (lane 1), 
heterozygous AG (lane 2) and 
homozygous GG (lane 3) for the 
rs6422747 polymorphism  
Fragment sizes are indicated with 
arrows on the sides of the image with a 
100bp size standard in lane 4.  Samples 
















dbSNP ID:   rs9505888 
CHROMOSOMAL POSITION:  6:169625874 
BASE PAIR CHANGE:  R; A>G 
MINOR ALLELE FREQUENCY:  42.3% 








Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 55˚C 
Mg
2+




Amplicon size 381bp 
RESTRICTION CONDITIONS: 
Nuclease BstUI 
Cutting site  CG’CG 
Reaction Buffer Fermentas Buffer R 
BSA concentration 0% 
Incubation temperature 37˚C 
Fragment sizes 
A allele - 381bp 




Figure B.3: A typical 6% PAGE 
image discriminating restriction 
fragments from individuals who are 
homozygous AA (lane 1), 
heterozygous AG (lane 2) and 
homozygous GG (lane 3) for the 
rs9505888 polymorphism  
Fragment sizes are indicated with 
arrows on the sides of the image with a 
100bp size standard in lane 4.  Samples 
















dbSNP ID:   rs730079 
CHROMOSOMAL POSITION:  19:18903495 
BASE PAIR CHANGE:  S; C>G 
MINOR ALLELE FREQUENCY:  27.5% 
HETEROZYGOSITY:  0.417 
 
FASTA SEQUENCE:  
GAGTTACAAAACCCCTTAACCTCCTGSAATCAGTTAACACTCTCCACTCCCA 
Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™) 
    Assay ID C___2257395_10 
 
 
Figure B.4: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 

















dbSNP:   rs28494505 
CHROMOSOMAL POSITION:  19:18893811 
BASE PAIR CHANGE:  R; A>G 
MINOR ALLELE FREQUENCY:  15.0% 








Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 58˚C 
Mg
2+




Amplicon size 415bp 
RESTRICTION CONDITIONS: 
Nuclease MspI 
Cutting site  C’CG_G 
Reaction Buffer New England Biolabs® Inc. Buffer 4 
BSA concentration 0% 
Incubation temperature 37˚C 
Fragment sizes 
T allele – 258 and 157bp 
C allele – 157, 151 and 107bp 
 
 
Figure B.5: A typical 6% PAGE 
image discriminating restriction 
fragments from individuals who 
are homozygous TT (lane 1), 
heterozygous TC (lane 2) and 
homozygous CC (lane 3) for the 
rs28494505 polymorphism, 
together with an uncut PCR 
amplicon (UPA) in lane 4 and a 
100bp size standard (lane 5)  
Fragment sizes are indicated with 
arrows on the sides of the image.  
Samples were electrophoresed at 

















2. PCR CONDITIONS FOR COL27A1 & TNC POLYMORPHISMS INVESTIGATED IN CHAPTER 
THREE 
 
dbSNP ID:   rs4143245 
CHROMOSOMAL POSITION:  9:117033022 
BASE PAIR CHANGE:  Y – T>C 
MINOR ALLELE FREQUENCY:  43.8% 
HETEROZYGOSITY:   0.473 
 








Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 57˚C 
Mg
2+




Amplicon size 525bp 
RESTRICTION CONDTIONS 
Nuclease XhoI 
Cutting site  C’TCGA_G 
Reaction Buffer New England Biolabs® Inc. Buffer 2 
BSA concentration 10% 
Incubation temperature 37˚C 
Fragment sizes 
C allele - 351, 165 and 9bp 
T allele - 516 and 9bp 
 
  
Figure B.6: A typical PAGE image 
discriminating restriction fragments 
from individuals who are homozygous 
TT (lane 1), homozygous CC (lane 2) and 
heterozygous CT (lane 3) for the 
rs4143245 polymorphism, together with 
an uncut PCR amplicon (UPA) in lane 4 
and a 100bp size standard (lane 5)  
Fragment sizes are indicated with arrows on 
the sides of the image.  Samples were 















dbSNP:    rs1249744 
CHROMOSOMAL POSITION:  9: 117043352 
BASE PAIR CHANGE:  R; A>G 
MINOR ALLELE FREQUENCY:  21.2% 












Polymerase New England Biolabs® Inc. Taq DNA Polymerase 
Cycling  T-ARMS protocol 
Annealing temperature 56˚C 
Mg
2+







Control – 394bp 
A Allele – 167bp 





Figure B.7: A typical agarose gel image 
discriminating restriction fragments 
from individuals who are heterozygous 
AG (lane 1), homozygous AA (lane 2) 
and homozygous GG (lane 3) for the 
rs1249744 polymorphism, together 
with a 100bp size standard (lane 4)  
Fragment sizes are indicated with arrows on 
the sides of the image.  Samples were 















dbSNP ID:   rs753085 
CHROMOSOMAL POSITION:  9: 117045447 
BASE PAIR CHANGE:  Y; C>T 
MINOR ALLELE FREQUENCY:  25.0% 













Polymerase Super Therm DNA Polymerase 
Cycling  T-ARMS protocol 
Annealing temperature 60.5˚C 
Mg
2+







Control – 477bp 
T Allele – 157bp 
C Allele – 375bp 
 
Figure B.8: A typical agarose gel image discriminating restriction fragments from 
individuals who are homozygous TT (lane 1), homozygous CC (lanes 2 & 3) and 
heterozygous TC (lane 4) for the rs753085 polymorphism, together with a 100bp size 
standard (lane 5) 
Fragment sizes are indicated with arrows on the sides of the image.  Samples were electrophoresed 















dbSNP:    rs946053 
CHROMOSOMAL POSITION:  9: 117049891 
BASE PAIR CHANGE:  K; T>G 
MINOR ALLELE FREQUENCY:  46.5% 









Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 52˚C 
Mg
2+




Amplicon size 457bp 
RESTRICTION CONDITIONS 
Nuclease BglI 
Cutting site  GCC_ _ _ _ ‘_GGC 
Reaction Buffer New England Biolabs® Inc. Buffer 3 
BSA concentration 0% 
Incubation temperature 37˚C 
Fragment sizes 
T allele - 457bp 
G allele - 361 and 96bp 
 
Figure B.9: A typical agarose image 
discriminating restriction fragments from 
individuals who are homozygous TT (lane 1), 
heterozygous TG (lane 2) and homozygous GG 
(lane 3) for the rs946053 polymorphism, 
together with an uncut PCR amplicon (UPA) in 
lane 4 and a 100bp size standard (lane 5)  
Fragment sizes are indicated with arrows on the 
sides of the image.  Samples were electrophoresed 















dbSNP:    rs13321 
CHROMOSOMAL POSITION:  9: 117792583 
BASE PAIR CHANGE:  S; C>G 
MINOR ALLELE FREQUENCY:  30.0% 









 Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 55.0˚C 
Mg
2+




Amplicon size (RFLP) 438bp 
RESTRICTION CONDITIONS 
Nuclease BbvCI 
Cutting site  CC’TCA_GC 
Reaction Buffer New England Biolabs® Inc. Buffer 4 
BSA concentration 0% 
Incubation temperature 37˚C 
Fragment sizes 
C allele - 438bp 
G allele - 148 and 289bp 
 
Figure B.10: A typical PAGE image 
discriminating restriction fragments from 
individuals who are homozygous CC (lane 1), 
homozygous GG (lane 2) and heterozygous 
CG (lane 3) for the rs13321 polymorphism, 
together with an uncut PCR amplicon (UPA) 
in lane 4 and a 100bp size standard (lane 5)  
Fragment sizes are indicated with arrows on the 
sides of the image.  Samples were electrophoresed 















dbSNP:    rs2104772 
CHROMOSOMAL POSITION:  9: 117808785 
BASE PAIR CHANGE:  W; T>A 
MINOR ALLELE FREQUENCY:  41.7% 







Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 52.0˚C 
Mg
2+




Amplicon size 262bp 
RESTRICTION CONDITIONS 
Nuclease MseI 
Cutting site  T’TAA 
Reaction Buffer New England Biolabs® Inc. Buffer 4 
BSA concentration 10% 
Incubation temperature 37˚C 
Fragment sizes 
A allele - 262bp 
T allele - 175 and 87bp 
 
Figure B.11: A typical PAGE image 
discriminating restriction fragments from 
individuals who are homozygous TT (lane 1), 
heterozygous AT (lane 2) and homozygous AA 
(lane 3) for the rs2104772 polymorphism, 
together with a 100bp size standard (lane 4)  
Fragment sizes are indicated with arrows on the 
sides of the image.  Samples were electrophoresed 















dbSNP:    rs1330363 
CHROMOSOMAL POSITION:  9: 117813990 
BASE PAIR CHANGE:  R; A>G 
MINOR ALLELE FREQUENCY:  39.8% 









Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 55.0˚C 
Mg
2+




Amplicon size (RFLP) 420bp 
RESTRICTION CONDITITIONS 
Nuclease TaaI (HpyCH4III) 
Cutting site  AC_n’GT 
Reaction Buffer Fermentas Life Sciences Buffer Tango 
BSA concentration 0% 
Incubation temperature 65˚C 
Fragment sizes 
A allele - 182 and 238bp 




Figure B.12: A typical PAGE image 
discriminating restriction fragments from 
individuals who are heterozygous AG  
(lane 1), homozygous GG (lane 2) and 
homozygous AA (lane 3) for the rs1330363 
polymorphism, together with an uncut 
PCR amplicon (UPA) in lane 4 and a 100bp 
size standard (lane 5)  
Fragment sizes are indicated with arrows on the 
sides of the image.  Samples were 















3. PCR CONDITIONS FOR COL5A3, COL3A1 AND COL5A2 POLYMORPHISMS INVESTIGATED 
IN CHAPTER FOUR 
dbSNP:   rs2161468 
CHROMOSOMAL POSITION:  19:10088271 
BASE PAIR CHANGE:  S; C>G 
MINOR ALLELE FREQUENCY:  36% 




Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™) 





Figure B.13: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 
















dbSNP:    rs1559186 
CHROMOSOMAL POSITION:  19:10106936 
BASE PAIR CHANGE:  S; C>G 
MINOR ALLELE FREQUENCY:  40% 







Underlined sequences indicate oligonucleotide primer sequences; Bolded base pairs indicate SNP 
location; Highlighted sequences indicate nuclease cutting sites. 
 
PCR CONDITIONS: 
Polymerase Super Therm DNA Polymerase 
Cycling  Standard PCR for 35 cycles 
Annealing temperature 58.0˚C 
Mg
2+




Amplicon size 325bp 
RESTRICTION CONDITIONS 
Nuclease PvuII 
Cutting site  CAG’CTG 
Reaction Buffer Fermentas Buffer G 
BSA concentration 0% 
Incubation temperature 37˚C 
Fragment sizes 
C allele - 325bp 
G allele - 192 and 133bp 
 
  
Figure B.14: A typical PAGE image 
discriminating restriction fragments from 
individuals who are heterozygous CG (lane 1), 
homozygous CC (lane 2) and homozygous GG 
(lane 3) for the rs1559186 polymorphism, 
together with an uncut PCR amplicon 
(UPA)(lane 4) and a 100bp size standard (lane 
5) 
Fragment sizes are indicated with arrows on the 
sides of the image.  Samples were electrophoresed 















dbSNP:   rs2303099 
CHROMOSOMAL POSITION:  19:10116375 
BASE PAIR CHANGE:  M; A<C 
MINOR ALLELE FREQUENCY:  46% 




Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™) 





Figure B.15: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 


















dbSNP:   rs2056156 
CHROMOSOMAL POSITION:  2:189848468 
BASE PAIR CHANGE:  Y; T>C 
MINOR ALLELE FREQUENCY:  38.80% 




Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™) 




Figure B.16: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 

















dbSNP:   rs3106796 
CHROMOSOMAL POSITION:  2:189849773 
BASE PAIR CHANGE:  R; A>G 
MINOR ALLELE FREQUENCY:  38.2% 




Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™) 




Figure B.17: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 
















dbSNP:   rs1800255 
CHROMOSOMAL POSITION:  2:189864080 
BASE PAIR CHANGE:  R; G>A 
MINOR ALLELE FREQUENCY:  20.9% 




Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™) 




Figure B.18: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 
















dbSNP:   rs13031549 
CHROMOSOMAL POSITION:  2:190030816 
BASE PAIR CHANGE:  K; T>G 
MINOR ALLELE FREQUENCY:  48.6% 




Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™)  





Figure B.19: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 

















dbSNP:   rs4667264 
CHROMOSOMAL POSITION:  2:190009718 
BASE PAIR CHANGE:  S; C>G 
MINOR ALLELE FREQUENCY:  39.1% 




Bolded base pair indicates SNP location 
 
PCR CONDITIONS:  TaqMan® SNP Genotyping Assays (Applied Biosystems™) 





Figure B.20: A typical allelic discrimination plot using the TaqMan® SNP Genotyping Assay 
















(C) SUPPLEMENTARY RESULTS 
Table C.1: Allele combination frequency distributions in CON and TEN participants for 
significant interactions in the modulation of risk of AT 
Values are frequencies with P-values for specific differences in allele combinations between CON and 
TEN 
 
rs1249744 rs1800795 CON TEN P  rs1249744 rs16944 CON TEN P 
A C 0.33 0.25 0.002  A C 0.41 0.40 0.952 
A G 0.40 0.41 0.760  A T 0.32 0.26 0.010 
G C 0.13 0.13 0.761  G C 0.13 0.21 0.011 
G G 0.14 0.21 0.001  G T 0.14 0.13 0.316 
           
rs1249744 rs1143627 CON TEN P  rs1249744 rs1045485 CON TEN P 
A C 0.28 0.26 0.134  A C 0.14 0.09 0.031 
A T 0.45 0.40 0.284  A G 0.59 0.57 0.253 
G C 0.13 0.11 0.583  G C 0.07 0.05 0.982 
G T 0.14 0.23 0.005  G G 0.20 0.29 0.005 
           
rs1249744 rs3834129 CON TEN P  rs946053 rs1800795 CON TEN P 
A CTTACT 0.34 0.27 0.007  T C 0.24 0.15 0.002 
A del 0.38 0.39 0.945  G C 0.22 0.22 0.682 
G CTTACT 0.15 0.19 0.156  T G 0.25 0.28 0.704 
G del 0.12 0.16 0.022  G G 0.29 0.35 0.012 
           
rs946053 rs16944 CON TEN P  rs13321 rs1800795 CON TEN P 
T T 0.23 0.15 0.005  C C 0.33 0.27 0.020 
T C 0.26 0.28 0.806  G C 0.13 0.11 0.345 
G T 0.23 0.25 0.649  C G 0.38 0.40 0.320 

















rs2104772 rs1800795 CON TEN P  rs2104772 rs16944 CON TEN P 
T C 0.21 0.12 0.000  T T 0.19 0.13 0.007 
A C 0.25 0.26 0.887  T C 0.24 0.25 0.547 
T G 0.23 0.26 0.825  A T 0.26 0.27 0.796 
A G 0.31 0.37 0.010  A C 0.30 0.36 0.014 
           
rs2104772 rs1045485 CON TEN P  rs2104772 rs3834129 CON TEN P 
T C 0.08 0.04 0.047  T CTTACT 0.21 0.18 0.052 
T G 0.35 0.33 0.115  T del 0.22 0.19 0.213 
A C 0.13 0.10 0.514  A CTTACT 0.28 0.27 0.891 
A G 0.44 0.52 0.004  A del 0.29 0.35 0.007 
           
rs1330363 rs1800795 CON TEN P  rs1330363 rs1045485 CON TEN P 
A C 0.28 0.20 0.003  A C 0.10 0.07 0.081 
G C 0.18 0.18 0.823  A G 0.49 0.45 0.208 
A G 0.30 0.32 0.777  G C 0.11 0.07 0.362 
G G 0.24 0.30 0.004  G G 0.30 0.41 0.005 
           
rs1330363 rs3831429 CON TEN P  rs2303099 rs1800795 CON TEN P 
A CTTACT 0.31 0.22 0.004  G C 0.22 0.14 0.017 
A del 0.28 0.30 0.704  T C 0.24 0.23 0.256 
G CTTACT 0.18 0.24 0.147  T G 0.28 0.32 0.233 
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